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A B S T R A C T
Background
Probiotics may be eJective in reducing the duration of acute infectious diarrhoea.
Objectives
To assess the eJects of probiotics in proven or presumed acute infectious diarrhoea.
Search methods
We searched the trials register of the Cochrane Infectious Diseases Group, MEDLINE, and Embase from inception to 17 December 2019, as
well as the Cochrane Controlled Trials Register (Issue 12, 2019), in the Cochrane Library, and reference lists from studies and reviews. We
included additional studies identified during external review.
Selection criteria
Randomized controlled trials comparing a specified probiotic agent with a placebo or no probiotic in people with acute diarrhoea that is
proven or presumed to be caused by an infectious agent.
Data collection and analysis
Two review authors independently applied inclusion criteria, assessed risk of bias, and extracted data. Primary outcomes were measures
of diarrhoea duration (diarrhoea lasting ≥ 48 hours; duration of diarrhoea). Secondary outcomes were number of people hospitalized in
community studies, duration of hospitalization in inpatient studies, diarrhoea lasting ≥ 14 days, and adverse events.
Main results
We included 82 studies with a total of 12,127 participants. These studies included 11,526 children (age < 18 years) and 412 adults (three
studies recruited 189 adults and children but did not specify numbers in each age group). No cluster-randomized trials were included.
Studies varied in the definitions used for "acute diarrhoea" and "end of the diarrhoeal illness" and in the probiotic(s) tested. A total of 53
trials were undertaken in countries where both child and adult mortality was low or very low, and 26 where either child or adult mortality
was high.
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Risk of bias was high or unclear in many studies, and there was marked statistical heterogeneity when findings for the primary outcomes
were pooled in meta-analysis. EJect size was similar in the sensitivity analysis and marked heterogeneity persisted. Publication bias was
demonstrated from funnel plots for the main outcomes.
In our main analysis of the primary outcomes in studies at low risk for all indices of risk of bias, no diJerence was detected between
probiotic and control groups for the risk of diarrhoea lasting ≥ 48 hours (risk ratio (RR) 1.00, 95% confidence interval (CI) 0.91 to 1.09; 2
trials, 1770 participants; moderate-certainty evidence); or for duration of diarrhoea (mean diJerence (MD) 8.64 hours shorter, 95% CI 29.4
hours shorter to 12.1 hours longer; 6 trials, 3058 participants; very low-certainty evidence).
EJect size was similar and marked heterogeneity persisted in pre-specified subgroup analyses of the primary outcomes that included
all studies. These included analyses limited to the probiotics Lactobacillus rhamnosus GG and Saccharomyces boulardii. In six trials (433
participants) of Lactobacillus reuteri, there was consistency amongst findings (I2 = 0%), but risk of bias was present in all included studies.
Heterogeneity also was not explained by types of participants (age, nutritional/socioeconomic status captured by mortality stratum, region
of the world where studies were undertaken), diarrhoea in children caused by rotavirus, exposure to antibiotics, and the few studies of
children who were also treated with zinc. In addition, there were no clear diJerences in eJect size for the primary outcomes in post hoc
analyses according to decade of publication of studies and whether or not trials had been registered.
For other outcomes, the duration of hospitalization in inpatient studies on average was shorter in probiotic groups than in control groups
but there was marked heterogeneity between studies (I2 = 96%; MD -18.03 hours, 95% CI -27.28 to -8.78, random-eJects model: 24 trials,
4056 participants). No diJerences were detected between probiotic and control groups in the number of people with diarrhoea lasting ≥
14 days (RR 0.49, 95% CI 0.16 to 1.53; 9 studies, 2928 participants) or in risk of hospitalization in community studies (RR 1.26, 95% CI 0.84
to 1.89; 6 studies, 2283 participants).
No serious adverse events were attributed to probiotics.
Authors' conclusions
Probiotics probably make little or no diJerence to the number of people who have diarrhoea lasting 48 hours or longer, and we are uncertain
whether probiotics reduce the duration of diarrhoea. This analysis is based on large trials with low risk of bias.
P L A I N   L A N G U A G E   S U M M A R Y
Do probiotics help to treat acute infectious diarrhoea?
What is the aim of this review?
Acute infectious diarrhoea is a major global disease that particularly aJects people in low- and middle-income countries. We wanted to
know if taking probiotics is helpful in shortening the time taken for symptoms to resolve. We searched for studies that looked at the use of
probiotics in people with acute diarrhoea. We looked for studies in which the treatments people received were decided randomly; these
usually give reliable evidence.
Key messages
Probiotics may not aJect how long acute diarrhoea lasts. We do not know if they can shorten the time to recovery from diarrhoea. We need
reliable evidence from further studies to determine whether probiotics help treat acute infectious diarrhoea.
What was studied in the review?
”Diarrhoea” is the name for frequent bowel movements or the passing of unusually soT or watery faeces. Infections of the gut by bacteria,
viruses, or parasites cause acute diarrhoea and are most oTen spread through water contaminated with faeces. Acute diarrhoea usually
improves within a few days. However, in severe acute diarrhoea, water, salts, and nutrients that may be lost from the body are substantial,
causing dehydration and even death. Treatments for acute diarrhoea aim to prevent or reverse dehydration, speed up recovery time, and
shorten the time that a person may pass the infection to others.
Probiotics are live bacteria and yeasts that are thought to restore the natural balance of bacteria in the gut (intestines) when this has been
disrupted by illness or treatment. Probiotics are oTen described as "good" or "friendly" bacteria; they may be present in yoghurts or taken
as food supplements. In acute infectious diarrhoea, probiotics may act against the harmful microbes that are causing diarrhoea, help the
gut to fight them, or reduce inflammation and damage to the gut.
What are the main results of the review?
We found 82 studies in 12,127 people (mostly children) with acute diarrhoea. Only 26 studies took place in countries that had high numbers
of deaths (of any cause) among adults and children.
These studies compared the eJects of diJerent types of probiotics with no additional treatment or with a placebo (dummy) treatment.
We were interested in:
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• how many people had diarrhoea longer than 48 hours; and
• how long, on average, the symptoms of diarrhoea lasted.
There were many diJerences in the ways these studies were designed and carried out. Studies used diJerent definitions of "acute
diarrhoea" and "the end of diarrhoea symptoms," and they tested many diJerent probiotics. Therefore, we could not include the results
of all studies in our analysis.
We did not detect a diJerence between taking a probiotic and taking a placebo or no additional treatment in the number of children who
had diarrhoea longer than 48 hours (two studies in high-income countries; 1770 children). We are uncertain whether taking probiotics
aJects the length of time that the symptoms of diarrhoea last (six studies; 3058 people). These findings were not aJected by age, nutritional
and socioeconomic status, region, or rotavirus infection of participants, nor by whether they were taking antibiotic medicines or zinc
supplements.
Taking probiotics may not have aJected:
• how many people had diarrhoea longer than 14 days (nine studies; 2928 people); or
• how many people were admitted to hospital with diarrhoea (six studies; 2283 people).
It was unclear whether taking probiotics shortened the time spent in hospital compared with taking a placebo or no additional treatment
(24 studies; 4056 people). Few studies reported on any unwanted eJects of probiotics; no serious unwanted eJects were reported among
people who took probiotics.
How reliable are these results?
Previous published editions of this review drew conclusions from the many small studies in this field and indicated an eJect.
This new analysis shows that in this topic there is publication bias, with small studies demonstrating a positive eJect more likely to be
published, which skews the results. This fresh analysis takes this into account.
How up-to-date is this review?
We included evidence published up to 17 December 2019.
Probiotics for treating acute infectious diarrhoea (Review)





































































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Summary of findings table 1
Probiotic compared to placebo for treating acute infectious diarrhoea (analysis limited to studies at low risk of bias)
Patient or population: children and adults with acute infectious diarrhoea
Setting: trials undertaken in health facilities and/or in the community in any country
Intervention: probiotic
Comparison: placebo or no probiotic/standard care



























Probiotics probably make little or no difference to
the number of people who have diarrhoea lasting




- MD 8.64 hours lower






Due to imprecision and in-
consistency
We are uncertain whether or not probiotics reduce
the duration of diarrhoea
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded by 1 for indirectness. Both trials conducted in high-income countries and evaluating two probiotics.
bDowngraded by 1 for imprecision. 95% confidence interval for the pooled estimate of probiotic eJect includes a significant beneficial eJect as well as the possibility that the
duration of diarrhoea may be longer in people receiving probiotics.




































































Cochrane Database of Systematic Reviews
B A C K G R O U N D
Probiotics are recommended by some authorities for treatment
of acute infectious diarrhoea, but the evidence base is limited.
We updated our previous review (Allen 2010), to re-evaluate the
evidence for their use.
Description of the condition
Diarrhoea is defined by the World Health Organization (WHO) as
three or more loose or watery stools (taking the shape of the
container) in a 24-hour period. Diarrhoea is classified as acute if the
illness started less than 14 days previously, and as persistent if the
episode has lasted 14 days or longer (Anonymous 1988). Normal
infants who are exclusively breast-fed may pass loose, "pasty"
stools frequently. For this group, the definition is usually based on
what the mother considers to be diarrhoea (WHO 1990). Infectious
diarrhoea is an episode of diarrhoea that is caused by an infectious
agent.
Although mortality due to diarrhoea fell by more than 30% between
2000 and 2015, diarrhoea accounted for 526,000 under five deaths
in 2015 and was the second leading cause of death in children aged
one to 59 months (Liu 2016a). Mortality rates amongst children have
decreased despite low global usage of oral rehydration solution
(ORS) and zinc for acute diarrhoea, with 43% of children globally
receiving ORS between 2011 and 2016, and only an additional 9%
receiving ORS plus zinc within the same period (UNICEF 2018). In
industrialized countries, the trend is quite diJerent, with deaths
from infectious diarrhoea occurring mainly among the elderly
(Savarino 1993). The incidence of childhood diarrhoea has seen a
less promising decline (Das 2014). For children under five in low-
and middle-income countries, diarrhoea incidence declined from
3.4 episodes per child per year to 2.9 episodes between 1990 and
2010 (Fischer-Walker 2012), and diarrhoea still accounts for a large
proportion of hospital admissions (Das 2014).
More than 20 viruses, bacteria, and parasites are associated
with acute diarrhoea (Gadewar 2005). The 2013 Global Enteric
Multicenter Study (GEMS) and its subsequent reanalysis in 2016
identified six pathogen groups responsible for 77.8% of moderate
to severe diarrhoeal episodes in children under five in countries
in Africa and Asia: the bacteria Shigella spp, Campylobacter spp,
and heat-stable enterotoxin-producing Escherichia coli (ST-ETEC);
the viruses rotavirus and adenovirus 40/41; and the parasite
Cryptosporidium spp (KotloJ 2013; Liu 2016b). Although Shigella
spp was the dominant pathogen associated with dysentery, it also
accounted for a large burden of watery diarrhoea (Liu 2016b).
In an extension of the GEMS study, the spectrum of pathogens
causing less severe diarrhoea in under five children was similar
to that causing more severe episodes, with norovirus GII also
identified as an important pathogen in children under one year
(KotloJ 2019). Acute diarrhoea is frequent among travellers, in
whom enterotoxigenic E coli is particularly common (Black 1986).
In practice, most episodes of acute diarrhoea that are assumed to
be caused by an infectious agent are treated without identification
of the causative agent. WHO guidelines base treatment on
clinical presentation (level of dehydration, malnutrition) and
recommend additional management only for dysentery or
suspected cholera (WHO 2005). Similarly, the European Society for
Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN)
recommends that, although some clinical features vary with
diJerent infectious diarrhoeal aetiologies, children with acute
gastroenteritis do not routinely need to undergo investigation for
the causative pathogen (Guarino 2014). Current WHO guidelines
for children in low- and middle-income countries recommend that
in addition to fluid therapy for children with acute non-bloody
diarrhoea without severe dehydration, zinc supplementation
should be given (WHO 2005).
Description of the intervention
The aims of treatment are to prevent or reverse dehydration,
shorten the duration of illness (important for preventing
progression to persistent diarrhoea, which is associated with
adverse outcomes such as malnutrition), and reduce the period
that a person is infectious. Available treatment options include
oral and parenteral rehydration, zinc supplementation in children,
antibiotics, adsorbents such as smectite, and probiotics.
For treatment of acute diarrhoea, Cochrane Reviews have
examined ORS versus IV fluid (Hartling 2006), zinc supplementation
(Lazzerini 2016), smectite (Pérez-Gaxiola 2018), rice-based
oral rehydration solution (Fontaine 1998), polymer-based oral
rehydration solution (Gregorio 2016), and antiemetics in children
and adolescents (Fedorowicz 2011). This review examines
probiotics.
A recent expert panel created by the International Scientific
Association for Probiotics and Prebiotics (ISAPP) recommended
retaining the Food and Agriculture Organization of the
United Nations (FAO)/WHO definition for probiotics as “live
microorganisms that, when administered in adequate amounts,
confer a health benefit on the host” (Hill 2014). Common probiotics
include the Lactobacillus and Bifidobacterium species of bacteria
and the Saccharomyces species of yeast (Williams 2010).
How the intervention might work
Probiotics may improve infectious diarrhoea through multiple
mechanisms including overt anti-pathogen eJects (competition for
nutrients and binding sites within the gut, producing substances
such as bacteriocins and organic acids, and neutralizing bacterial
toxins) and general eJects such as stimulation of mucosal
immune responses and reduction of intestinal inflammation and
permeability (Guarner 2012; Halloran 2019; Surendran Nair 2017).
Relevant to pooling results of diJerent probiotic organisms, the
ISAPP expert panel proposes that there may be "core" mechanisms,
such as competitive exclusion of pathogens, that are common to
many probiotics, whilst mechanisms such as immunological eJects
are likely to be species or strain specific. The panel concludes that a
specific strain and dose must be defined before a health claim can
be made for a probiotic (Hill 2014). Therefore, reliable identification
of organisms at the strain level is necessary for clinical studies.
A 2011 systematic review on the safety of probiotics, based on
their use in clinical trials, concluded that no increase in adverse
outcomes was seen in probiotic groups (Hempel 2011). However,
case studies suggest that particularly vulnerable patients may be at
increased risk for adverse events, mostly gastrointestinal in nature,
such as diarrhoea, vomiting, and constipation. An overview of
specific populations studied in clinical trials identified one case of
invasive disease in an immunocompromised patient and noted that
better documentation on the safety of probiotics is needed (Doron
2015). Concerns regarding the safety of probiotics are especially
Probiotics for treating acute infectious diarrhoea (Review)
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pertinent for highly vulnerable patients such as children receiving
intensive care (Yelin 2019), as well as adults with severe acute
pancreatitis (Besselink 2008).
Why it is important to do this review
Findings from the previous version of this Cochrane Review
show that when probiotics were used, the mean duration of
diarrhoea was shorter, and fewer children had diarrhoea lasting
four days or longer. However, due to substantive heterogeneity of
eJect size between studies, evidence was insuJicient to show a
specific probiotic regimen as more eJective than another (Allen
2010). Since the 2010 review, probiotics for the treatment of
acute infectious diarrhoea have been evaluated in many more
randomized controlled trials. However, in spite of this increased
evidence base, recent systematic reviews have not identified a
specific probiotic preparation for use in clinical practice. In a
meta-analysis, probiotics reduced the duration of diarrhoea among
children (weighted mean diJerence -0.67 days, 95% confidence
interval (CI) -0.95 to -0.38; Salari 2012). In children from middle-
and high-income countries, probiotics reduced diarrhoea duration
by 14% (95% CI 3.8% to 24.2%) and stool frequency on day two
by 13.1% (95% CI 0.8% to 25.3%; Applegate 2013). In both meta-
analyses, evidence was insuJicient to support a specific strain or
regimen. Finally, two recent studies each recruited a large number
of participants, potentially making a significant contribution to the
evidence base (Freedman 2018a; Schnadower 2018).
The 4th Triennial Yale/Harvard Workshop on Probiotic
Recommendations considered that there was a good level
of evidence to recommend Lactobacillus GG, Saccharomyces
boulardii, and Lactobacillus reuteri SD2112 for treatment of
infectious childhood diarrhoea (Floch 2015). In contrast, the
European Society of Paediatric Gastroenterology and Nutrition
strongly recommended two strains - Saccharomyces boulardii and
Lactobacillus rhamnosus GG - but with support of only low-quality
evidence (Guarino 2015). Consistent with findings of the meta-
analysis, a review of six guidelines on the use of probiotics in acute
infectious diarrhoea in children highlighted marked variability
in the recommendations for which probiotic strain and dose
should be used in clinical practice (Guarino 2015). A recent clinical
practice guideline based on a systematic review by the American
Gastroenterological Association recommended that probiotics
should not be used for treatment of acute infectious diarrhoea
in children in the USA and Canada (conditional recommendation
based on moderate-quality evidence; Su 2020).
We intended to assess whether the addition of trials
undertaken since our previous review would reduce the statistical
heterogeneity between studies, and whether there was greater
evidence for any specific probiotic preparation. We also aimed to
identify evidence gaps to ensure that further research informs the
development of clinical guidelines.
O B J E C T I V E S
To assess the eJects of probiotics in proven or presumed acute
infectious diarrhoea.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials reporting the eJects of probiotic(s)
on acute infectious diarrhoea. To maximize the use of available
data, we included participants of all ages and non-blinded (open)
studies; however, to keep results as robust as possible, we did not
include quasi-randomized and unpublished studies. We also did
not include studies of probiotics in acute diarrhoea that did not
report clinical outcomes (e.g. eJect on rotavirus shedding in stools).
Types of participants
Adults and children with acute diarrhoea (duration < 14 days) that
was proven or presumed to be caused by an infectious agent. To
maximize the relevance of our findings for clinical practice, we
included studies in which participants with acute diarrhoea had
received antibiotics.
We excluded studies on diarrhoea known or thought to have other




Specific probiotic preparations (single strains and combinations of
organisms).
Excluded was yogurt or other fermented foods in which specific
probiotic organisms were not identified and killed probiotics.
Control
Placebo or no probiotic.
Intervention and control arms to be otherwise treated identically in
relation to other treatments and drugs including zinc.
Types of outcome measures
In view of recent expert recommendations for a core outcome
measurement set for acute diarrhoea in children (Karas 2016), we
revised our outcomes to include the number of people hospitalized
in community studies and the duration of hospitalization in
inpatient studies as secondary outcomes. The Expert Panel also
recommended degree of dehydration as an outcome measure.
However, we did not include this outcome as it was rarely reported
in trials included in our previous review (Allen 2010). We included
diarrhoea lasting 14 days or longer to examine the proportion of
patients progressing to persistent diarrhoea (Walker-Smith 1993).
We included studies that reported one or more of the following
primary or secondary outcomes.
Primary outcomes
• Diarrhoea lasting ≥ 48 hours
• Duration of diarrhoea
Secondary outcomes
• Numbers of people hospitalized in community studies
• Duration of hospitalization in inpatient studies
Probiotics for treating acute infectious diarrhoea (Review)
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• Diarrhoea lasting ≥ 14 days
Adverse events
• Incidence of adverse events (serious and non-serious)
Search methods for identification of studies
Electronic searches
We attempted to identify all relevant studies regardless of
language.
We searched the Cochrane Infectious Diseases Group's trials
register using the following search terms: diarrhoea/; diarr
$(tw); diarrhoea(tw); probiotic(tw); Lactobacill$(tw); Lactococc
$(tw); Bifidobacter$(tw); Enterococc$(tw); Streptococc$(tw);
Saccharomyces(tw). Full details of the methods of the Cochrane
Infectious Diseases Group and the journals handsearched are
published in the Cochrane Library in the section on 'Collaborative
Review Groups'.
We searched the Cochrane Controlled Trials Register, published
on the Cochrane Library, using the following search terms:
diarrhea/; diarr$(tw); diarhea(tw); probiotic(tw); Lactobacill$(tw);
Lactococc$(tw); Bifidobacter$(tw); Enterococc$(tw); Streptococc
$(tw); Saccharomyces(tw).
We searched MEDLINE and Embase using the search strategy
defined by Cochrane (Clarke 2003), and we used the following
search terms: diarrhea/; diarr$(tw); diarhea(tw); probiotic(tw);
Lactobacill$(tw); Lactococc$(tw); Bifidobacter$(tw); Enterococc
$(tw); Streptococc$(tw); Saccharomyces(tw).
The detailed search strategy is shown in Appendix 1.
Searching other resources
In preparation for the original review (Allen 2003), we contacted
organizations and individuals working in the field, as well
as the following pharmaceutical companies that manufacture
probiotic agents, to help identify additional published trials:
BioGaia Biologics, Lund, Sweden; Nestle Foundation, Lausanne,
Switzerland; Probiotics International Ltd, Somerset, UK; Ross
Products Division of Abbott Laboratories, Columbus, Ohio, USA;
and Yakult, London, UK. We did not re-contact individuals or
companies for this update.
We also drew on existing reviews of this topic and checked the
citations of all trials identified by the above methods.
Data collection and analysis
SC, AD, and SA independently extracted data using standard forms.
The number of participants recruited and the number for whom
outcome data were reported were extracted and included in the
Characteristics of included studies table.
In keeping with the ISAPP understanding of potential beneficial
eJects that are common to all probiotics (Hill 2014), the primary
analysis pooled the findings from all eligible studies of probiotics
in acute diarrhoea. We pooled data from studies that used
comparable outcome measures. We reported the proportion of
participants for whom outcome data were available in a ’Risk of
bias’ table for each study.
Selection of studies
Two review authors independently reviewed the titles of articles
and, when available, abstracts generated by the search to identify
potentially relevant studies. All articles that could meet the
inclusion criteria as identified by either of the review authors
were selected and the full article reviewed. Eligibility was assessed
independently by these two people using a standard form and
based on the information presented in the article. We planned to
contact trial authors if eligibility was unclear. Discrepancies among
reviewers' eligibility assessments were resolved by discussion. Trial
reports were scrutinized to ensure that multiple publications from
the same trial were included only once. We have listed excluded
studies and the reasons for their exclusion in the Characteristics of
excluded studies table.
Data extraction and management
Two review authors independently extracted data using standard
forms and compared the results. Key data items were participants'
characteristics (nutrition and hydration status), location (countries
classified according to region and mortality stratum, reflecting
the level of child and adult mortality; WHO 2001), aetiology
and duration of diarrhoea, details of probiotic organism(s),
management as inpatients versus outpatients; and the outcome
measures listed above. The number of participants recruited and
the number for whom outcome data were reported were extracted,
and details of studies were entered into the Characteristics of
included studies table.
For dichotomous outcomes, we extracted the number of
participants experiencing the event and the total number of
participants in each intervention group. For continuous outcomes,
we extracted arithmetic means, standard deviations (SDs), and
numbers of participants in each intervention group. We calculated
mean and standard deviation from median and interquartile range
for non-skewed data.
We also reported in the Characteristics of included studies table
findings of trials that presented data that could not be included
in pooled analyses (e.g. median and interquartile range (IQR) from
skewed data) and outcomes other than primary and secondary
outcomes.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias for
each trial using the Cochrane ’Risk of bias’ assessment tool (Higgins
2012). Risk of bias was based on primary outcomes and was
categorized as low (adequate measures taken), high (inadequate
measures taken), or unclear.
Risk of bias was assessed according to generation of allocation
sequence, allocation concealment, blinding of participants,
blinding of outcome assessment, loss to follow-up, and outcome
reporting, and was recorded on a standard form.
We considered the generation of allocation sequence to be
adequate if the study authors stated that they used a method
resulting in unpredictable sequences (such as a random numbers
table or list or computer-generated random numbers), unclear if
a trial was stated to be randomized but no further information
was provided, and inadequate when allocation could be related to
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prognosis and therefore was at risk of selection bias (e.g. based on
date of birth or date of admission to hospital).
We considered allocation concealment to be adequate if
assignment to arms of the study could not be predicted by
the investigators or participants (e.g. central randomization or
numbered, identical drug containers), unclear if the method used
was not described, and inadequate if a method such as alternation
was used by which the allocation of participants could be predicted.
We considered blinding of participants to be adequate when an
identical placebo was used and recruitment to intervention or
control arms was not known by the participant, unclear if methods
of blinding were not described adequately, and inadequate when
blinding was not used.
We considered blinding of outcome assessment to be adequate
when recruitment to intervention or control arms was not known
by the investigator, unclear if methods of blinding or assessors were
not described adequately, and inadequate when blinding was not
used or when study authors stated that unblinding had occurred.
We considered loss to follow-up to be adequate when study
endpoints were reported in both intervention and control groups
for 90% or more of participants enrolled at the beginning,
inadequate when follow-up was less than 90% in either group, and
unclear when the number of participants recruited at the beginning
of the study and/or the number of participants who completed the
study was not clear.
We considered outcome reporting to be adequate if all outcomes
specified in the methods were reported fully in the results;
inadequate if any intended outcomes were not reported or were
not reported adequately, or if reported outcomes were not pre-
specified; and unclear if it was not possible to judge based on the
information given.
An independent person resolved disagreements regarding the
assessment of risk of bias.
Measures of treatment e;ect
For the number of participants with diarrhoea lasting ≥ 48 hours,
the number of people hospitalized in community studies, and the
number with diarrhoea lasting 14 days or longer, we calculated
a pooled estimate of the risk ratio (RR) among probiotic and
non-probiotic groups. For duration of diarrhoea and duration of
hospitalization in inpatient studies, we achieved a pooled estimate
of treatment eJect by calculating the weighted mean diJerence
between groups.
Unit of analysis issues
For trials with multiple treatment groups but a single control arm
(no additional treatment or placebo), we selected the treatment
group that was most relevant to contributing to the evidence base
for use of a specific probiotic preparation. All intervention groups
are detailed in the Characteristics of included studies table.
Dealing with missing data
We performed intention-to-treat analysis of available case data
with no imputation of missing values; we excluded data if reported
only from a per-protocol analysis. In studies reporting continuous
outcomes, if required, we calculated SDs from 95% CIs and
standard errors.
Assessment of heterogeneity
We inspected forest plots to detect non-overlapping CIs, applied
the Chi2 test and implemented the I2 statistic (with value ≥ 50%) to
assess heterogeneity in findings.
Assessment of reporting biases
We inspected funnel plots and undertook statistical analysis for the
primary outcomes to assess publication bias.
Data synthesis
For analysis according to the intention-to-treat principle using
an available case analysis approach, we planned to use fixed-
eJect analysis unless there was significant heterogeneity (P < 0.1)
for outcomes across studies assessed by the Chi2 test, or when
weighting was high for a small number of studies, in which case a
random-eJects model would be used.
Network meta-analysis (NMA)
NMA can compare the relative eJicacy of probiotics that have
been tested against placebo in diJerent trials but without head-
to-head comparisons. We planned to undertake NMA if we found
suJicient trials and homogeneity in findings for specific probiotic
preparations.
Certainty of the evidence
We assessed the certainty of evidence using the GRADE approach
(Guyatt 2011). We rated the certainty of evidence for primary and
secondary outcomes as:
• high: we are very confident that the true eJect lies close to that
of the estimate of the eJect;
• moderate: we are moderately confident in the eJect estimate.
The true eJect is likely to be close to the estimate of the eJect;
• low: our confidence in the eJect estimate is limited. The true
eJect may be substantially diJerent from the estimate of the
eJect; or
• very low: we have very little confidence in the eJect estimate.
The true eJect is likely to be substantially diJerent from the
estimate of eJect.
We downgraded the certainty of evidence if we noted significant
risk of bias, imprecision, inconsistency, indirectness, and
publication bias. We reported our overall assessment of the
certainty of evidence for primary and secondary outcomes
according to GRADE criteria in Summary of findings 1.
Subgroup analysis and investigation of heterogeneity
We undertook pre-planned subgroup analysis to explore the
eJects of clinical diversity on heterogeneity in results between
studies and to re-assess the evidence base for specific probiotic
preparations to better inform clinical practice. We also undertook
subgroup analysis according to specific cause of diarrhoea when
identified, age of participants, WHO region, mortality stratum to
attempt to capture diJerences in major causes of diarrhoea, host
characteristics such as nutritional/immune status, and exposure to
infections according to availability of clean water and sanitation.
Exposure to antibiotics may prolong diarrhoea duration or modify
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the eJect of the probiotic; therefore, subgroup analysis also
considered antibiotic exposure. Finally, to date, no reviews have
assessed the eJects of probiotics for treatment of acute infectious
diarrhoea when zinc is also provided; therefore, we performed a
subgroup analysis of studies that also provided zinc.
We conducted pre-planned subgroup analyses for the primary
outcomes according to the following variables when there were five
or more studies in each subgroup.
• Strain(s) of probiotic organism.
• Major causes of diarrhoea as identified in children in the
GEMS multi-country study in Africa and Asia: Shigella spp,
Campylobacter spp, heat-stable enterotoxin-producing E coli
(ST-ETEC), rotavirus, adenovirus 40/41, and Cryptosporidium spp
(Liu 2016b), as well as any additional pathogens that were
reported such as norovirus.
• Age (0 to 5 years, 6 to 17 years, 18 to 64 years, 65 years plus).
• Severity of diarrhoeal illness according to whether participants
were managed as inpatients versus outpatients.
• Countries where studies were conducted classified according to
WHO region (Africa (Afr), Americas (Amr), Eastern Mediterranean
(Emr), Europe (Eur), South-East Asia (Sear), and Western Pacific
(Wpr)) and country mortality stratum (A - very low child
mortality, low adult mortality; B - low child mortality, low adult
mortality; C - low child mortality, high adult mortality; D - high
child mortality, high adult mortality; or E - high child mortality,
very high adult mortality; WHO 2001).
• Exposure to antibiotics.
• Treatment of children with zinc.
We also conducted post hoc subgroup analysis according to
publication decade, trial registration, and study setting to further
investigate heterogeneity.
Sensitivity analysis
To investigate the robustness of findings, we conducted sensitivity
analyses according to each of the six criteria of trial methodological
quality (as part of the GRADE approach; GRADEpro GDT 2014) for
the two primary outcomes. Sensitivity analysis was conducted in
the subset of studies that were scored at low risk of bias for each of
these criteria in turn and also in studies for which risk of bias was
rated as low for all six parameters.
R E S U L T S
Description of studies
Results of the search
Our search identified 192 potentially relevant studies published
since the 2010 review, 30 of which met the inclusion criteria. Of
the 63 studies included in the 2010 review, 46 met the updated
inclusion criteria. Six additional studies were identified through
peer review (Figure 1). In total, 82 studies met the inclusion criteria
(Characteristics of included studies). Eligibility regarding inclusion
in this review was clear for all studies, and clarification from trial
authors was not required. No studies were cluster-randomized.
 
Figure 1.   Study flow diagram.
 
Eight studies were ongoing (search undertaken 17 December 2019;
Characteristics of ongoing studies).
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Included studies
Publication status
Of the 82 included studies, 17 were published in the 1980s and
1990s, 28 between 2000 and 2009, and 37 between 2010 and 2019.
Study locations
According to country mortality strata for children/adults (WHO
2001), 53 trials were undertaken in countries where both child
and adult mortality was classified as low or very low, and 26
where either child or adult mortality was high. Two international
studies recruited participants from countries crossing the mortality
strata (Guandalini 2000; Jasinski 2002), and Ritchie 2010 was
undertaken in Australia (very low child and low adult mortality)
but recruited Aboriginal children who commonly had comorbidities
such as pneumonia and malnutrition related to poverty and social
disadvantage in the top end of the Northern Territory. Therefore,
data from these three studies were not included in analysis
according to country mortality strata. A total of 58 studies were
conducted at a single centre; 22 recruited participants from 2 to
19 centres. The number of recruitment centres was unclear in two
studies (D'Apuzzo 1982; Dinleyici 2015a).
Participants
The 82 selected studies recruited a total of 12,127 participants,
including 11,526 children (age < 18 years) and 412 adults. In three
studies (189 participants), the exact ages of participants were
not clear or outcomes were not reported for children and adults
separately (Bruno 1983; Simadibrata 2013; Wunderlich 1989). A
total of 53 studies recruited inpatients, 11 recruited outpatients,
and 14 recruited both inpatients and outpatients. It is unclear in
four studies whether participants were inpatients or outpatients
(Billoo 2006; Cetina-Sauri 1994; D'Apuzzo 1982; Kowalska-Duplaga
1999). Hydration status of participants was reported in 54 studies;
25 studies included participants with severe dehydration, 27
included participants with mild or moderate dehydration, 1
excluded participants with dehydration, and 1 presented median
hydration scores but did not make clear whether any participants
with severe dehydration were included.
Although all studies recruited participants with acute diarrhoea,
the criteria for acute diarrhoea varied markedly among studies
(see Characteristics of included studies). Criteria used for stool
consistency included watery, loose(r), or liquid stools; semi-liquid
or semi-watery; increased fluidity; mucus-y; and non-formed,
taking the shape of the container or a combination of these terms.
The minimum number of stools per day was specified in 58 studies;
this ranged from one or more to five or more stools, with the most
commonly used criteria being three or more (35 studies) and four
or more (13 studies) stools in 24 hours. One study specified stool
frequency as at least twice normal frequency (Kurugol 2005), and in
another study, stool consistency was taken into account (Mao 2008).
The maximum duration of diarrhoea at recruitment was specified
in 43 studies and varied between 1 and 14 days. One study excluded
children with chronic diarrhoea but did not specify the duration
(Hochter 1990).
Criteria used for the end of the diarrhoeal episode were reported
in 58 studies and varied markedly. The most common were last
liquid, watery, or fluid stool and first normal stool. Many studies
used various criteria based on stool frequency and consistency
in a specified period (e.g. first formed stool if followed by two
consecutive non-watery stools, 12 hours without evacuation; Mao
2008). Four studies also included the resolution of associated
symptoms (e.g. fewer than two stools/d; formed, yellow/brown
stools without mucus; no abdominal pain, vomiting, or fever for the
whole day; D'Apuzzo 1982).
Twenty-seven studies were restricted to children with rotavirus
diarrhoea or reported relevant outcomes for a subgroup of children
with rotavirus diarrhoea (two study authors kindly provided
this information on request: Freedman 2018a and Szymanski
2019). Twelve studies did not exclude participants with bloody
diarrhoea, whereas 39 studies did exclude these participants.
It is unclear whether participants with bloody diarrhoea were
included in 31 studies. Thirty-seven studies excluded participants
who had received antibiotic treatment before recruitment, 12
included participants who had received antibiotic treatment before
recruitment, and this information was unclear in 33 studies.
No study specifically recruited or excluded travellers, and none
identified any participants as suJering from travellers' diarrhoea.
No study specifically recruited participants known to have HIV
infection, and no study stated HIV positivity as an exclusion
criterion, but many studies excluded participants with chronic
illness or immunosuppression, or both. Seven studies recruited
malnourished children only or included malnourished children.
Forty studies excluded children with severe malnutrition; 10 of
these also excluded children with moderate malnutrition.
Interventions
Many diJerent probiotics were tested. Most studies tested
preparations of lactic acid bacteria and bifidobacteria. Several
studies identified probiotic organisms only by species name
without specific identification details such as culture collection
number. Few studies undertook analyses to confirm the identity or
viability of the organism(s).
FiTy-seven studies tested a single organism, and 25 tested
combinations of two to eight organisms. The organisms most
commonly evaluated were S boulardii (21 studies), L casei strain GG
(15 studies), and L reuteri spp (7 studies, 4 of which tested L reuteri
DSM17938). Canani 2007 allocated children to one of five diJerent
probiotic regimens and compared outcomes with those of a single
control group. For the purposes of this review, we selected the L
casei GG group because several other studies tested this probiotic
and we wanted to maximize the data available for meta-analysis.
Similarly, Bhat 2018, Erdogan 2012, and Vidjeadevan 2018 allocated
children to one of two diJerent probiotic regimens and compared
outcomes with those of a single control group. For the purposes of
this review, we selected S boulardii as the most commonly studied
organism across the other included studies.
Three studies compared diJerent dosages (number of organisms)
of the same probiotic with a single control (Basu 2009; Mao 2008;
Shornikova 1997b). We selected the higher probiotic dose group for
inclusion in meta-analysis but included results from the lower dose
group in the Characteristics of included studies table. Freedman
2015 compared administration of a probiotic once daily and twice
daily to use of a single control, presenting results separately and
as a combined figure; the combined outcome was selected for
inclusion in the review. Overall, 15 studies used a higher dose of
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organisms (> 1010 colony-forming units (CFUs)/d), 39 used a lower
dose (≤ 1010 CFUs/d), and the dose was unclear in 27 studies.
As well as diJerences in doses or organisms, clinical variation
between studies was marked with wide variation in treatment
regimens according to timing of intervention, means of
administration, and duration of treatment. Probiotics were
administered directly to participants or were mixed with a variety
of fluids and foods. Although expressed breast milk was used
to administer probiotics in some studies, other studies excluded
exclusively breast-fed infants.
FiTy-four studies used a placebo in the no probiotic control group;
the remaining studies treated participants according to usual
clinical practice.
Risk of bias in included studies
Risk of bias varied considerably (see Characteristics of included
studies; Figure 2). Forty-one (50.0%) studies were considered low
risk for generation of the allocation sequence, 12 (14.6%) for
concealment of allocation, 36 (43.9%) for blinding of participants
and personnel, 30 (36.6%) for blinding of outcome assessment, 65
(79.3%) for loss to follow-up, and 71 (86.6%) for selective reporting
(Figure 3). Seven studies (8.5%) were at low risk for all of the six
methodological quality assessment parameters.
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Aggarwal 2014 + ? - - + +
Azim 2014 + ? - ? + +
Basu 2007 + + + + + +
Basu 2009 + + + + + +
Bhat 2018 ? ? - - + +
Bhatnagar 1998 + ? - ? + +
Billoo 2006 ? ? - ? + +
Boudraa 2001 ? ? - ? + +
Bruno 1981 ? ? ? ? + +
Bruno 1983 ? ? ? ? + +
Burande 2013 + ? - - + +
Burki 2017 ? - - ? - +
Buydens 1996 + ? + + - +
Canani 2007 + ? - + + +
Cetina-Sauri 1994 + ? ? ? ? ?
Chen 2010 + ? + + + +
Correa 2011 + ? + + + +
Costa-Ribeiro 2003 ? ? + ? + +
D'Apuzzo 1982 ? ? ? ? + +
Dalgic 2011 ? ? - ? + +
Das 2016 ? + ? ? + +
Dinleyici 2014 + ? - + + +
Dinleyici 2015a + ? - ? + +
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Figure 2.   (Continued)
Dinleyici 2014 + ? - + + +
Dinleyici 2015a + ? - ? + +
Dinleyici 2015b + ? - + + +
Dubey 2008 ? ? + ? + -
Dutta 2011 + + + + + +
El-Soud 2015 ? + ? ? + +
Erdogan 2012 ? ? - ? + +
Francavilla 2012 + ? + + + +
Freedman 2015 + + + + + +
Freedman 2018a + + + + + +
Guandalini 2000 ? ? + + - +
Guarino 1997 + ? - - + +
Hamid 2019 ? ? - - + +
Hegar 2015 + + + ? + +
Henker 2007a + ? + + + +
Henker 2008 + ? + + + +
Hernandez 1998 ? ? ? ? + -
Hochter 1990 ? ? ? ? + ?
Hong Chau 2018 + + + + + +
Huang 2014 + ? - - + +
Isolauri 1994 ? ? - ? + -
Jasinski 2002 - ? ? + + +
Javeed 2018 ? + ? ? + +
Khan 2017 ? ? ? ? + +
Kianifar 2009 + ? + + + -
Kowalska-Duplaga 1999 ? ? ? ? + +
Kowalska-Duplaga 2004 - - ? ? + ?
Kurugol 2005 ? ? + ? - +
Lee 2001 ? ? - ? + +
Maity 2019 + ? + + + +
Mao 2008 ? ? ? ? + +
Narayanappa 2008 ? ? ? ? + +
Nixon 2012 + ? + + - +
Ozkan 2007 ? ? + ? + +
Pant 1996 ? ? + + - +
Park 2017 ? ? ? ? + +
Phavichitr 2013 + ? + ? + +
Rafeey 2008a + ? - ? + ?
Raza 1995 ? ? + + + +
Rerksuppaphol 2010 + ? + + + +
Riaz 2012 + ? + ? + +
Ritchie 2010 + ? + + - +
Rosenfeldt 2002a ? ? ? ? - +
Rosenfeldt 2002b ? ? + ? - +
Sarkar 2005 + ? + + + +
Schnadower 2018 + + + + + +
Shornikova 1997a ? ? ? ? + +
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Schnadower 2018 + + + + + +
Shornikova 1997a ? ? ? ? + +
Shornikova 1997b ? ? - ? - +
Shornikova 1997c ? ? + ? + +
Simadibrata 2013 ? ? ? ? - +
Sirsat 2017 + ? - ? + +
Sudha 2019 + + ? + + +
Szymanski 2006 + ? + + + +
Szymanski 2019 + ? + + - +
Teran 2009 + ? - - - +
Urganci 2001 ? ? ? ? ? +
Vidjeadevan 2018 + ? + - + +
Villarruel 2007 + ? + + - +
Vivatvakin 2006 ? ? - - + +
Wunderlich 1989 ? ? + ? - -
Xie 2013 ? ? ? ? + +
 
 
Figure 3.   Risk of bias graph: review authors' assessments about each risk of bias item presented as percentages
across all included studies.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
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Low risk of bias Unclear risk of bias High risk of bias
 
E;ects of interventions
See: Summary of findings 1 Summary of findings table 1
Primary outcomes
We used random-eJects analysis because of marked statistical
heterogeneity in findings. The risk of diarrhoea lasting ≥ 48 hours
was reduced in people receiving a probiotic compared with controls
(36 trials/6053 participants; risk ratio (RR) 0.64, 95% confidence
interval (CI) 0.52 to 0.79; Analysis 1.1). Mean duration of diarrhoea
was also reduced in the probiotic group (56 trials/9138 participants;
mean diJerence (MD) 21.3 hours, 95% CI 15.7 to 26.9; Analysis 1.2).
However, heterogeneity between studies was very high for both
primary outcomes and this undermined confidence in estimates of
probiotic eJect.
A notable finding was that two recently conducted large trials
undertaken in children did not show a probiotic eJect for the
number of children with diarrhoea lasting ≥ 48 hours (Analysis 1.1)
or for mean duration of diarrhoea (Analysis 1.2; Freedman 2018a;
Schnadower 2018).
The funnel plots are suggestive of publication bias for diarrhoea
lasting ≥ 48 hours (Figure 4; Habord test; t = -4.57, P < 0.001) and
possibly also mean duration of diarrhoea (Figure 5; Egger’s test; t =
-3.33, P = 0.002).
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Figure 4.   Funnel plot of comparison: 1 Primary diarrhoea outcomes, outcome: 1.1 Diarrhoea lasting ≥ 48 hours.











Probiotics for treating acute infectious diarrhoea (Review)










Cochrane Database of Systematic Reviews
Figure 5.   Funnel plot of comparison: 1 Primary diarrhoea outcomes, outcome: 1.2 Mean duration of diarrhoea.










Below we explore the heterogeneity in relation to potential
subgroup eJects and in relation to risk of bias in the studies, taking
into account the likelihood of publication bias.
Secondary outcomes
Secondary outcomes were reported in fewer studies. As for primary
outcomes, random-eJects analysis was used for all analyses
because of marked statistical heterogeneity in findings or high
weighting attributed to a small number of studies.
In seven trials (2333 participants) of acute diarrhoea in the
community, probiotics did not reduce the risk of hospitalization
(RR 1.21, 95% CI 0.86 to 1.69) with consistency in findings
between studies (I2 = 0%; Analysis 2.1). In 24 inpatient trials
(4056 participants), duration of hospitalization was reduced in the
probiotic arm (MD 18.0 hours, 95% CI 8.8 to 27.3) but with marked
statistical heterogeneity (I2 = 95%; Analysis 2.2). In nine trials (2928
participants), probiotics did not reduce the risk of diarrhoea lasting
≥ 14 days (RR 0.49, 95% CI 0.16 to 1.53) with heterogeneity in
findings between studies (I2 = 60%; Analysis 2.3).
Exploration of heterogeneity
Strain(s) of probiotic organisms
Either or both of the two primary outcomes were reported in five or
more studies for three probiotic preparations.
The Lactobacillus casei group comprises the closely related species
L casei, L paracasei, and L rhamnosus, including L rhamnosus
GG, and it is diJicult to diJerentiate between these species (Hill
2018). Terminology varied between studies. Amongst studies that
specified strain GG, six studies (1557 participants) reported the
number of participants with diarrhoea lasting ≥ 48 hours (Analysis
3.1: subgroup 1) and 14 studies (3344 participants) reported mean
duration of diarrhoea (Analysis 3.2: subgroup 1). The eJects in these
analyses were similar to the main analysis of all probiotics, and
marked statistical heterogeneity persisted in both analyses.
The eJect estimate for diarrhoea lasting ≥ 48 hours among
participants taking S boulardii was similar to the main analysis
but was not statistically significant and findings show marked
heterogeneity (RR 0.70, 95% CI 0.37 to 1.33; 9 studies, 1823
participants; I2 = 99%; Analysis 3.1: subgroup 2). The reduction in
duration of diarrhoea was similar to that in the main analysis, and
marked statistical heterogeneity persisted (MD 24.6 hours, 95% CI
14.0 to 35.3; 11 studies, 1617 participants; I2 = 89%; Analysis 3.2:
subgroup 2).
In fewer studies, the eJect estimate for L reuteri in reducing the
duration of diarrhoea was similar to that in the main analysis but
with less heterogeneity across studies (6 studies/433 participants;
MD 22.8 hours, 95% CI 13.7 to 32.0; I2 = 48%; Analysis 3.2: subgroup
3). However, risk of bias was present in all of the included studies.
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Given the high degree of quantitative heterogeneity in studies that
evaluated the same probiotic organism, we did not proceed to NMA.
The identity and viability of probiotic organisms were evaluated by
bacteriology and molecular methods in seven studies (Freedman
2015; Freedman 2018a; Hong Chau 2018; Mao 2008; Rosenfeldt
2002a; Rosenfeldt 2002b; Schnadower 2018), and were evaluated
independently of the study team in two of these studies (Freedman
2015; Schnadower 2018). Hegar 2015 reported that stability of the
probiotic organisms at diJerent storage temperatures had been
confirmed. Stools were tested for probiotic organisms in eight
studies (Chen 2010; Isolauri 1994; Lee 2001; Rosenfeldt 2002a;
Rosenfeldt 2002b; Shornikova 1997b; Shornikova 1997c; Szymanski
2006). The identity and viability of the probiotic organisms were not
evaluated in 74 studies.
Diarrhoea pathogen
Rotavirus was the only infectious cause of diarrhoea for which
suJicient studies reported outcomes to consider meta-analysis.
In 20 studies (1414 participants, all of whom were children), the
reduction in duration of diarrhoea was similar to that in the main
analysis, and marked statistical heterogeneity between studies
persisted (MD 22.1 hours, 95% CI 14.2 to 29.9; I2 = 84%; Analysis 4.1).
Age of participants
For children younger than five years, the eJect estimate for
diarrhoea lasting ≥ 48 hours was lower than in the main analysis
(26 studies, 5033 children; RR 0.72, 95% CI 0.59 to 0.88) and marked
statistical heterogeneity persisted (I2 = 97%; Analysis 5.1: subgroup
1). The reduction in diarrhoea duration was similar to the main
analysis, and marked statistical heterogeneity persisted (45 studies,
6697 children; Analysis 5.2).
We were unable to extract data according to the other pre-specified
age groups; however, in fewer studies of adults (≥ 18 years; 5
studies, 393 participants), probiotics reduced the RR of diarrhoea
lasting ≥ 48 hours to a lesser degree than in the main analysis but
with consistency between studies (RR 0.62, 95% CI 0.54 to 0.71; I2 =
0%; Analysis 5.1: subgroup 2).
Severity of diarrhoea
Diarrhoea lasting ≥ 48 hours was reported in 21 studies (2354
participants) of participants who required admission and therefore
were likely to have more severe illness. The eJect estimate in these
trials (RR 0.62, 95% CI 0.52 to 0.74) was similar to all studies, and
marked heterogeneity in findings persisted (I2 = 75%; Analysis 6.1).
Mean duration of diarrhoea was reported in 36 inpatient studies
(5071 participants) and in 8 outpatient studies (828 participants).
The eJect estimate was similar in these two groups, and marked
heterogeneity was present in both analyses (I2 = 97% and 94%,
respectively; Analysis 6.2).
Country mortality stratum
For both diarrhoea lasting ≥ 48 hours and mean duration of
diarrhoea, eJect estimates were similar when studies were grouped
according to mortality stratum (Analysis 7.1; Analysis 7.2).
Geographical region
EJect estimates were also similar when studies were grouped
according to geographical region. Statistical heterogeneity
persisted in these analyses with the exception of studies done in the
Eur-A region (Analysis 8.1: subgroup 3; I2 = 27%).
Exposure to antibiotics
For both diarrhoea lasting ≥ 48 hours and mean duration
of diarrhoea, eJect estimates were similar in studies where
participants may have been exposed to antibiotics before
recruitment and marked statistical heterogeneity between studies
persisted (Analysis 9.1; Analysis 9.2).
Treatment of children with zinc
The eJect estimate for probiotics on the duration of diarrhoea in
children treated with zinc was similar to that in the main analysis,
and marked statistical heterogeneity persisted (Analysis 10.1).
Sensitivity analysis for primary outcomes
For both primary outcomes, we conducted sensitivity analysis
against each individual risk of bias, examining the eJect estimates
for low risk against each parameter. This did not explain the
heterogeneity (Analysis 11.1; Analysis 11.2).
When analysis was restricted to studies where all indicators of
risk of bias were low, there was no heterogeneity with consistent
estimates of null eJect in the two large studies meeting these
criteria for number of participants with diarrhoea lasting ≥ 48 hours
between study arms (RR 1.00, 95% CI 0.91 to 1.09; I2 = 0%; two trials,
1770 participants; Analysis 11.1: subgroup 7). Similarly, for trials
reporting mean duration of diarrhoea that were at low risk of bias
for all six indices of study quality, no diJerence was demonstrated
between intervention and control (MD 8.6 hours less, 95% CI 29.4
less to 12.1 hours more; 6 trials, 3058 participants). Heterogeneity
persisted (I2 = 97%; Analysis 11.2: subgroup 7).
Given the marked statistical heterogeneity in nearly all analyses
that was not explained by sensitivity analysis, we assessed in post
hoc analyses whether eJect estimates varied according to decade
of publication. The eJect estimate for diarrhoea lasting ≥ 48 hours
was similar according to decade of publication (Analysis 12.1),
and the diJerence between groups was of borderline statistical
significance in the most recent studies (from 2010; 15 trials/3972
participants; RR 0.78, 95% CI 0.63 to 0.98; Analysis 12.1; subgroup
4). For mean duration of diarrhoea, eJect estimates according
to decade of publication were also similar to the main analysis
(Analysis 12.2).
FiTeen studies were registered in a trial database. For both primary
outcomes, eJect estimates were similar to the main analysis
in these studies, and marked statistical heterogeneity persisted
(Analysis 13.1; Analysis 13.2).
In the light of the marked quantitative and qualitative
heterogeneity unexplained by subgroup analysis; the clear
evidence of publication bias; and the large, recent, well conducted
trials showing null eJect, we concluded that the most robust and
reliable analysis is for trials with low risk of bias in all parameters,
and this analysis we used in our summary of findings table.
Adverse events
FiTy studies reported that no adverse events (AEs) were attributed
to the probiotic(s), and two studies stated that no serious AEs (SAEs)
were attributed to the probiotic (Phavichitr 2013; Simadibrata
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2013). Javeed 2018 reported no deaths in either group. Khan 2017
commented that the probiotic was safe but did not present adverse
event data. Henker 2008 reported one participant with a mild
hypersensitivity reaction that was possibly related to E coli strain
Nissle 1917. Schnadower 2018 reported similar rates of adverse
events in the two groups, except that wheezing was more common
in children receiving L rhamnosus GG than in controls (5/472 versus
0/479 children; P = 0.03; borderline statistical significance in view
of multiple comparisons); SAEs occurred in a similar number of
children in each group. Freedman 2015 reported that AEs including
abdominal cramps and rash occurred in both groups but frequency
was higher in the control group; no SAEs occurred. Freedman 2018a
reported that the frequency of AEs was similar in the two groups;
no SAEs occurred in the probiotic group. Szymanski 2019 reported
a similar frequency of AEs in both groups; no SAEs occurred. The
remaining 17 studies did not report on adverse events.
D I S C U S S I O N
Summary of main results
This review included 82 studies with a total of 12,127 participants.
Because of marked heterogeneity in the pooled analyses and
high or unclear risk of bias in many studies, we report the main
comparisons in studies at low risk of bias in the 'Summary of
findings' table. In these studies at low risk of bias, we consider that
there was moderate certainty evidence that probiotics probably
make little or no diJerence to the risk of diarrhoea lasting 48 hours
or more. We cannot make a reliable estimate of the eJicacy of
probiotics in reducing the duration of diarrhoea because certainty
of evidence was very low.
We do not know whether or not probiotics reduce the duration
of hospitalization or diarrhoea lasting 14 or more days due to
marked statistical heterogeneity between studies. Probiotics did
not prevent hospitalization with acute diarrhoea, with consistency
in study findings.
Probiotics were not associated with adverse events, but reporting
was limited.
Overall completeness and applicability of evidence
The included trials were undertaken in many diJerent countries
from diJerent world regions and, therefore, were adequate
to address the main research question. However, most study
participants were children, and available data for adults are sparse.
Despite the addition of 36 studies undertaken since our previous
review (Allen 2010), there was marked heterogeneity between
studies. EJect sizes were similar and heterogeneity persisted in
our pre-planned subgroup analyses according to probiotic strain,
diarrhoea caused by rotavirus, age, severity of illness, country
mortality stratum or region, exposure to antibiotics, treatment with
zinc in children, and risk of bias. Between-study heterogeneity may
be due to other diJerences between trials such as the definitions
used for "acute diarrhoea" and "the end of the diarrhoeal episode."
Also great variability in reported outcomes is evident, which limited
data available for meta-analysis for the primary outcomes. Further
development of core outcome sets for clinical trials in acute
diarrhoea (e.g. to include patient/public perspectives and adult
patients), which also include criteria for diagnosis of gastroenteritis
(Karas 2016), should help to ensure greater consistency in trial
methods and reporting outcomes that will strengthen the evidence
base for the treatment of diarrhoea.
The recent 2013 Global Enteric Multicenter Study (GEMS) in
children in sub-Saharan Africa and south Asia has highlighted the
multiple infectious agents responsible for acute diarrhoea and the
importance of bacteria as common diarrhoeal pathogens (KotloJ
2013; KotloJ 2019; Liu 2016b). Although many studies included
participants with bacterial diarrhoea or bloody stools, too few
studies reported outcomes for these participants for meta-analysis
to be performed. DiJerences in causes of diarrhoea likely account
for some of the statistical heterogeneity between studies and have
likely changed over time, for example, as a result of immunization
programmes such as those for rotavirus. Future studies should
determine main infectious causes of diarrhoea and should archive
samples for analysis as enteric diagnostic technology evolves.
Confirmation of probiotic identity, viability, and number of
organisms by quantitative culture and molecular methods was
done in only eight trials but should be standard in research studies
(Rijkers 2010; Wolvers 2010).
Although post hoc analysis limited to registered trials did not
significantly modify the eJect estimate, the absence of published
trial protocols for most trials limited our assessment of bias due to
selective outcome reporting. In addition, we found that publication
bias may have limited the research studies included in this review;
a recent systematic review of probiotics in the management of
constipation also reported evidence of publication bias (Harris
2019). However, a recent review found no evidence that the source
of funding for trials of probiotics in diarrhoea had aJected trial
results (Saa 2019).
Although most studies reported absence of adverse events due
to probiotics, few studies provided a description of the methods
used for detecting and classifying adverse events and few reported
specific data on adverse events. This is consistent with poor adverse
event reporting in probiotic trials in general and highlights the need
for improved practice in reporting of harms in probiotic studies
especially in vulnerable people (Bafeta 2018; Besselink 2008; Yelin
2019).
Certainty of the evidence
Details of downgrading for GRADE for the few trials at low risk of
bias are contained in Summary of findings 1. For diarrhoea lasting
48 hours or longer, certainty of evidence was moderate due to
indirectness resulting from the inclusion of only two trials, both of
which were conducted in high-income countries, and evaluation
of only two probiotics. For mean duration of diarrhoea, certainty
of evidence was very low due to marked variability in findings
between studies and imprecision in the eJect estimate.
Among all trials included in this review, there was evidence of
publication bias in trials reporting numbers of participants with
diarrhoea lasting 48 hours or longer, with a greater number of
smaller studies reporting a positive eJect of probiotics (Figure 4).
Although less clear, this may have also been the case for studies
reporting mean duration of diarrhoea (Figure 5).
There was great variability in the methodological quality of trials,
but this did not appear to have contributed to heterogeneity.
Heterogeneity was not resolved in sensitivity analysis according
to individual parameters of risk of bias nor in subgroup analysis
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of trials where risk of bias for all six parameters was low.
The importance of careful assessment of risk of bias in studies
included in meta-analyses has been highlighted recently (Harris
2019; Schnadower 2019a). Because of the persistence of marked
statistical heterogeneity in the subgroup analyses, we also
analysed primary outcomes according to decade of publication
(Analysis 12.1; Analysis 12.2) and whether or not trials had been
registered in a trial database (Analysis 13.1; Analysis 13.2; Kaplan
2015). However, there were no clear diJerences in eJect sizes in
these analyses, and heterogeneity persisted.
Based on our criterion of five or more trials reporting the
primary outcomes, we pooled data for Lactobacillus rhamnosus
GG, Saccharomyces boulardii, and Lactobacillus reuteri. Pooled
estimates of probiotic eJect for these strains were similar to our
overall findings, and statistical heterogeneity persisted for the
first two strains. Of note, a recent large, well-conducted trial of L
rhamnosus GG in children in the USA did not observe a probiotic
eJect (Schnadower 2018). Trials that evaluated L reuteri had less
heterogeneity but risk of bias was present in all included studies.
In keeping with clinical management, diarrhoea aetiology was
determined in only a minority of studies and meta-analysis was
possible only for rotavirus diarrhoea. All of these studies were done
in children. For this diarrhoeal pathogen, the eJects of probiotics
were similar to those in the main analyses, but again with marked
statistical heterogeneity and risk of bias in many studies.
Although there was greater consistency among trials of adults (I2 =
0%), only a few of these trials were included in this analysis and risk
of bias was present in many.
We categorized trials according to World Heath Organization (WHO)
world region and country mortality stratum (WHO 2001) in an
attempt to capture regional diJerences in diarrhoea aetiology,
exposure to infection, and host characteristics. Heterogeneity
persisted in these analyses with the exception of studies done in
the Eur-A region, where consistency was greater when diarrhoea
lasting 48 hours or longer was reported (I2 = 27%) but marked
heterogeneity persisted for the mean duration of diarrhoea (I2 =
78%), and risk of bias was present in many of the included studies
for both outcomes.
Marked statistical heterogeneity and presence of risk of bias were
also evident in studies that included people exposed to antibiotics
and in the few studies of children treated with zinc.
Agreements and disagreements with other studies or
reviews
Our previous review concluded that probiotics appeared to shorten
the duration of acute infectious diarrhoea although there was
insuJicient evidence to recommend a specific probiotic regimen
(Allen 2010). In this update, the use of GRADE has highlighted
limitations in the evidence and we also found clear evidence of
publication bias. As a result, we limited our evaluation to trials at
low risk of bias. Analysis of these trials has changed our conclusion
as they do not provide evidence of probiotic eJicacy.
Other reviews on this topic have also reported marked statistical
heterogeneity and low certainty of evidence. A recent systematic
review and network meta-analysis of interventions for acute
diarrhoea in children reported high statistical heterogeneity for
duration of diarrhoea for L rhamnosus GG, S boulardii, and
other probiotics grouped together versus standard treatment and
certainty of evidence was graded as low or very low (Florez
2018). A recent update of a meta-analysis of L rhamnosus GG in
acute diarrhoea in children reported high statistical heterogeneity
between studies (Szajewska 2019a). Correspondence following
this review highlighted that the eJect of the probiotic was not
statistically significant when analysis was limited to studies at low
risk of bias (Schnadower 2019b), and that marked heterogeneity
persisted in these analyses (Szajewska 2019b). Similarly, marked
statistical heterogeneity in the duration of diarrhoea was reported
in another recent review of L rhamnosus GG in paediatric diarrhoea
(Li 2019).
A systematic review of L reuteri DSM 17938 for treating
acute gastroenteritis in children reported marked statistical
heterogeneity and very low certainty of evidence for both duration
of diarrhoea and duration of hospitalization (Patro-Gołab 2019).
Our findings regarding rotavirus diarrhoea in children are
consistent with a review that reported marked heterogeneity
between studies (Ahmadi 2015). A recent systematic review that
summarised trials of S boulardii in children with rotavirus diarrhoea
(n = 548 children; five RCTs) reported a modest reduction in
diarrhoea duration (MD –0.57 days; 95% CI –0.83 to –0.30)
with consistency in findings (I2 = 0%) and moderate certainty
evidence (Padayachee 2019). However, small sample sizes, unclear
and inconsistent quality of methodology, and possible reporting
bias prevented the authors from making a definitive conclusion
regarding the eJicacy of S boulardii and they emphasised the need
for further research.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Our findings do not support the use of probiotics for the treatment
of acute infectious diarrhoea. In analysis limited to trials evaluating
the same probiotic strain, there was marked heterogeneity in
findings and risk of bias in many of the included trials. Our findings
do not support recommendations for the use of specific probiotics
for acute infectious diarrhoea in children (Floch 2015; Guarino
2018; SniJen 2018). The challenge of selecting specific probiotics
for particular patient groups is highlighted by two well-conducted
recent studies that reported negative results (Freedman 2018a;
Schnadower 2018).
Implications for research
Given the large number of studies already reported, the ways
further research will contribute significantly to the evidence base
that informs clinical practice needs careful consideration. The very
marked heterogeneity between studies in this and other reviews
argues against "core" properties shared by diJerent probiotics that
are eJective against diarrhoea due to many diJerent infectious
agents and its occurrence in diJerent populations and regions
(Hill 2014). This finding is consistent with the importance of
considering strain-specific eJects of probiotics. With the exception
of a recent trial in children in the USA that did not find Lactobacillus
rhamnosus GG to be eJective (Schnadower 2018), large-scale, high-
quality studies that follow up on previously encouraging findings
of specific probiotics in specific populations have not been done.
Future studies should focus on probiotics that have evidence of
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possessing properties that address specific underlying pathogenic
mechanisms, which may be limited to specific infectious agents
and populations (Brüssow 2019; Florez 2018; Glanville 2015).
Marked variability in study design likely contributed to the
high level of statistical heterogeneity. Future studies should use
standardized definitions for acute diarrhoea and resolution of the
illness, determine diarrhoea aetiology, and confirm the identity of
the probiotic being tested and the number of viable organisms at
the point of use.
Finally, we identified evidence of publication bias. EJect estimates
may vary according to whether or not trials are registered (Kaplan
2015). To improve the reliability of findings, future systematic
reviews of probiotics should consider including only trials that have
been registered in a clinical trials database.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Open-label randomized controlled trial; 1 centre
Duration: 18 months (October 2010 to March 2012)
Participants Inclusion criteria: aged 6 months to 5 years; presented with acute diarrhoea (less than 7 days' duration)
to the outpatient department (OPD) or to paediatric emergency services
Exclusion criteria: severe malnutrition (weight for height < 3 SD of WHO charts); dysentery (presence
of visible blood in stools); clinical evidence of coexisting acute systemic illness (e.g. meningitis, sepsis,
pneumonia); clinical evidence of chronic disease (e.g. chronic gastrointestinal disease, chronic liver
disease, chronic renal disease, nephrotic syndrome); use of probiotics in the preceding 3 weeks; use of
antibiotics for current episode of diarrhoea
Number completing the study: 87/100* (87%) in the probiotic group (6 non-contactable, 6 discontinued
intervention); 88/100* (88%) in the control group (10 non-contactable; 3 discontinued intervention). All
randomized patients analysed for primary outcomes. *Numbers lost to follow-up do not add up in the
paper
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Interventions • Lyophilized Lactobacillus casei, strain GG; contents of 1 capsule (Culturelle Probiotic, Amerifit, Pitts-
burgh, PA, USA) containing 10 billion CFUs/d, dissolved in milk, for 5 days
Timing of start of administration not stated. All participants were given reduced osmolarity ORS and
zinc sulphate dispersible tablets 20 mg/d for 14 days and continued feeding. Severe dehydration was
managed with IV Ringer's lactate as per WHO guidelines
Outcomes • Duration of diarrhoea (time in hours from enrolment to the last abnormal (loose or liquid) stool)
• Time to change in stool consistency (evaluated on a Likert scale with improvement recorded when
there was improvement by at least 1 score)
• Last abnormal stool (when child passed normal stool or no stool for next 24 hours)
• Number of loose stools per day during the entire episode
• Duration of vomiting
• Duration of hospital stay
• Adverse effects
No adverse events were attributed to the probiotic
Notes Study location: India (high child and adult mortality)
Cause of diarrhoea: rotavirus identified in 21/85 (24.7%) probiotic and 20/85 (23.5%) control. Bloody di-
arrhoea excluded
Nutritional status: weight for height 86.07% (± 8.44) probiotic and 84.25% (± 10.80) control. Severe mal-
nutrition excluded (weight for height < 3 SD of WHO charts)
Hydration status: no dehydration 70 (70%) probiotic, 64 (64%) control; some dehydration 28 (28%) pro-
biotic, 31 (31%) control; severe dehydration 2 (2%) probiotic, 5 (5%) control
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomization
Allocation concealment
(selection bias)
Unclear risk Unclear method of allocation concealment. Open study – fixed block size may





High risk Open-label study
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Primary outcomes reported for > 90% in both groups
Selective reporting (re-
porting bias)
Low risk All pre-stated primary outcomes reported
Aggarwal 2014  (Continued)
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Study characteristics
Methods Randomized controlled trial; 1 centre
Duration: 7 months (April to October 2010)
Participants Inclusion criteria: children aged 1 to 5 years; acute diarrhoea with dehydration
Exclusion criteria: severe dehydration with danger signs as defined by WHO classification for dehydra-
tion assessment; grade 3 and 4 malnutrition as defined by modified Gomez classification; dysentery;
more than 2 episodes of diarrhoea in the past 2 months; any other coexisting acute systemic illness
Number completing the study: 45/45 in the probiotic group (100%); 45/45 in the control group (100%)
Interventions Saccharomyces boulardii, 250 mg twice daily for 5 days
Timing of start of intervention not stated
All participants were given oral/parenteral rehydration therapy and electrolyte replacement when
needed
Outcomes • Presence of vomiting
• Presence of fever
• Presence of dehydration
• Stool frequency
• Duration of hospitalization
No adverse events attributed to probiotic
Notes Study location: Pakistan (high child and adult mortality)
Causes of diarrhoea: dysentery excluded
Nutritional status: grade 3 and 4 malnutrition excluded (modified Gomez classification)
Hydration status: all participants had moderate dehydration
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)








High risk No placebo used
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Not stated
Azim 2014 
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Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: 1 year (January to December 2003)
Participants Inclusion criteria: inpatients; infants and children with ≥ 3 watery stools/d without visible blood or mu-
cus (duration not stated); < 10 white blood cells/high power field and no red cells, mucus flakes, or bac-
teria on stool microscopy; negative hanging drop preparation; negative bacterial stool culture
Exclusion criteria: systemic illness other than diarrhoea on admission; systemic complication of diar-
rhoea during hospital stay; failure to give informed consent
Number completing the study: 323/330 (97.9%) in the probiotic group (3 participants had electrolyte
imbalance, 2 had septicaemia, 2 withdrew consent); 323/332 (97.3%) in the control group (3 partici-
pants had electrolyte imbalance, 2 had septicaemia, 2 withdrew consent, 1 was discharged, 1 died)
Interventions • Live L rhamnosus GG (120 × 106 CFUs/d for 7 days)
• ORF
Dehydration was corrected using oral rehydration fluid (ORF) according to WHO guidelines
Outcomes • Frequency of diarrhoea
• Duration of diarrhoea (time to 2 consecutive soT or formed stools or no stool for 12 consecutive hours)
• Duration of vomiting
• Length of hospital stay
No adverse events attributed to probiotic
Notes Study location: India (high child and adult mortality)
Cause of diarrhoea: bacterial diarrhoea excluded. Rotavirus identified in 241 (74.6%) probiotic and 249
(77.1%) control
Nutritional status: most participants malnourished - probiotic: 198/323 moderately malnourished,
31/323 severely malnourished; control: 185/323 moderately malnourished, 33/323 severely malnour-
ished
Hydration status: all participants dehydrated - probiotic: 48 mild, 173 moderate, 102 severe dehydra-
tion; control: 51 mild, 168 moderate, 104 severe dehydration
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Basu 2007 
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Random sequence genera-
tion (selection bias)
Low risk Computer randomization
Allocation concealment
(selection bias)





Low risk Identical placebo; intervention in numbered packets
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: 1 year (period not stated)
Participants Inclusion criteria: inpatients; infants and children with ≥ 3 watery stools/d without macroscopic blood
or mucus; < 10 white cells per high power field and absent red blood cells; mucus flakes and bacteria on
stool microscopy; negative hanging drop preparation; negative bacterial stool culture
Exclusion criteria: symptoms of illness other than diarrhoea; development of any systemic complica-
tion of diarrhoea during hospitalization; failure to give informed consent
Numbers completing the study: probiotic group: 186/196 (94.9%; withdrawals: 5 electrolyte imbalance,
3 septicaemia, 2 withdrawal of consent); placebo group: 185/196 (94.4%; withdrawals: 4 electrolyte im-
balance, 3 septicaemia, 2 withdrawal of consent, 1 discharge on request, 1 death)
Interventions • Live L rhamnosus GG 2 × 101º CFUs/d for minimum 7 days or until diarrhoea stopped (data not extract-
ed for meta-analysis)
• Live L rhamnosus GG 2 × 1012 CFUs/d for minimum 7 days or until diarrhoea stopped (data extracted
for meta-analysis)
• ORF
Interventions started after initial rehydration and stabilization
Outcomes • Frequency of diarrhoea by day
• Average duration of diarrhoea
• Average duration of vomiting
• Average duration of IV therapy
• Average duration of hospital stay
No adverse events attributed to probiotic
Basu 2009 
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Notes Study location: India (high child and adult mortality)
Cause of diarrhoea: bacterial diarrhoea excluded. Rotavirus identified in 106 (57.0%) probiotic and 102
(55.1%) control
Nutritional status: severe malnutrition in 17 (9.1%) probiotic and 12 (6.5%) control; mild/moderate
malnutrition in 102 (54.8%) probiotic and 100 (54.1%) control
Hydration status: severe dehydration in 35 (18.8%) probiotic and 39 (21.1%) control; mild/moderate
dehydration in 121 (65.1%) probiotic and 122 (66.0%) control
Source of funding not stated, but no study authors had a financial arrangement regarding this study
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random numbers
Allocation concealment
(selection bias)





Low risk Identical placebo; intervention in numbered packets
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Open-label randomized controlled trial; 1 centre
Duration: 2 years (2010 to 2012)
Participants Inclusion criteria: children aged 6 months to 5 years; admitted to hospital with acute watery diarrhoea
of less than or equal to 48 hours' duration
Exclusion criteria: history of blood or pus in stools; severely dehydrated (WHO criteria); severely mal-
nourished (grade III and IV according to IAP classification); treatment with antibiotics, probiotics, or
prebiotics within 2 weeks before enrolment; history of conditions known to produce immunodeficien-
cy (AIDS, other congenital immunodeficiency syndrome, drug therapy with steroids, anticancer drugs
etc.); presence of acute systemic illness (meningitis, pneumonia, sepsis); chronic diarrhoea; known hy-
persensitivity to Bacillus clausii and Saccharomyces boulardii or other probiotics
Bhat 2018 
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Number completing study: 40/40 in both probiotic groups (100%); 40/40 in control group (100%)
Interventions • Saccharomyces boulardii, 250 mg twice daily; duration not stated (data extracted for probiotic group)
• Bacillus clausii, 2 billion spores twice a day; duration not stated
Timing of start of intervention not stated. All participants received oral rehydration therapy and zinc
Outcomes • Total duration of diarrhoea after admission: hours from time of admission to time the child passed
the last abnormal (loose or liquid) stool
• Mean number of stools per day
• Duration of vomiting
• Duration of fever (> 37.5°)
• Duration of hospital stay
No comment regarding adverse events
Notes Study location: India (high child and adult mortality)
Cause of diarrhoea: bloody diarrhoea excluded
Nutritional status: no malnutrition: 19 (47.5%), grade 1 malnutrition: 18 (45%), grade 2 malnutrition: 3
(7.5%) in S boulardii group; no malnutrition: 21 (52.5%), grade 1 malnutrition: 17 (42.5%), grade 2 mal-
nutrition: 2 (5%) in B clausii group; no malnutrition: 24 (60.0%), grade 1 malnutrition: 14 (35.0%), grade
2 malnutrition: 2 (5%) in control group
Hydration status: some dehydration in 24 (60%) in the S boulardii group, 29 (72.5%) in the B clausii
group, and 22 (55.0%) in the control group. Severe dehydration excluded
Source of funding: no funding sources identified
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomization not stated
Allocation concealment
(selection bias)





High risk Open-label trial; no placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)
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Study characteristics
Methods Randomized controlled trial; 2 centres
Duration: 16 months
Participants Inclusion criteria: inpatients; malnourished boys aged 4 to 48 months (weight for height < 80% NCHS
median) with diarrhoea (≥ 5 liquid stools in preceding 24 hours) for ≤ 96 hours. Nearly all children were
dehydrated (48/49 milk group and 43/47 yogurt group)
Exclusion criteria: female; severe non-gastrointestinal illness; gross blood in the stools; exclusive
breast-feeding
Numbers completing study: 47/49 (95.9%) in probiotic group (2 were withdrawn because of cholera in
stool cultures); 49/53 (92.5%) in control group (2 were withdrawn because of cholera in stool cultures, 2
leT against medical advice)
Interventions • Yogurt formula (Lactogen-2 (Nestle India Ltd, Gurgaon, Haryana); after fermentation with 90 g Strep-
tococcus thermophilus and Lactobacillus bulgaricus standard starter (International Yoghurt Manufac-
turers Club, Paris, France), 120 mL/kg/d for at least 72 hours added to milk formula)
• Non-fermented Lactogen-2
Given after 8 hours' initial observation. All participants received rehydration fluids (IV if stool > 4 g/kg/
h), IV cephalosporin, and gentamicin, and were fed with rice lentil oil gruel
Outcomes • Proportion recovered at 48 hours and 72 hours (defined as 2 consecutive formed stools, ≤ 3 stools in
24 hours, of which at least 2 were formed, or no stool for 12 hours)
• Median duration of diarrhoea
• Treatment failure (episode of diarrhoea after 72 hours or stool weight > 150 g/kg on any day)
No comment regarding adverse events
Notes Study location: India (high child and adult mortality)
Cause of diarrhoea: excluded if gross bloody stools
Nutritional status: all malnourished boys (weight for height < 80% NCHS median); mean weight for
length and length for age (% NHCS median) similar in both groups
Hydration status: nearly all children were dehydrated: 43/47 (91.5%) probiotic and 48/49 (98.0%) con-
trol
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomization list
Allocation concealment
(selection bias)





High risk Interventions not identical
Bhatnagar 1998 
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Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized trial; probably open study; 1 centre
Duration: not stated
Participants Inclusion criteria: inpatients; infants and children with acute watery diarrhoea of mild to moderate
severity
Exclusion criteria: severe intercurrent illness; severe diarrhoea and dehydration requiring admission
and IV rehydration; temperature > 38.5° C; anti-diarrhoeals or antibiotics in last 24 hours; severe malnu-
trition
Numbers completing study: 50/50 (100%) in probiotic group; 50/50 (100%) in control group
Interventions • S boulardii (500 mg/d for 5 days)
• ORF and nutritional support only
Timing of interventions not stated
Outcomes • Mean duration of diarrhoea (not defined), days: 3.6 in probiotic group, 4.8 in placebo group (P = 0.001)
• Weight gain
• Daily stool frequency and consistency: mean numbers of stools on days 3 and 6 were significantly
lower in the probiotic group than in the placebo group
• Tolerance and acceptability of intervention
No adverse events attributed to probiotic
Notes Study location: Pakistan (high child and adult mortality)
Cause of diarrhoea: rotavirus identified in 8 (16.0%) probiotic and 10 (20.0%) control. Bacterial diar-
rhoea identified in 13 (26.0%) probiotic and 6 (12.0%) control
Nutritional status: severe malnutrition excluded; no further data presented
Hydration status: severe dehydration excluded; no further data presented
Source of funding: supported by Laboratoires Biocedex (France); Hilton Pharma (Pvt) Ltd (Pakistan)
Risk of bias
Bias Authors' judgement Support for judgement
Billoo 2006 
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Random sequence genera-
tion (selection bias)
Unclear risk Randomized controlled trial but methods not described
Allocation concealment
(selection bias)





High risk No placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: not stated
Participants Inclusion criteria: inpatients; well-nourished children aged 3 to 24 months with watery diarrhoea < 5
days' duration and > 3 watery stools in previous 24 hours. All children were dehydrated, including some
with severe dehydration
Exclusion criteria: exclusive breast-feeding; history of allergy to cow's milk; severe malnutrition (weight
or height < 70% or oedema)
Numbers completing study: 49/56 (87.5%) in probiotic group (3 with urinary tract infection and 1 with
bronchopneumonia were withdrawn, others were withdrawn by parents); 48/56 (85.7%) in non-probi-
otic group (2 with urinary tract infection and 1 with amebiasis were withdrawn, 1 failed to attend for
follow-up, others were withdrawn by parents). Reasons for withdrawal by parents not stated. Diarrhoea
outcomes reported for all randomized children
Interventions • Infant formula (Enapal-Sopad, Nestlé, Courbevoie, France) fermented with L bulgaricus and S ther-
mophilus (Yalacta, Caen, France; total 2 × 108 CFUs/g)
• Infant formula acidified with lactic acid to match pH of fermented formula
180 mL/kg/d of fermented or non-fermented infant formula given after initial oral rehydration. All in-
fants also received other foods
Outcomes • Weight gain
• Cessation of diarrhoea (defined as last liquid or semi-liquid stool before 2 formed stools). Means and
95% CIs stated
• Food and liquid intake
Frequency of vomiting similar in both groups. No other comment regarding adverse events
Boudraa 2001 
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Notes Study location: Algeria (high child and adult mortality)
Cause of diarrhoea: rotavirus identified in 25/56 (44.6%) probiotic and 26/56 (46.4%) control. No bacte-
rial pathogens isolated
Nutritional status: all well nourished
Hydration status: all dehydrated; severe dehydration 5 (8.9%) probiotic and 4 (7.1%) control
Reduced duration of diarrhoea in probiotic compared with non-probiotic group observed only in chil-
dren with reducing substances in stools
Source of funding: not stated
Secondary outcome reporting: outcome data presented for < 90% in both groups
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





High risk Interventions not identical
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Outcomes reported for > 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: not stated
Participants Inclusion criteria: inpatients; adults with acute enteritis (diarrhoea, fever, vomiting, nausea, abdominal
pain with or without toxicity; duration not stated)
Exclusion criteria: typhoid cases
Number completing study: stool cultures available after randomization; participants with Salmonel-
la typhi were withdrawn (number not stated); for non-typhoid participants, results were presented for
25/25 (100%) probiotic and 24/24 (100%) control
Bruno 1981 
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Interventions • Enterococcus LAB SF68 (Bioflorin; ≥ 75 × 106 lyophilized bacteria tds for 10 days)
• Placebo
Timing of start of administration not stated
Outcomes • Proportion of participants with diarrhoea by day of treatment
Resolution of diarrhoea defined as 2 or fewer formed stools/d and no abdominal pain or fever
No adverse events attributed to probiotic
Notes Study location: Italy (very low child and adult mortality)
Cause of diarrhoea: non-typhoid. Bacterial stool culture (probiotic group/placebo group): Salmonella
4/3; enteropathogenic E coli 18/20; other enteropathogen 1/3
Nutritional status: no data presented
Hydration status: no data presented
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





Unclear risk Blinding not adequately described
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: not stated
Participants Inclusion criteria: inpatients; adults (although ages not specified) with acute febrile enteritis (duration
of diarrhoea not stated)
Bruno 1983 
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Exclusion criteria: typhoid cases
Numbers completing study: 10/10 (100%) probiotic, 11/11 (100%) control
Interventions • Enterococcus LAB SF68 (Bioflorin; ≥ 75 × 106 lyophilized bacteria thrice daily for at least 10 days)
• Placebo
Intervention started after initial treatment with chloramphenicol (all participants) and after stool cul-
ture results available
Outcomes • Proportion of participants with diarrhoea by day of treatment (definition for recovery from diarrhoea
not stated)
No adverse events attributed to probiotic
Notes Study location: Italy (very low child and adult mortality)
Cause of diarrhoea: non-typhoid
Nutritional status: no data presented
Hydration status: no data presented
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomization unclear
Allocation concealment
(selection bias)





Unclear risk Placebo not described
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Prospective, parallel, single-blind, randomized controlled trial; 1 centre
Duration: 2 years (July 2009 to July 2011)
Burande 2013 
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Participants Inclusion criteria: children diagnosed with acute diarrhoea (≥ 3 unformed stools in last 24 hours with
duration < 48 hours); no dehydration or some dehydration as per WHO criteria
Exclusion criteria: concurrent chronic illness; severe and very severe undernutrition (weight for age <
60% of 50th percentile - CDC 2000 Standards); severe dehydration (as per WHO criteria); allergy or his-
tory of use of probiotic, antibiotic, or anti-diarrhoeal in last 24 hours
Numbers completing study: 35/36 (97%) probiotic (1 lost to follow-up); 35/36 (97%) control (1 lost to
follow-up). Reasons for loss to follow-up not given
Interventions • Lyophilized Saccharomyces boulardii, 250 mg orally twice a day for 5 days
Timing of start of administration not stated. All participant children received ORS ad libitum (as much
as required after passing of each stool or vomiting, or both, and whenever child demand for it) until res-
olution of diarrhoea, and zinc (10 mg/d if aged < 6 months and 20 mg/d if aged ≥ 6 months) for 14 days.
Paracetamol was given as required for fever
Outcomes • Recovery from diarrhoea (passage of 2 consecutive formed stools as per King scoring system or no
stool for 12 hours)
• Recovery from vomiting (duration in days until last episode of vomiting) or up to 14 days, whichever
occurred later
• Adverse events
No specific comment regarding adverse events
Notes Study location: India (high child and adult mortality)
Cause of diarrhoea: Vibrio cholerae, Entamoeba histolytica, and Giardia lamblia excluded
Nutritional status: severe undernutrition excluded (weight for age < 60% of 50th percentile - CDC 2000
Standards)
Hydration status: no dehydration 32 (91.4%) probiotic, 31 (88.6%) control; some dehydration 3 (8.6%)
probiotic, 4 (11.4%) control. Severe dehydration excluded
Source of funding: DY Patil University, Kolhapur, and management to provide financial support
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random numbers
Allocation concealment
(selection bias)





High risk No placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Burande 2013  (Continued)
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Selective reporting (re-
porting bias)





Methods Prospective randomized study; 1 centre
Duration: 4 months (May to October 2016)
Participants Inclusion criteria: children aged 6 months to 5 years, irrespective of hydration status; present or past
status of use of antibiotics; ability to tolerate Saccharomyces boulardii
Exclusion criteria: recurrent or chronic diarrhoea; acute dysentery; thalassaemia; congenital heart dis-
ease
Numbers completing study: 200/234 (85.5%) both probiotic and control (21 patients prematurely dis-
charged and 13 leT against medical advice). Unclear number originally allocated to each group and
from which group withdrawals came; 100 ultimately allocated to both probiotic and control groups
Interventions • Saccharomyces boulardii (dose, frequency, and duration not stated; not stated whether probiotic alive
or killed)
Timing of start of administration not stated. All participants received 'routine management' of acute di-
arrhoea (not described)
Outcomes • Stool frequency
• Stool consistency
• Mean duration of diarrhoea (days)
No specific comment regarding adverse events
Notes Study location: Pakistan (high child and adult mortality)
Cause of diarrhoea: acute dysentery excluded
Nutritional status: not stated
Hydration status: mild dehydration 17 (17%) probiotic, 14 (14%) control; moderate dehydration 57
(57%) probiotic, 66 (66%) control; severe dehydration 26 (26%) probiotic, 20 (20%) control
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not adequately described
Allocation concealment
(selection bias)




High risk No placebo
Burki 2017 
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All outcomes
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Follow-up < 90%
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 2 centres
Duration: not stated
Participants Inclusion criteria: inpatients and outpatients; adults with acute diarrhoea (≥ 3 watery or loose stools in
last 24 hours)
Exclusion criteria: diarrhoea > 3 days; blood in faeces; faecal leukocytes; temperature > 39° C; friable
and haemorrhagic mucosa in rectosigmoid; history of chronic diarrhoea; polyps; colon cancer; Crohn's
disease; ulcerative colitis; malabsorption; use of anti-diarrhoeals or antibiotics in past 7 days; severe di-
arrhoea (dehydration with weight loss > 10%); associated major disease
Numbers completing study: 93/105 (88.6%) probiotic (4 violated protocol, 5 did not comply with study
medications, 3 were lost to follow-up); 92/106 (86.8%) control (5 violated protocol, 7 did not comply
with study medications, 2 were lost to follow-up)
Interventions • Enterococcus strain SF68, lyophilized (Bioflorin; 75 × 106 CFUs thrice daily for ≥ 5 days)
• Placebo
Started on day of presentation
Outcomes • Number of participants with diarrhoea by day of treatment
• Mean stool frequency by day of treatment
Diarrhoea resolved when stool frequency < 3/d and semi-solid or solid and no associated symptoms
No adverse events attributed to probiotic
Notes Study location: Belgium (very low child and adult mortality)
Cause of diarrhoea: bloody diarrhoea excluded. Bacterial diarrhoea identified in 12 (11.4%) probiotic
and 16 (15.1%) control
Nutritional status: no data presented
Hydration status: > 10% dehydration excluded; no further data presented
Highly significant reduction in duration of diarrhoea in probiotic group confirmed by intention-to-treat
analysis, which included excluded participants as non-recovered on day 7 (but no data shown)
Source of funding: not stated
Buydens 1996 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomization by central computer
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Follow-up < 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 6 centres
Duration: 12 months (October 1999 to September 2000)
Participants Inclusion criteria: outpatients; infants and children aged 3 to 36 months with > 2 loose or liquid stools/
d for < 48 hours
Exclusion criteria: malnutrition; severe dehydration; coexisting acute systemic illness (meningitis, sep-
sis, pneumonia); immunodeficiency; underlying severe chronic disease; cystic fibrosis; food allergy or
other chronic GI disease; use of probiotics in the previous 3 weeks; antibiotic or any other anti-diar-
rhoeal medication in the previous 3 weeks; poor compliance (< 4 doses of study medication adminis-
tered)
Numbers completing study: 95/100 probiotic (2 did not receive allocated intervention, 1 faster remis-
sion, 1 worsening symptoms, 1 poor compliance); 88/92 control (1 did not receive allocated interven-
tion, 1 worsening symptoms, 1 contracted pneumonia, 1 coeliac disease)
Interventions • Live Lactoacillus casei rhamnosus GG (Dicoflor 60; 12 × 109 CFUs/d for 5 days)
• Placebo, no details given but same appearance as active intervention
Intervention started within 48 hours of admission. ORF given for 3 to 6 hours after admission, lac-
tose-containing formula milk or cow's milk according to age
Outcomes • Diarrhoea duration (time of last loose or liquid stool preceding a normal stool)
• Number and consistency (scoring system) of stools/d recorded by parents
• Vomiting
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• Fever (> 37.5° C)
• Number of hospital admissions
1 participant with poor compliance in the probiotic group; 31 and 34 participants with vomiting in pro-
biotic and placebo groups, respectively. No adverse events attributed to probiotic
Notes Study location: Italy (very low child and adult mortality)
Cause of diarrhoea: stool culture in only a few participants; no data presented
Nutritional status: malnutrition excluded
Hydration status: severe dehydration excluded; no other data presented
Source of funding: none
Single-blind trial: parents instructed to buy probiotic preparation
This study also allocated children to 4 other probiotic groups: (1) S boulardii 5 × 109 live organisms dai-
ly (Codex) for 5 days; (2) B clausii O/C84, N/R84, T84, SIN84 (Enterogermina) 109 CFUs bd for 5 days; (3)
combination of L delbrueckii var bulgaricus LMG-P17550 109 CFUs daily, L acidophilus LMG-P 17549 109
CFUs daily, S thermophilus LMG-P 17503 109 CFUs daily, and B bifidum LMG-P 17500 5 × 108 CFUs daily
(Lactogermina) for 5 days; (4) Enterococcus faecium SF 68 (Bioflorin) 7.5 × 107 CFUs daily for 5 days; and
compared each of the probiotic groups with the single control group. Mean duration of diarrhoea and
mean stool frequency on days 2 and 3 were significantly shorter for intervention groups 1 and 3 than for
the control group. These outcomes were similar to the control group for the other probiotic groups
To avoid a unit of analysis error as a result of multiple comparisons between intervention groups and
the single control group, we elected to include data for the L rhamnosus GG group only in this review.
We selected L rhamnosus GG because this was the probiotic most frequently evaluated in acute in-
fectious diarrhoea, and we wished to maximize the body of evidence. We rejected the alternative ap-
proach of pooling data from all of the different probiotic intervention groups into a single group be-
cause this would not be helpful in selecting a specific probiotic intervention for use in clinical practice
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomization list; allocation in blocks of 6
Allocation concealment
(selection bias)





High risk Parents of participants told which treatment to purchase
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)
Low risk All pre-stated outcomes reported
Canani 2007  (Continued)
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Methods Randomized controlled trial; 1 centre
Duration: 11 months (1 April 1988 to 15 March 1989)
Participants Inclusion criteria: unclear whether inpatients or outpatients, or both; children aged 3 months to 3 years
with acute (duration not stated) non-bloody diarrhoea; no dehydration; no concomitant illness; no an-
tibiotics or drugs affecting gut motility.
Numbers completing study: unclear how many participants randomized; participants who deteriorat-
ed, developed concomitant illness, and needed other drugs, or who wished to withdraw, were exclud-
ed from the analysis (details not given)
Interventions • S boulardii (live Saccharomyces cerevisiae Hansen CBS 5926; 600 mg/d; duration not stated)
• Glucose placebo (diluted in 5 mL cold water)
No details of when interventions started
Outcomes • Number of stools per day
• First day stools formed
• Side effects
Cure defined as < 4 stools in 24 hours and absence of liquid stools
No adverse events attributed to probiotic
Notes Study location: Mexico (low child and adult mortality)
Cause of diarrhoea: bloody diarrhoea excluded
Nutritional status: all well nourished
Hydration status: dehydration excluded
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random numbers table
Allocation concealment
(selection bias)





Unclear risk Unclear whether placebo and probiotic identical
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Unclear who assessed outcomes
Incomplete outcome data
(attrition bias)
Unclear risk Unclear how many participants were randomized at start of study
Cetina-Sauri 1994 
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Methods Randomized controlled trial; 1 centre
Duration: 22 months (February 2006 to November 2007)
Participants Inclusion criteria: inpatients; children aged 3 months to 6 years with acute diarrhoea defined as 3 or
more loose or liquid stools per day of less than 72 hours' duration
Exclusion criteria: immunodeficiency; severe abdominal distension with risk of bowel perforation; se-
vere infection or sepsis; history with gastrointestinal tract surgery; use of probiotics in the preceding
week
Numbers completing study: 304 children enrolled and 293 were included in the analysis (150 probiotic
and 143 control). Overall, 7 children discontinued medication and 4 were lost to follow-up; group allo-
cation unclear 
Interventions • Live Bacillus mesentericus, Enterococcus faecalis, and Clostridium butyricum (Bio-three; 2.5 × 107 CFUs/
kg/d) for 7 days
• Starch powder of identical appearance to probiotic preparation
When interventions were started is not stated
Outcomes • Duration of diarrhoea (time from inclusion into the study until the first normal stool was passed)
• Number of diarrhoea episodes
• Mean stool frequency on days 2 and 3
• Diarrhoea lasting ≥ 3 days
• Duration of fever
• Duration of vomiting
• Appetite/intake score
• Abdominal pain episodes
• Length of hospital stay
Duration of diarrhoea also reported for children with rotavirus diarrhoea and those with bacterial diar-
rhoea
No adverse events attributed to probiotic
Notes Study location: Taiwan (low child and adult mortality)
Cause of diarrhoea: 47 (31.3%) children in probiotic group and 44 (30.8%) in control group had ro-
tavirus in stools. Norovirus and adenovirus were also identified. 27 (18.0%) children in probiotic group
and 30 (20.0%) in control group had bacteria in stools (either Salmonella enterica or Campylobacter je-
juni)
Nutritional status: no data presented
Hydration status: no data presented
Source of funding: this study was supported in part by a grant from Chang Gung Memorial Hospital re-
search project grant XMRPG440021, Northern Taiwan
Chen 2010 
Probiotics for treating acute infectious diarrhoea (Review)










Cochrane Database of Systematic Reviews
First author was contacted and was asked to clarify
• Whether children who had received antibiotics before recruitment were included
• Whether children with blood in stools were included




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomization
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Double-blind randomized placebo-controlled parallel-group trial; 2 centres
Duration: 18 months (April 2007 to September 2008)
Participants Inclusion criteria: children of both sexes aged 6 to 48 months; no other diarrhoea episode or use of an-
tibiotics 2 weeks before the trial; acute diarrhoea within 72 hours before hospitalization
Exclusion criteria: exclusive breast-feeding; macroscopic blood in the faeces; severe malnutrition
(weight/height < 70% National Center for Health Statistics); impossibility of oral nutrition; existence
of underlying pathology (e.g. sepsis, cystic fibrosis, renal insufficiency, liver disease); children needing
specific treatment
Numbers completing study: 90/95 (94.7%) probiotic group (3 lost to follow-up (needed antibiotics);
2 did not complete treatment (no reason)); 86/91 (94.5%) control (2 lost to follow-up (needed antibi-
otics); 3 did not complete treatment (no reason given)). All randomized patients were analysed under
intention-to-treat analysis
Correa 2011 
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Interventions • Lyophilized Saccharomyces boulardii, capsules (Floratil; Merck S.A., Rio de Janeiro, Brazil) containing
200 mg of yeast (4 × 109 viable cells) and magnesium stearate, lactose, and sucrose as excipients, 12-
hourly for 5 days
• Placebo capsules (Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, Brazil) containing
200 mg of the excipients 12-hourly for 5 days
Timing of start of administration not stated
Outcomes • Clinical cure for diarrhoea (if no improvement after 4 days of intervention, therapy was discontinued
and child was remanded for further treatment)
No adverse events attributed to probiotic
Notes Study location: Brazil (low child and adult mortality)
Cause of diarrhoea: rotavirus detected in 58.5% in probiotic group and in 56.3% in control group.
Bloody diarrhoea excluded
Nutritional status: severe malnutrition excluded
Hydration status: 88/90 (97.8%) probiotic had moderate to grave dehydration, as did 85/86 (98.8%)
control
Source of funding: supported by Conselho Nacional de Desenvolvimento Cient́ıfico e Tecnológico (CN-
Pq) and Coordenac ̧ão de Aperfeic ̧oamento do Pessoal de Ensino Superior (CAPES)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated numbers
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Costa-Ribeiro 2003 
Probiotics for treating acute infectious diarrhoea (Review)










Cochrane Database of Systematic Reviews
Duration: not stated
Participants Inclusion criteria: inpatients; boys age 1 to 24 months with acute diarrhoea (3 or more watery or loose
stools per 24 hours during at least one 24-hour period in the 72 hours before admission) with moderate
dehydration or severe dehydration after correction by rapid IV fluids
Exclusion criteria: systemic infection requiring antibiotic; severe malnutrition (weight for age < 65% of
NCHS standards); bloody diarrhoea
Numbers completing study: 61/61 (100%) probiotic and 63/63 (100%) control
Interventions • L casei subspecies rhamnosus 10 × 109 CFUs/d
• Inulin 320mg/d
Interventions started after correction of severe dehydration if required
Outcomes • Duration of diarrhoea (cessation of diarrhoea defined as passage of 2 formed or semi-formed stools
or no stools for 24 hours). Note: SDs quoted for mean duration of diarrhoea in each group appeared
small in comparison with other trials. Study authors contacted and clarification awaited
• Diarrhoea lasting 3 days or longer
• Diarrhoea lasting 4 days or longer
• 24-hour and total stool output
• Unscheduled IV fluids
• Vomiting during first 24 hours after randomization
• Hyponatraemia at 24 hours after randomization
No comment regarding adverse events
Notes Study location: Brazil (low child and adult mortality)
Cause of diarrhoea: bloody diarrhoea excluded; 52% of children probiotic and 48% control had ro-
tavirus in stools; no data shown for outcomes in rotavirus diarrhoea, although stated as "no significant
difference" between groups
Nutritional status: severe malnutrition excluded; median WHZ score -1.13 (IQR -1.63 to -0.43) in control
group and -1.22 (-1.87 to -0.62) in probiotic group
Hydration status: all dehydrated; moderate or severe dehydration in 92% probiotic and 94% control
Source of funding: this study was supported in part by a grant from Pronex/CNPq (661086/1998-4),
Brazil
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not adequately described
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
Unclear risk Unclear who assessed outcomes
Costa-Ribeiro 2003  (Continued)
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Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; unclear whether single centre or multi-centre
Duration: not stated
Participants Inclusion criteria: unclear whether inpatients or outpatients, or both; children with acute enteritis (du-
ration and definition not given)
Exclusion criteria: none stated
Numbers completing study: 21/21 (100%) probiotic and 18/18 (100%) control
Interventions • Live Streptococcus faecium (S faecium 68; 75 × 106 bacteria thrice daily for 7 days)
• Placebo (details not given)
When interventions started is not stated
Outcomes • Number of participants with < 2 stools/d
• Formed yellow/brown stools without mucus
• No abdominal pain, vomiting, or fever for the whole day
No adverse events attributed to probiotic
Notes Study location: Switzerland (very low child and adult mortality)
Cause of diarrhoea: 7 participants in each group had positive stool culture for bacteria
Nutritional status: no data presented
Hydration status: no data presented
S faecium 68 also appeared to promote recovery from abdominal pain, fever, and vomiting
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)
Unclear risk Not described
D'Apuzzo 1982 
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Unclear risk Not adequately described
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Prospective randomized single-blind controlled trial; 1 centre
Duration: 22 months (September 2008 to June 2010)
Participants Inclusion criteria: time between onset of diarrhoea and hospitalization < 96 hours; presenting with an
episode of 3 or more watery or looser-than-normal stools within a 24-hour period and/or forceful vom-
iting (excluding post-tussive vomiting); mild to moderate dehydration; on admission, stool positive for
rotavirus antigen
Exclusion criteria: malnutrition as judged by the ratio of weight to height; duration of diarrhoea > 96
hours; severe dehydration; exclusively breast-feeding; toxic clinical appearance; immunosuppression;
any known allergies to any drugs or foods
Numbers completing study: 60/60 (100%) probiotic plus zinc; 60/60 (100%) zinc only
Interventions • Saccharomyces boulardii
• Zinc (data extracted for control group)
• Lactose-free formula
• Saccharomyces boulardii and zinc (data extracted for probiotic group)
• Saccharomyces boulardii and lactose-free formula
• Zinc and lactose-free formula
• Saccharomyces boulardii, zinc, and lactose-free formula
• ORS and/or IV rehydration only
Saccharomyces boulardii: 250 mg once daily, for a minimum of 5 days (not stated whether probiotic
alive or killed)
Zinc: zinc acetate suspension, 10 mg twice daily for infants < 6 months of age; 20 mg daily for all other
participants
Lactose-free formula: Bebelac Lactose Free Formula, 400 g; Nutricia, Istanbul, Turkey
Intervention started directly after randomization. All participants offered ORS for rehydration, with IV
rehydration given if excessive vomiting or clinical signs of dehydration
Outcomes • Duration of diarrhoea
• Number of vomiting episodes
Dalgic 2011 
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• Number of bowel movements
• Rectal temperature
• Days of hospitalization
No adverse events attributed to probiotic
Notes Study location: Turkey (low child and adult mortality)
Cause of diarrhoea: all patients had rotavirus diarrhoea
Nutritional status: severe malnutrition excluded (Z score ≤ -3)
Hydration status: mild dehydration in 7.7% probiotic plus zinc and in 8.5% zinc only; moderate dehy-
dration in 4.8% probiotic plus zinc and in 4% zinc only. Severe dehydration excluded
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not adequately described
Allocation concealment
(selection bias)





High risk Different treatments given in each arm
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Double-blind randomized controlled trial; 1 centre
Duration: 17 months (November 2007 to March 2009)
Participants Inclusion criteria: children with acute rotavirus diarrhoea of < 48 hours' duration; moderate to severe
dehydration; aged between 3 months and 5 years
Exclusion criteria: severe malnutrition (weight for height < 3 SD of WHO growth chart); coexisting sys-
temic illness and chronic disease; taking probiotics including during preceding week; taking antibiotics
for current episode of diarrhoea; history of receiving rotavirus vaccine
Das 2016 
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Numbers completing study: 30/30 (100%) probiotic; 28/30 (93.3%) control (2 non-contactable). All ran-
domized participants analysed under intention-to-treat analysis
Interventions • Lyophilized Saccharomyces boulardii (Econorm, Dr Reddy’s Laboratories), 250 mg mixed in 15 mL nor-
mal water, twice daily for 5 days
• Control: 'similar product' in colour and taste, twice daily for 5 days
Intervention started after participant was clinically stabilized and maintained hydration and random-
ization. All cases managed as per WHO guidelines for management of acute diarrhoea (details not giv-
en). Carers advised to avoid any warm/hot food within 2 hours of giving probiotics
Outcomes • Duration (hours) of acute diarrhoea
• Duration (hours) of vomiting
• Duration (hours) of fever
• Duration (hours) of hospitalization
• Proportion of children requiring parenteral rehydration
• Proportion of children having diarrhoea lasting beyond day 7
• Any adverse effects
No adverse events attributed to probiotic
Notes Study location: India (high child and adult mortality)
Cause of diarrhoea: rotavirus detected in 100% of participants in probiotic and control groups
Nutritional status: severe malnutrition excluded
Hydration status: no dehydration in 14 (46.7%) probiotic and in 15 (50%) control; some dehydration in
8 (26.7%) probiotic and in 7 (23.3%) control
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not adequately described
Allocation concealment
(selection bias)





Unclear risk Unclear whether different advice given for both arms
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)
Low risk Pre-stated outcomes reported
Das 2016  (Continued)
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Methods Randomized single-blind parallel-group controlled trial; 11 centres
Duration: not stated
Participants Inclusion criteria: children aged 3 to 60 months; acute watery diarrhoea lasting 12 to 72 hours; hospital-
ized in 1 of 11 Turkish centres; clinical signs of mild to moderate dehydration (prolonged capillary refill
time, abnormal skin turgor, and 3% to 9% loss of body weight)
Exclusion criteria: clinical features of hypovolaemic shock and/or necessitating admission to intensive
care unit; use of antibiotics or probiotics up to 1 month before admission; malnutrition (weight < P3);
chronic underlying disease, including immunocompromised condition
Numbers completing study: 64/70 (91.4%) probiotic (3 antibiotic prescriptions (post randomization);
1 parental refusal to continue; 2 lack of data after hospital discharge (lack of parental compliance));
63/70 (90%) control (3 antibiotic prescriptions (post randomization); 1 parental refusal to continue; 1
detection of underlying disease during hospitalization; 1 lack of data after hospital discharge (lack of
parental compliance); 1 unaccounted for)
Interventions • Lactobacillus reuteri DSM 17938 (BioGaia drops, BioGaia AB, Sweden; distributed by Eczacibasi in
Turkey) 1 × 108 CFUs daily for 5 days (not stated whether probiotic alive or killed)
Intervention administered after randomization. All participants received hypo-osmolar ORS and/or IV
therapy
Outcomes • Duration of diarrhoea (time in hours from admission until cessation of diarrhoea - time when first
normal stool was recorded (according to Bristol score; a score < 5 is described as normalization of
stool)
• Duration of hospitalization (days)
• Number of children with diarrhoea at each day of intervention
• Mean frequency of daily stools
• Percentage of prolonged diarrhoea (presence of diarrhoea 7 days after intervention)
• Adverse events
• Length of hospitalization (days from admission until discharge)
No adverse events attributed to probiotic
Notes Study location: Turkey (low child and adult mortality)
Cause of diarrhoea: bloody diarrhoea excluded
Nutritional status: malnutrition excluded
Hydration status: hypovolaemic shock excluded
Source of funding: no funding; free medication provided (unclear from whom)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomization
Allocation concealment
(selection bias)
Unclear risk No specific details of allocation concealment
Dinleyici 2014 
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High risk No placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized single-blind case-control trial; number of centres not stated
Duration: not stated
Participants Inclusion criteria: age 3 to 60 months; acute infectious diarrhoea (passage of 3 or more loose or watery
stools per day) lasting 12 to 72 hours before presentation at the outpatient clinic; followed up with am-
bulatory care
Exclusion criteria: need for hospitalization; use of antibiotics or probiotics for 1 month before a new
episode of diarrhoea; severe malnutrition; severe chronic underlying disease, including immunocom-
promising conditions
Numbers completing study: 29/32 (90.6%) probiotic (3 discontinued intervention (antibiotic prescrip-
tion)); 31/32 (96.9%) control (1 discontinued intervention (antibiotic prescription))
Interventions • Lactobacillus reuteri DSM 17938 (BioGaia®, Stockholm, Sweden) 5 drops containing 1 × 108 CFUs daily
for 5 days (not stated whether probiotic alive or killed)
Timing of start of administration not stated. All participants received hypo-osmolar ORS
Outcomes • Duration of diarrhoea (hours)
• Number of children with diarrhoea at each day of the 5 days of intervention
• Adverse events
No adverse events attributed to probiotic
Notes Study location: Turkey (low child and adult mortality)
Cause of diarrhoea: acute watery diarrhoea. No comment regarding specific cause of diarrhoea
Nutritional status: severe malnutrition excluded
Hydration status: not stated
Source of funding: not stated
Risk of bias
Dinleyici 2015a 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomization
Allocation concealment
(selection bias)





High risk No placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Prospective single-blind randomized controlled trial; 8 centres
Duration: not stated
Participants Inclusion criteria: hospitalized and ambulatory children aged 3 to 60 months (ECU and outpatients);
acute watery diarrhoea lasting 12 to 72 hours; clinical signs of mild to moderate dehydration (pro-
longed capillary refill time, abnormal skin turgor, and percentage loss of body weight)
Exclusion criteria: use of antibiotics or probiotics up to 1 month before admission; malnutrition (weight
under the third percentile); chronic underlying disease including immunocompromised condition. For
hospitalized children, also clinical features of hypovolaemic shock, and/or need for ICU admission
Numbers completing study: 220/240 (91.7%) (148/160 hospitalized; 72/80 ambulatory) probiotic (hos-
pitalized: 2 had had antibiotics, 2 discontinued intervention as needed antibiotics, 8 were lost to fol-
low-up; ambulatory: 3 had had antibiotics, 5 were lost to follow-up); 143/160 (89.4%) (72/80 hospital-
ized; 71/80 ambulatory) control (hospitalized: 3 had had antibiotics, 5 were lost to follow-up; ambula-
tory: 4 had had antibiotics, 3 discontinued intervention due to antibiotics, 2 were lost to follow-up). NB
combined results of all participants in probiotic groups used in analyses
Interventions • Lyophilized Saccharomyces boulardii CNCM 1-745 (Reflor Sachet, Biocodex, Gentilly, France) 250 mg
(5 × 109 CFUs) twice daily for 5 days
Timing of start of administration not stated. All participants received ORS and/or IV therapy
Outcomes • Duration of diarrhoea (time in hours from admission until cessation of diarrhoea)
• Duration of hospitalization (days)
• Number of children with diarrhoea at each of the 5 days of intervention
• Adverse events
Dinleyici 2015b 
Probiotics for treating acute infectious diarrhoea (Review)










Cochrane Database of Systematic Reviews
• Frequency and consistency of stool
No adverse events attributed to probiotic
Notes Study location: Turkey (low child and adult mortality)
Cause of diarrhoea: acute watery diarrhoea. No comment regarding specific cause of diarrhoea
Nutritional status: malnutrition excluded
Hydration status: hypovolaemic shock excluded
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomization
Allocation concealment
(selection bias)





High risk No placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Overall follow-up ≥ 90%; no marked differences between arms
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: February 2005 to February 2007
Participants Inclusion criteria: inpatients; infants and children with watery diarrhoea (defined as watery stools) < 72
hours' duration due to rotavirus infection; parental consent
Exclusion criteria: systemic infection; chronic disease; body weight < 60% NCHS standard; vomiting;
need for antibiotics
Numbers completing study: 113/113 (100%) probiotic and 111/111 (100%) control. Six children did not
complete the study; no group allocation reported or reasons given
Dubey 2008 
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Interventions • L acidophilus, L paracasei, L bulgaricus, L plantarum, B breve, B infantis, B longum, S thermophilus
(VSL#3; body weight < 5 kg: 180 billion organisms/d; body weight 5 to 10 kg: 360 × 109 organisms/d
for 4 days)
• Placebo (details not given although placed in identical sachets)
When interventions were started is not stated
Outcomes Significantly lower mean stool frequency seen in probiotic group from days 2 to 4; otherwise results be-
tween groups comparable. Significantly improved stool consistency in probiotic group on day 2. Probi-
otic group received significantly smaller volume of ORS on days 2 and 3
Overall recovery rate was better in the probiotic group (89.4% vs 39.6%; P < 0.001)
No adverse effects were attributed to probiotic
Notes Study location: India (high child and high adult mortality)
Cause of diarrhoea: all rotavirus
Nutritional status: severe malnutrition excluded; statement: "malnutrition status similar in two
groups"
Hydration status: dehydration status similar in 2 groups at baseline but no data presented
Source of funding: supported by grant from VSL
Secondary outcome reporting: all pre-stated outcomes reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





Low risk Identical interventions; participants and personnel unaware of assignment to
arms
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)
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Methods Double-blind randomized placebo-controlled trial; 1 centre
Duration: 23 months (September 2003 to July 2005)
Participants Inclusion criteria: boys (for ease of collection of stool and urine separately); aged 6 to 24 months; suf-
fering from dehydrating acute watery diarrhoea of less than 3 days’ duration; clinical signs and symp-
toms of ‘some’ dehydration (thirst or eagerness to drink, sunken eyes, dry mouth and tongue, loss of
skin elasticity)
Exclusion criteria: history of an episode of diarrhoea within 1 month of the present illness to exclude re-
current and persistent diarrhoea; exclusively breast-fed; severe dehydration; diarrhoea associated with
another systemic illness (e.g. septicaemia, pneumonia, urinary tract infection, otitis media) or chronic
underlying disease (e.g. tuberculosis, liver disease); severe malnutrition; needing extensive care (e.g.
life support system, blood transfusion, total parental nutrition); received an antibiotic before enrol-
ment
Numbers completing study: 78/80 (97.5%) probiotic (2 discontinued intervention due to unwillingness
of parents); 70/80 (87.5%) control (10 discontinued intervention due to unwillingness of parents)
Interventions • Lactobacillus sporogenes (Bacillus coagulans) (M⁄ S ESKAG Pharma Private Limited, Kolkata, India) 2
tablets (60 million spores/tablet) dispersed in 15 mL water, twice daily until recovery/for 5 days if not
recovered before that (not stated whether probiotic alive or killed)
• Placebo (M⁄ S ESKAG Pharma Private Limited, Kolkata, India) identical in colour, shape, and size
Timing of start of administration not stated. All participants received reduced osmolar ORS solution
to correct initial dehydration and continued as maintenance; more fluid and/or plain water if want-
ed/clinical indication; IV Ringer’s lactate for severe dehydration/intractable vomiting. Participants al-
lowed to continue breast-feeding, formula feeding, animal milk, or normal diet
Outcomes • Cure rate
• Duration of diarrhoea
• Stool frequency
• Volume of diarrhoea
• Intake of ORS
• Liquid/plain water intake
No adverse events attributed to probiotic
Notes Study location: India (high child and adult mortality)
Cause of diarrhoea: rotavirus detected in 25 (32%) probiotic and in 26 (37.1%) control. A range of other
pathogens were detected less commonly, including V cholerae, Shigella spp, E coli, astrovirus and Cryp-
tosporidium. No pathogens were identified in 18 (23.1%) probiotic and in 17 (24.3%) control
Nutritional status: severe malnutrition excluded
Hydration status: severe dehydration excluded
Source of funding: supported by the Indian Council of Medical Research (ICMR) as intramural project of
National Institute of Cholera and Enteric Diseases, Kolkata, India
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random numbers
Dutta 2011  (Continued)
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Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Overall follow-up ≥ 90%; no marked differences between arms
Selective reporting (re-
porting bias)





Methods Prospective double-blind randomized study; 1 centre
Duration: 3 months (July to September 2014)
Participants Inclusion criteria: aged 1 to 23 months; acute diarrhoea due to gastroenteritis
Exclusion criteria: severe malnutrition (weight for height < 3 SD of WHO charts); dysentery; clinical ev-
idence of coexisting acute systemic illness (e.g. meningitis, sepsis, pneumonia); clinical evidence of
chronic disease (e.g. chronic gastrointestinal disease, chronic liver disease, chronic renal disease); pro-
biotics used in the preceding 4 weeks; antibiotics used for current episode of diarrhoea; severe dehy-
dration
Numbers completing study: 25/25 (100%) probiotic; 25/25 (100%) control
Interventions • Bifidobacterium lactis 14.5 × 106 CFUs/100 mL supplemented into milk formula, daily for 7 days (not
stated whether probiotic alive or killed)
Timing of start of administration is not stated. All participants received usual treatment according to
WHO guidelines and milk formula
Outcomes • Frequency of diarrhoea
• Duration of diarrhoea
• Duration of hospital stay
• Duration of fever
• Vomiting episodes
• Safety and tolerance
No adverse events are attributed to probiotic
Notes Study location: Egypt (low child and adult mortality)
Cause of diarrhoea: dysentery excluded. Rotavirus detected in 66% of participants. No samples were
positive for routine bacterial culture
El-Soud 2015 
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Nutritional status: severe malnutrition excluded
Hydration status: severe dehydration excluded
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not adequately described
Allocation concealment
(selection bias)





Unclear risk Not described
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: 8 months (October 2009 to May 2010)
Participants Inclusion criteria: children aged 5 months to 5 years; admitted to Bezmialem Hospital Pediatric Emer-
gency Department with 3 or more episodes of watery diarrhoea per day in the last 48 hours; diagnosed
as rotavirus gastroenteritis
Exclusion criteria: severe dehydration; stool tests and microscopic examination positive for bacterial
pathogens
Numbers completing study: 25/25 (100%) in both probiotic groups; 25/25 (100%) in control group
Interventions • Saccharomyces boulardii (spp I-745, Reflor Sache, Biocodex, Gentilly, France), 282.5 mg/d; duration
not stated (data extracted for probiotic group)
• Bifidobacterium lactis (spp B94, culture number: N◦118529, Maflor Sache, Mamsel), 30 mg/d; duration
not stated
Treatment start following detection of rotavirus antigen
All participants received oral rehydration therapy and rapid refeeding with a normal diet
Erdogan 2012 
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Outcomes • Mean duration of diarrhoea
• Proportion vomiting by day
No comment regarding adverse events
Notes Study location: Turkey (low child and adult mortality)
Cause of diarrhoea: all participants positive for rotavirus antigen
Nutritional status: not stated
Hydration status: dehydration < 5%: 12 (48%), 5% to 10%: 13 (52%) in S boulardii group; < 5%: 14 (44%),
5% to 10%: 11 (56%) in B lactis group; < 5%: 13 (52%), 5% to 10%: 12 (48%) in control group
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomization not stated
Allocation concealment
(selection bias)





High risk No placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized double-blind placebo-controlled trial; 3 centres
Duration: 7 months (January to July 2009)
Participants Inclusion criteria: aged 6 to 36 months; hospitalized with acute diarrhoea (no longer than 7 days); clin-
ical signs of mild to moderate dehydration (prolonged capillary refill time, abnormal skin turgor, per-
centage loss of body weight); no features of hypovolaemic shock
Exclusion criteria: underlying chronic disease; bloody stools at the moment of first examination; cur-
rent use of antibiotic/probiotic/anti-diarrhoeal medication; demonstration of a bacterial cause for diar-
rhoea; need for parenteral rehydration
Francavilla 2012 
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Numbers completing study: 35/37 (94.6%) probiotic (2 parental non-compliance); 34/37 (91.9%) control
(2 protocol deviation; 1 parental non-compliance)
Interventions • Live Lactobacillus reuteri DSM 17938 (NOOS, Rome, Italy; Biogaia, Stockholm, Sweden) 5 drops twice
daily (4 × 108 CFUs/d) for 7 days
• Placebo (NOOS, Rome, Italy; Biogaia, Stockholm, Sweden), 5 drops twice daily
Intervention started immediately after informed consent given. All participants received ORS to correct
dehydration
Outcomes • Rate of unresolved diarrhoea after 3 days of treatment (proportion of patients in each study group
with continuing diarrhoea)
• Duration of diarrhoea (time in hours from admission until cessation of diarrhoea)
• Duration of hospitalization (time in hours from admission until discharge from hospital)
• Total intake of oral rehydration solution (volume of ORS taken from admission until cessation of diar-
rhoea expressed in millilitres per kilogram of body weight)
No adverse events attributed to probiotic
Notes Study location: Italy (very low child and adult mortality)
Cause of diarrhoea: rotavirus detected in 22/37 (59.5%) in both probiotic and control groups; aden-
ovirus detected in 6 (16.2%) in the probiotic group and in 5 (13.5%) in the control group; no pathogens
identified in 9 (24.3%) in the probiotic group and in 10 (27%) in the control group. Bloody diarrhoea ex-
cluded. Bacterial cause of diarrhoea excluded
Nutritional status: not stated
Hydration status: mild dehydration 25/37 (67.6%) probiotic and 26/37 (70.3%) control; moderate de-
hydration in 12/37 (32.4%) in the probiotic group and in 11/37 (29.7%) in the control group. No partici-
pants in either group had severe dehydration
Source of funding: no funding interests to declare
Discrepancy between data in text and tables for proportion of participants with ongoing diarrhoea at
48 hours; data not used. There was no statistically significant difference in duration of hospital stay be-
tween groups, but no data were presented
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomization
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Francavilla 2012  (Continued)
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Selective reporting (re-
porting bias)





Methods Prospective double-blind randomized placebo-controlled trial; 3 centres
Duration: 4 years, 5 months (April 2009 to September 2013)
Participants Inclusion criteria: aged 4 to 48 months; attended day care (≥ 2 half-days (2.5 hours/d per week atten-
dance) at a day care centre or at home or in someone else’s home, where there are, on average, ≥ 3 chil-
dren including the index child); diagnosed by supervising physician as having gastroenteritis; alterna-
tive diagnostic terminologies (e.g. viral illness, diarrhoea, vomiting, viral infection) that reflect a similar
diagnosis were acceptable; duration of vomiting or diarrhoea < 96 hours
Exclusion criteria: if they (or a family member living in the house) had an indwelling vascular access
line or congenital heart disease, were taking immunosuppressive therapy, or had a known immunod-
eficiency disorder; oral or gastrointestinal surgery within the preceding 7 days; pancreatic dysfunc-
tion; bloody diarrhoea; chronic gastrointestinal disease (not including constipation, irritable bowel
syndrome, gastroesophageal reflux); short bowel syndrome; undergoing radiation therapy; bilious or
bloody vomitus; previous enrolment in the trial; inability to speak or read English or French; supple-
mental probiotics in the form of powder or pill; exclusively breast-fed
Numbers completing study: high dose: 30/32 (93.8%), low dose: 31/34 (91.2%) in the probiotics group
(5 lost to follow-up); 62/66 (93.9%) in the control group (4 lost to follow-up)
Interventions • Probiotic preparation of live Lactobacillus (L helveticus Rosell-52 (5%) and L rhamnosus Rosell-11
(95%)) along with maltodextrin, magnesium stearate, and ascorbic acid; 1 active sachet (4 × 109 viable
colony forming units (CFUs) per sachet) BD for 5 days
• Probiotic preparation of live Lactobacillus (L helveticus Rosell-52 (5%) and L rhamnosus Rosell-11
(95%)) along with maltodextrin, magnesium stearate, and ascorbic acid; 1 active sachet every morn-
ing along with a placebo sachet every night for 5 days
• Placebo containing only inert excipients; identical in appearance, taste, texture, and smell
Intervention was started immediately in the emergency department. All participant caregivers were
instructed to give ORS and to continue normal meals. All interventions were manufactured by Institut
Rosell Inc (Montreal, Quebec, Canada)
NB combined results of both probiotics groups used in analyses
Outcomes • Proportion of children missing at least 1 full day of day care related to vomiting, diarrhoea, dehydra-
tion, fever, or fluid refusal, within 2 weeks of randomization
• Symptoms (e.g. vomiting, diarrhoea) that persisted into weekend days
• Unscheduled visits to healthcare provider related to vomiting, diarrhoea, dehydration, fever, or fluid
refusal, within 2 weeks
• Subsequent hospital visit at which time IV rehydration fluids were administered within 2 weeks of
randomization
• Duration of vomiting and diarrhoea (time from treatment initiation until last diarrhoeal stool or
episode of vomiting)
• Numbers of days of day care and work absenteeism
• Side effects
Side effects including abdominal cramps and rash recorded for both groups; frequency of side effects
higher in control group. No serious adverse events attributed to probiotic
Freedman 2015 
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Notes Study location: Canada (very low child and adult mortality)
Cause of diarrhoea: 39 (30%) had stools tested for viruses; rotavirus detected in 9/18 (50%) probiot-
ic and in 12 (57%) control; adenovirus detected in 2 (11%) probiotic and in 1 (5%)control; no common
bacterial pathogens detected in either group. Bloody diarrhoea excluded
Nutritional status: not stated
Hydration status: baseline clinical dehydration scale score (mean ± SD) 1.6 ± 1.7 probiotic and 1.3 ± 1.7
control
Source of funding: funding to conduct the study provided to Stephen Freedman by Institut Rosell Lalle-
mand Inc, which also provided study drug and placebo. Philip Sherman is the recipient of a Canada Re-
search Chair in Gastrointestinal Disease
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomization
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Double-blind randomized placebo-controlled trial; 6 centres
Duration: 4 years, 5 months (November 2013 to April 2017)
Participants Inclusion criteria: aged 3 to 48 months; 3 or more episodes of watery stools in a 24-hour period; vomit-
ing or diarrhoea for less than 72 hours; clinical diagnosis of acute intestinal infection
Exclusion criteria: they or person living in their household having an indwelling vascular access
catheter; structural heart disease; immunocompromised or receiving immunosuppressive therapy;
hematochezia; bilious vomiting; chronic gastrointestinal disorder; pancreatic dysfunction or insuffi-
ciency; use of probiotics during the preceding 14 days; allergy to soy; inability to complete follow-up;
undergone oral or gastrointestinal surgery within preceding 7 days; previously participated in the trial
Freedman 2018a 
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Numbers completing the study: 414/444 (93%) probiotics (18 lost to follow-up, 12 withdrew) and
413/442 (93%) control (10 lost to follow-up, 19 withdrew)
Interventions • Lyophilized powder of L rhamnosus R0011 and L helveticus R0052 (Lallemand Health Solutions) in a
95:5 ratio; 4 × 109 CFUs twice daily for 5 days
• Placebo (Lallemand Health Solutions) twice daily for 5 days
Participants given IV fluids as needed
Outcomes • Modified Vesikari scale symptom score
• Duration of diarrhoea and vomiting
• Unscheduled physician visits
• Adverse events
• Number of repeat visits to the ED
• Intravenous rehydration
• Hospitalization
• Number of days of work missed by parents or guardians
• Number of days of day care missed by participants
Adverse events were reported in 144 (34.8%) probiotics and in 160 (38.7%) placebo; 2 (0.5%) in the
placebo group had serious adverse events
Notes Study location: Canada (very low child and adult mortality)
Cause of diarrhoea: of those who had a stool sample tested (432 probiotic and 428 placebo), 124
(28.7%) and 85 (19.9%) had rotavirus A detected, 102 (23.6%) and 124 (29.0%) had norovirus GI/GII
detected, 50 (11.6%) and 45 (10.5%) had adenovirus 40/41 detected, 51 (11.8%) and 61 (14.3%) had
Clostridium difficile toxon A/B detected, and 11 (2.6%) and 9 (2.1%) had Salmonella detected in probiot-
ic and placebo groups, respectively
Nutritional status: not stated
Hydration status: median clinical dehydration scale score (IQR): 1 (0 to 2) probiotic and 0 (0 to 2) place-
bo
Source of funding: Canadian Institutes of Health Research (grants 286384 and 325412), Alberta Chil-
dren’s Hospital Foundation Professorship in Child Health and Wellness (to Dr Freedman), grant from
the Alberta Children’s Hospital Foundation to the Pediatric Emergency Medicine Research Associates’
Program, Calgary Laboratory Services (in kind), Provincial Laboratory for Public Health–Alberta Public
Laboratories, Luminex, and Copan Italia. Dr Sherman reports receiving fees for continuing medical edu-
cation from Abbott Nutrition, advisory board fees from Mead Johnson Nutritionals, fees for attending a
workshop from Nestlé Nutrition Institute, and grant support from Lallemand Health Solutions and Bio-
K Plus International
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number-generating software used
Allocation concealment
(selection bias)
Low risk Assignment sequence restricted to research pharmacy at the co-ordinating





Low risk Double-blind trial: participants and all staJ unaware of allocations
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Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; multi-centre
Duration: 1 year (1996)
Participants Inclusion criteria: inpatients and outpatients; infants and children with > 4 liquid or semi-liquid stools/
d for 1 to 5 days
Exclusion criteria: previous probiotic usage; underlying chronic untreated small bowel disease; inflam-
matory bowel disease; any underlying chronic disease or immunosuppressive disease or treatment
Numbers completing study: 287 forms (269 participants) of total of 323 forms (88.9%) received at the
co-ordinating centre were analysed (36 incomplete data or not compliant with protocol); unclear
whether withdrawals occurred at participating centres
Interventions • Lactobacillus GG (ATC 53103, ≥ 10 × 109 CFUs/250 mL) with ORF
• ORF with placebo
Interventions added to ORF and started at recruitment
Outcomes • Number of treatment failures (need for IV fluids)
• Mean duration of diarrhoea (time to last recorded fluid stool)
• Weight gain
• Proportion of children with diarrhoea longer than 7 days
• Mean stool frequency by day of treatment (SDs not given)
• Mean hospital stay
Some outcomes also reported for rotavirus, bacterial infection, and no organism-isolated subgroups
No comment regarding adverse events
Notes Study locations: Poland (low child and adult mortality), Egypt (high child and high adult mortality),
Croatia, Italy, Slovenia, The Netherlands, Greece, Israel, United Kingdom, Portugal (all very low child
and very low adult mortality)
Cause of diarrhoea: rotavirus (56 probiotic/45 placebo); bacterial infection (35/34); parasites (7/6); no
pathogen (45/54). 10 (6.8) probiotic and 15 (10.7) control had bloody diarrhoea
Nutritional status: no data presented
Hydration status: severe dehydration in 1 (0.7) probiotic and 1 (0.7) control; mild/moderate dehydra-
tion in 107 (72.7%) probiotic and 96 (68.2%) control
Guandalini 2000 
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Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not adequately described
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Unclear whether withdrawals occurred at participating centres; 36/323
(11.2%) participant data forms received at the co-ordinating centre were not
analysed as incomplete and/or not compliant with protocol
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: 3 months (November 1995 to January 1996)
Participants Inclusion criteria: consecutive outpatients attending 3 family physicians; infants and children with ≥ 3
watery stools/d of < 48 hours' duration
Exclusion criteria: antibiotic treatment in preceding 3 weeks, breast-feeding, weight:height ratio < 5th
percentile
Numbers completing study: 52/52 (100%) probiotic and 48/48 (100%) control
Interventions • Lyophilized L casei strain GG (Dicloflor 30; 6 × 109 million CFUs/d for maximum 5 days) re-suspended
in milk or formula feed
• ORF only
Interventions started after 6 hours of ORF
Outcomes • Mean duration of diarrhoea (time to last loose or liquid stool assessed by mothers)
Results for rotavirus subgroup also presented
No comment regarding adverse events
Notes Study location: Italy (very low child and adult mortality)
Cause of diarrhoea: rotavirus identified in 30 (57.7%) probiotic and 31 (64.6%) control
Guarino 1997 
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Nutritional status: weight:height ratio < 5th percentile excluded
Hydration status: all had mild to moderate dehydration
Study author clarified that Figure 5 in the published article reports mean and standard error for dura-
tion of diarrhoea; SDs derived from graph. We also extracted data from Canani 1997 (abstract), which
reports standard errors
Probiotic also reduced prevalence of rotavirus in stools on day 6
Source of funding: Ministero della Sanità, AIDS Project (9205.30)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random numbers table
Allocation concealment
(selection bias)





High risk No placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Single-blind randomized controlled trial; 1 centre
Duration: 1 year (March 2017 to February 2018)
Participants Inclusion criteria: previously healthy children aged 6 months to 6 years; acute watery diarrhoea
Exclusion criteria: shock; dysentery; chronic diarrhoea; other acute systemic illness; severe malnutri-
tion and/or immunosuppressive state; use of probiotic or antibiotic in previous 3 weeks
Numbers completing study: 160/160 (100%) probiotic; 150/150 (100%) control
Interventions • Bacillus clausii, 2 billion spores given 12-hourly for 5 days
Timing of start of intervention not stated
Hamid 2019 
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All participants received oral rehydration solution, intravenous fluid as indicated, and zinc supplemen-
tation
Outcomes • Duration of diarrhoea
• Frequency of diarrhoea
• Duration of hospital stay
No comment regarding adverse events
Notes Study location: Bangladesh (high child and adult mortality)
Cause of diarrhoea: dysentery excluded
Nutritional status: grade 1 malnutrition 48 (30%), grade 2 malnutrition 22 (14%) in probiotic group;
grade 1 malnutrition 42 (28%), grade 2 malnutrition 30 (20%) in control group
Hydration status: some dehydration 108 (72%), severe dehydration 29 (19%) in probiotic group; some
dehydration 114 (71%), severe dehydration 33 (21%) in control group
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomization not stated
Allocation concealment
(selection bias)





High risk No placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized double-blind placebo-controlled prospective trial; 1 centre
Duration: 5 months (January to May 2012)
Participants Inclusion criteria: acute diarrhoea (defined as (semi-) watery stools according to Bristol criteria > type 4
lasting 48 hours or less; mild to moderate dehydration; minimum level of parental education was junior
high school
Hegar 2015 
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Exclusion criteria: malnutrition (weight < P3); administration of zinc; chronic condition (such as known
chronic intestinal disease, cystic fibrosis, food allergy, immune deficiency, inflammatory bowel dis-
ease, GI malformation, abnormal GI motility); acute condition (antibiotic treatment during previous 7
days, macroscopic blood in the faeces, use of probiotics except for the probiotics present in infant for-
mula)
Numbers completing the study: 56/56 (100%) probiotic; 56/56 (100%) control
Interventions • Lactobacillus rhamnosus R0011 1.9 × 109 and Lactobacillus acidophilus R0052 0.1 × 109 CFUs/d (Lacid-
ofil®, Institute Rossel Inc, Canada, Dexa Meda, Indonesia) for 7 days (not stated whether probiotics
alive or killed)
• Placebo, identical capsule
Timing of start of administration not stated. All participants given ORS (Indoralite®) ad libitum, 20 mg
zinc sulphate/d for 10 days and normal food intake after initial rehydration
Outcomes • Median (IQR) diarrhoea duration (hours): 68.5 (13 to 165) in probiotic group, 61.5 (21 to 166) in placebo
group (P = 0.596)
• Median (IQR) frequency of defecation episodes: 5.0 (0 to 23) in probiotic group, 5.5 (0 to 29) in placebo
group (P = 0.795)
*Outcomes not stated in methods, but given in results
No adverse events attributed to probiotic
Notes Study location: Indonesia (low child and adult mortality)
Cause of diarrhoea: bloody diarrhoea excluded.
Nutritional status: malnutrition excluded
Hydration status: no participants were severely dehydrated
Source of funding: Dexa Medica (Jakarta, Indonesia) provided the probiotics, and Indofarma (Jakarta,
Indonesia) zinc and ORS, for free
Median (range) duration of diarrhoea (hours) 68.5 (13 to 165) probiotic and 61.5 (21 to 166) control (P =
0.596). We did not convert these data to mean (SD) because IQR was not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomization
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Not described
Incomplete outcome data
(attrition bias)
Low risk Follow-up ≥ 90% in both groups
Hegar 2015  (Continued)
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Methods Randomized controlled trial; 11 centres
Duration: 3 months (February to April 2005)
Participants Inclusion criteria: outpatients; infants and toddlers < 4 years with > 3 watery or loose and non-bloody
stools/d for ≤ 3 days
Exclusion criteria: > 5% dehydration; intake of E coli Nissle 1917 in last 3 months; intake of food supple-
ments or drugs that contain living micro-organisms or their metabolic products or components with-
in 7 days before enrolment or during the trial; other anti-diarrhoeal drugs; breast-feeding, premature
birth; severe or chronic disease of the bowel or severe concomitant disease. Antibiotics stated as exclu-
sion criteria but some children included
Numbers completing the study: 54/55 (98.2%) probiotic and 45/58 (77.6%) control. Reasons for with-
drawal in both groups stated as intervention no longer suitable or required other treatment. All ran-
domized participants included in analyses
Interventions • Live E coli strain Nissle 1917 (Mutaflor suspension; 100 to 300 × 106 organisms/d according to age)
• Placebo
Outcomes • Number of stools, stool consistency, admixture of blood or mucus
• Frequency of vomiting, abdominal pain, and cramps
• Fluid intake, concomitant medication, and general state of health for up to 10 days
Diarrhoea resolution: reduction in stool frequency to < 3 watery or loose stools in 24 hours over a peri-
od of at least 2 consecutive days
Adverse effects: in the probiotic group, 1 had rhinitis and 1 had abdominal cramps. In the placebo
group, 2 had acute otitis media and 1 showed poor compliance. No adverse events attributed to probi-
otic
Notes Study location: Ukraine, Russia (low child, high adult mortality)
Cause of diarrhoea: bloody diarrhoea excluded; 16/55 (29.1%) probiotic and 19/58 (32.8%) control had
viral diarrhoea. Bacterial pathogens isolated from 9/55 (16.4%) probiotic and 4/58 (6.8%) control
Nutritional status: most children well nourished
Hydration status: > 5% dehydration excluded; 0/55 probiotic and 1/58 control children had mild dehy-
dration
Better outcomes with probiotic than placebo for abdominal pain (28/30 vs 24/33) and abdominal
cramps (17/18 vs 21/26)
Parents reported slightly better tolerance of probiotic than placebo, although investigators noted no
difference
Study authors supplied data regarding SDs for diarrhoea duration
Source of funding: ARDEYPHARM provided verum and placebo medications and reimbursed study-re-
lated expenses
Henker 2007a 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomly permuted blocks of 4
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Outcomes reported for > 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 11 centres
Duration: 3 months (February to April 2005)
Participants Inclusion criteria: inpatients; > 3 loose or watery stools without blood/24 hours for > 4 days and < 14
days; moderate dehydration (5% to 10% loss of body weight)
Exclusion criteria: other severe organic or infectious disease; participation in another trial; intake of tri-
al preparation in the past 3 months; intake of probiotic preparation within the past 7 days; antibiotic
or anti-diarrhoeal; severe dehydration (> 10% weight loss); weight < 5th percentile; growth faltering;
breast-feeding; preterm birth
Numbers completing study: 72/75 (96.0%) probiotic (trial intervention no longer suitable/different
treatment needed 2; personal reasons 1); 59/76 (77.6%) control (trial intervention no longer suit-
able/different treatment needed 11; personal reasons 5; intolerable adverse event 1). All randomized
participants included in analyses
Interventions • Escherichia coli strain Nissle 1917 (Mutaflor Suspension, Germany; participants received 100 to 300 ×
106 organisms/d according to age)
• Placebo - Identical suspension
Outcomes • Resolution of diarrhoea (≤ 3 watery or loose stools/24 hours for 4 consecutive days)
• Clinical improvement
• General state of health
• Adverse events
• Tolerance of intervention
Henker 2008 
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1 participant in probiotic group had a mild hypersensitivity reaction, which was assessed as possibly
related to the intervention. In the control group, 1 participant had vomiting, 1 abdominal pain, and 1
dermatitis, and 1 withdrew because of influenza. Study authors commented that the probiotic was safe
and well tolerated
Notes Study location: Ukraine, Russia (low child, high adult mortality)
Cause of diarrhoea: bloody diarrhoea excluded; 12 (16.0) probiotic and 15 (21.1) control had viral diar-
rhoea. Bacterial pathogens isolated from 15 (20.0) probiotic and 19 (25.0) control
Nutritional status: weight < 5th percentile and growth faltering excluded; 2 (2.7) probiotic and 3 (3.9)
control had mild/moderate malnutrition
Hydration status: all had moderate dehydration (5% to 10% loss of body weight)
Fewer children with dehydration at the end of the study in the probiotic group than in the placebo
group. General state of health improved to a greater extent in the probiotic group than in the placebo
group
Significantly fewer children with diarrhoea > 21 days in the probiotic group than in the placebo group
At the end of the study, the rates of mucus in stool, abdominal cramps, and abdominal pain were all
lower in the probiotic group
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomly permuted blocks of 4
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Outcomes reported for > 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Hernandez 1998 
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Duration: not stated
Participants Inclusion criteria: inpatients; uncomplicated acute diarrhoea (not defined); mild dehydration
Exclusion criteria: fever; malnutrition; bloody stools
Numbers completing study: 25/25 (100%) probiotic; 25/25 (100%) control
Interventions • S boulardii (200 mg every 8 hours for 5 days)
• Placebo
Outcomes • Stool frequency
• Persistence of diarrhoea
No adverse events attributed to probiotic
Notes Study location: Mexico (low child and adult mortality)
Cause of diarrhoea: bloody diarrhoea excluded
Nutritional status: malnutrition (not defined) excluded.
Hydration status: all had mild dehydration.
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





Unclear risk Not adequately described
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; multi-centre
Hochter 1990 
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Duration: not stated
Participants Inclusion criteria: outpatients, attending general practitioners, gastroenterologists, and internal physi-
cians; adults with acute diarrhoea (> 3 liquid stools in last 24 hours; in great majority, duration 2 days or
less; 1 participant in the placebo group had diarrhoea for > 10 days)
Exclusion criteria: chronic diarrhoea; blood in stools; drug-induced diarrhoea; antimicrobial treatment;
inflammatory bowel disease
Numbers completing the study: 92/107 (86.0%) randomized participants completed the study (15 in-
eligible: 1 took additional drugs, 14 < 3 liquid stools at presentation). 3/92 participants dropped out (2
probiotic, 1 placebo) because intervention was not effective; results included in analysis
Interventions • S boulardii (perenterol; 600 mg/d for 2 days, then 300 mg/d on days 3 to 7)
• Placebo
Interventions started at presentation
Outcomes • Mean stool frequency on days 1, 3, and 8
• Score derived from stool frequency and consistency
Mean (SD) stool frequency on day 1: 7.6 (4.2) probiotic, 6.9 (3.3) placebo; day 3: 2.4 (2.1) probiotic, 3.0
(2.8) placebo (P = 0.019); day 8: 1.3 (1.1) probiotic, 1.6 (1.1) placebo
No adverse events attributed to probiotic
Notes Study location: Germany (very low child and adult mortality)
Cause of diarrhoea: stool analyses in first 50 participants only: 2 had rotavirus and 3 Salmonella
Nutritional status: all well nourished
Hydration status: no data presented
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





Unclear risk Not described
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Outcomes reported for > 90% in both groups
Hochter 1990  (Continued)
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Selective reporting (re-
porting bias)





Methods Randomized double-blind placebo-controlled trial; 1 centre
Duration: 1 year (October 2014 to September 2015)
Participants Inclusion criteria: children aged 9 to 60 months; hospitalized with acute watery diarrhoea; 3 watery
stools/d without visible blood or mucus (duration not stated)
Exclusion criteria: at least 1 episode of diarrhoea in the month before admission; known to have short
bowel syndrome or chronic (inflammatory) gastrointestinal disease; immunocompromised or im-
munosuppressed; on prolonged steroid therapy; diagnosed as severely dehydrated
Numbers completing study: 143/150 (95.3%) probiotics (3 withdrew; 1 was lost to follow-up; 3 were
self-prescribed); 147/150 (98%) control (2 withdrew; 1 took only 6 doses of study medication)
Interventions • L acidophilus LA-14 (Imexpharm Pharmaceutical Company (Cao Lanh, Vietnam)), 2 sachets of 1 × 108
CFUs twice daily for 5 days (not stated whether probiotic alive or killed)
• Placebo: 2 sachets of identical tasting product containing maltodextrin excipient only (Imexpharm
Pharmaceutical Company (Cao Lanh, Vietnam)) twice daily for 5 days
All participants received standard of care according to national guidelines, including ORS and zinc; typ-
ically participants were not given antimicrobials but were not excluded if they were
Outcomes • Time from first dose of study medication to the start of the first 24-hour period without diarrhoea,
hours, median (IQR): 35 (20 to 68) probiotic and 43 (15 to 66) placebo (P = 1.62)
• Total duration of hospitalization, median (IQR): 79 hours (54 to 104 hours) probiotic and 78 hours (53
to 104 hours) placebo
• Stool frequency in the first 3 days after enrolment
• Treatment failure (i.e. no resolution of diarrhoea during 5-day treatment, severe symptoms for which
treatment was stopped, requirement for additional anti-diarrhoeal treatment)
• Daily rotavirus and norovirus viral loads in patients with PCR amplification-positive faecal samples
• Dynamics of L acidophilus colonization over the course of study follow-up
• Adverse events
Additional exploratory outcomes
• Recurrence of diarrhoea (defined as a new diarrhoea episode since the initial episode, as assessed at
the day 14(+3) follow-up visit)
• Vomiting frequency in the first 3 days after enrolment
No adverse events attributed to probiotic
Notes Study location: Vietnam (low child and adult mortality)
Cause of diarrhoea: bloody diarrhoea excluded. Rotavirus detected in 64/150 (43%) probiotic and in
56/150 (37%) control; norovirus detected in 30/150 (20%) probiotic and in 38/150 (25%) control. Bac-
terial pathogens: Campylobacter in 11/150 (7%), Shigella in 17/150 (11%), and Salmonella in 14/150
(9%) in the probiotic group; Campylobacter in18/150 (12%), Shigella in 20/150 (13%), and Salmonella in
21/150 (14%) in the control group
Nutritional status: not stated
Hong Chau 2018 
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Hydration status: severe dehydration excluded
Source of funding: this work was supported by The Wellcome Trust and the OAK Foundation. SB is
funded by a Sir Henry Dale Fellowship from the Wellcome Trust and the Royal Society (100087/Z/12/Z)
Median (IQR) duration of diarrhoea (hours) 35 (20 to 68) probiotic and 43 (15 to 66) control (P = 1.62).
Median (IQR) duration of diarrhoea (hours) in children with rotavirus diarrhoea 45 (21 to 76) probiotic
(n = 64) and 48 (18 to 66) control (n = 56). We did not convert these data to mean (SD) because of non-
normal distribution
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomization list using block randomization
Allocation concealment
(selection bias)






Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Open-label randomized controlled trial; 1 centre
Duration: 21 months (February 2009 to October 2010)
Participants Inclusion criteria: aged 3 months to 14 years; hospitalized due to mild to moderate dehydration; acute
diarrhoea for < 72 hours
Exclusion criteria: immunodeficiency; severe abdominal distension with risk of bowel perforation; se-
vere infection or sepsis; history of gastrointestinal tract surgery; multiple pathogens identified on cul-
ture; probiotic or antibiotic used in the preceding week; Campylobacter-positive, adenovirus-positive,
or multiple pathogen-positive patients
Numbers completing the study: 82/82 (100%) probiotics; 77/77 (100%) control
Interventions • BIO-THREE (TOA Pharmaceutical Co. Ltd., Tokyo, Japan): Bacillus mesentericus, Clostridium butyricum,
and Enterococcus faecalis; participants aged 6 years or younger: 1 tablet (3.48 × 108 CFUs of a mixture
of E faecalis (3.17 × 108 CFUs), C butyricum (2.0 × 107 CFUs), and B mesentericus (1.1 × 107 CFUs)) 3 times
Huang 2014 
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daily; aged 6 to 12 years: 2 tablets 3 times daily; aged 12 years or older: 3 tablets 3 times daily for 7
days (not stated whether probiotics alive or killed)
Intervention was started after randomization. All participants received supportive treatment (IV fluid,
ORS, rice, and half-strength milk formula)
Outcomes • Severity of gastroenteritis (i.e. Vesikari score)
• Presence of diarrhoea after 7 days of probiotic treatment
• Average length of hospital stay
• Stool frequency after admission
No adverse events attributed to probiotic
Notes Study location: Taiwan (low child and adult mortality)
Cause of diarrhoea: rotavirus detected in 22/82 (26.8%) probiotic and in 20/77 (26%) control; Salmonel-
la detected in 23/82 (28%) probiotic and in 25/77 (32.5%) control; unknown origin in 37/82 (45.1%) pro-
biotic and in 32/77 (41.6%) control. Adenovirus, Campylobacter, and multiple-pathogen-positive pa-
tients excluded
Nutritional status: not stated
Hydration status: no participants had severe dehydration
Source of funding: supported by a Kaohsiung Veterans General Hospital research project grant (No.
VGHKS98-081)
Secondary outcome reporting: adverse events not pre-specified in the methods but reported in the re-
sults
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated 2-block randomization list
Allocation concealment
(selection bias)





High risk No placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)
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Study characteristics
Methods Randomized controlled trial; 1 centre
Duration: not stated
Participants Inclusion criteria: inpatients; infants and children with > 3 watery stools/d for < 7 days and stools posi-
tive for rotavirus. Average dehydration about 5% in both groups
Exclusion criteria: not stated
Number completing study: 21/21 (100%) probiotic and 21/21 (100%) control
Interventions • Live L casei strain GG (2 × 101º CFUs/d for 5 days)
• No probiotic
Interventions started after 6 hours ORF
Outcomes • Mean weight gain
• Mean duration of diarrhoea (definition for recovery from diarrhoea not stated)
• Proportion of participants with diarrhoea by day of treatment
No comment regarding adverse events
Notes Study location: Finland (very low child and adult mortality)
Cause of diarrhoea: all rotavirus diarrhoea
Nutritional status: all well nourished
Hydration status: mean dehydration about 5% in both groups
Source of funding: Academy of Finland and the Foundation for Nutrition Research (Finland)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





High risk No placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)
High risk Outcomes not pre-stated in methods
Isolauri 1994 
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Methods Randomized controlled trial; 12 centres
Duration: not stated
Participants Inclusion criteria: inpatients and outpatients; age 1 month to 3 years; acute diarrhoea (3 or more liquid
stools in 12 hours or single liquid or semi-solid stool with mucus or blood, or both, for 5 days or less)
Exclusion criteria: antibiotics or probiotics in last 5 days; chronic disease of small or large intestine (e.g.
coeliac, cow milk protein allergy, inflammatory bowel disease), immunosuppression, phenylketonuria
Numbers completing study: 45/45 (100%) probiotic and 52/52 (100%) placebo
Interventions • Live L GG ATCC 53103 (101º organisms in 250 mL ORF). ORF administered at 100 mL/kg over first 4
hours. Then either IV fluids or 10 to 15 mL/kg ORF per liquid/semi-solid stool
• ORF with placebo
Start time for administration unclear
Outcomes • Stool frequency, character
• Volume and length of use of ORF
• Duration of diarrhoea (until 2 consecutive normal stools)
• Use of antibiotics after recruitment
No comment regarding adverse events
Notes Study locations: Europe, Egypt, Africa, and single site (Montevideo) in South America (variable child
and adult mortality)
Cause of diarrhoea: bacterial pathogens: probiotic group 29 (64.4%) and placebo group 37 (71.2%); ro-
tavirus: probiotic group 18 (40.0%) and placebo group 21 (40.4%); parasites: probiotic group 2 (4.4%)
and placebo group 4 (7.7%); no pathogens identified: probiotic group 11 (24.4%) and placebo group 14
(26.9%)
Nutritional status: 15 (33.3%) in the probiotic group and 20 (38.5%) in the control group had at least
some malnutrition
Hydration status: mild/moderate dehydration in 15 (33.3%) probiotic and 17 (32.7%) control. More se-
vere dehydration in 0 in the probiotic group and in 2 (3.8%) in the control group
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Alternate allocation
Allocation concealment
(selection bias)





Unclear risk Not adequately described
Jasinski 2002 
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Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled open trial; 1 centre
Duration: 6 months (January to June 2017)
Participants Inclusion criteria: aged 6 months to 5 years; acute watery diarrhoea; hospitalized
Exclusion criteria: not stated
Number completing study: 157/157 (100%) in both probiotic and control groups
Interventions • Saccharomyces boulardii, 250 mg twice daily for 5 days
• No probiotic
Participants given ORS on admission; IV fluids as needed; ciprofloxacin if bacterial diarrhoea
Outcomes • Duration of diarrhoea
• Diarrhoea lasting ≥ 48 hours
• Diarrhoea lasting ≥ 14 days
Adverse events not stated
Notes Study location: Pakistan (high child and adult mortality)
Cause of diarrhoea: acute watery diarrhoea, cause not specified
Nutritional status: not stated
Hydration status: not stated
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not adequately described
Allocation concealment
(selection bias)
Low risk Opaque envelopes used
Javeed 2018 
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Unclear risk Not described
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: 6 months (April to October 2015)
Participants Inclusion criteria: both genders; aged 6 months to 5 years; duration of illness less than 7 days; watery
diarrhoea
Exclusion criteria: chronic diarrhoea; blood in stool; using antibiotics or probiotics; in coma; shock; per-
sistent vomiting
Whether children with dehydration were included/excluded is unclear
Numbers completing study: 48/48 (100%) in both probiotic and control groups
Interventions • Lactobacillus reuteri, 5 drops (100 million CFUs) per day for 5 days
• Placebo, for 5 days
Interventions started on admission. Participants given standard management protocol for diarrhoea
including ORT
Outcomes • Resolution of diarrhoea (not defined)
• Duration of illness ≤ 36 hours: 62.5% probiotic and 39.5% placebo (P = 0.041)
Adverse events not stated
Notes Study location: Pakistan (high child and adult mortality)
Cause of diarrhoea: not stated
Nutritional status: not stated
Hydration status: not clear
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Khan 2017 
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Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





Unclear risk Placebo not described
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: 18 months (April 2006 to September 2007)
Participants Inclusion criteria: inpatients; infants and children aged 6 to 36 months with acute non-bloody, non-bac-
terial diarrhoea (not defined) of less than 2 days' duration; moderate dehydration
Exclusion criteria: severe dehydration, antibiotic consumption, severe vomiting, convulsion, inflamma-
tory cells in stool samples
Numbers completing study: 32/34 (94.1%) probiotic and 30/34 (88.2%) placebo; participants excluded
because of poor compliance
Interventions • Live L acidophilus 3 × 109 and Bifidobacterium bifidum 3 × 109/d for 5 days (Infloran; Laboratorio Far-
maceutico SIT S.r.I., Mede, Pavia, Italy) in 5 to 10 mL of water
• Placebo (maltodextrin)
Start time for administration not stated
All children received IV fluid therapy, oral rehydration solution, and mother’s milk (breast-feeding in-
fants), or complementary food according to the patient's age
Outcomes • Duration of diarrhoea
• Reduction in defecation frequency
• Weight gain
• Duration of hospital admission
No adverse events attributed to probiotic
Notes Study location: Iran (low child and adult mortality)
Kianifar 2009 
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Cause of diarrhoea: non-bloody, non-bacterial diarrhoea (not defined)
Nutritional status: not stated
Hydration status: all had moderate dehydration; severe dehydration excluded
Source of funding: grant from the Vice Chancellery for Research, Mashad University of Medical Sciences
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random numbers table
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Overall follow-up ≥ 90%; no marked differences between arms
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: not stated
Participants Inclusion criteria: unclear whether inpatients or outpatients, or both; aged < 24 months with acute ro-
tavirus diarrhoea (> 3 loose or watery stools/24 hours lasting < 48 hours before inclusion)
Exclusion criteria: not stated
Numbers completing study: 33/33 (100%) probiotic and 30/30 (100%) control
Interventions • Live Bifidobacterium ruminatum (2 × 109 CFUs/d for 5 days)
• Placebo
Timing of administration not stated
Outcomes • Duration of diarrhoea, hours (definition for recovery from diarrhoea not stated), mean: 62 probiotic,
57 placebo (P = 0.6)
• Risk of diarrhoea lasting > 72 hours: RR 1.3 (95% CI 0.67 to 2.6)
Kowalska-Duplaga 1999 
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No adverse events attributed to probiotic
Notes Study location: Poland (low child and adult mortality)
Cause of diarrhoea: all rotavirus diarrhoea
Nutritional status: no data presented
Hydration status: dehydration status similar in both groups; no other data presented
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





Unclear risk Not adequately described
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 3 centres
Duration: not stated
Participants Inclusion criteria: inpatients; infants and children with 3 or more loose stools within 24-hour period of <
72 hours' duration
Exclusion criteria: history of acute diarrhoea within 14 days preceding inclusion in the study; antibiot-
ic treatment; received probiotic up to 7 days before participation in the study; exclusively breast-fed;
chronic alimentary disease; diagnosis of malabsorption; lack of parental consent; lack of diarrhoea
Numbers completing study: 86/87 (98.9%) probiotic and 87/89 (97.8%) placebo
Interventions • L acidophilus, B bifidum, L bulgaricus (3.2 × 109 CFUs/d for 5 days)
• Identical placebo (no details given)
Kowalska-Duplaga 2004 
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Interventions administered from recruitment
Outcomes • Duration of diarrhoea (defined as time to last loose stool)




• Duration of hospital stay
Mean duration of diarrhoea reported for children with rotavirus diarrhoea
No adverse effects attributed to probiotic
Notes Study location: Poland (low child and adult mortality)
Cause of diarrhoea: rotavirus identified in 31 (37.3%) probiotic and 22 (26.8%) placebo. Bacterial
pathogens identified in 6 (7.2%) probiotic and 14 (17%) placebo
Nutritional status: no data presented
Hydration status: no data presented
Source of funding: interventions provided by Allergon, Sweden
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Allocated according to order of presentation
Allocation concealment
(selection bias)





Unclear risk Not adequately described
Blinding of outcome as-
sessment (detection bias)
All outcomes












Methods Randomized controlled trial; 1 centre
Duration: not stated
Kurugol 2005 
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Participants Inclusion criteria: inpatients; aged 3 months to 7 years with acute diarrhoea (liquid, mucous, or bloody
stools passed at least twice as frequently as usual for ≥ 24 hours and < 7 days)
Exclusion criteria: chronic disease; malnutrition; use of antibiotic, anti-diarrhoeal, or other drug influ-
encing gut motility
Numbers completing study: probiotic 100/115 (87.0%; 10 required antibiotics, 5 non-compliant); con-
trol 100/117 (85.5%; 13 required antibiotics, 4 non-compliant)
Interventions • S boulardii (250 mg/d given with water or juice for 5 days)
• Placebo (no details given)
Interventions administered from admission. All children received ORF, normal food for age, and IV flu-
ids as required
Outcomes • Number of stools/d and number of watery stools/d
• Duration of diarrhoea (time to first normal stool)
• Duration of vomiting
• Duration of fever
• Duration of hospital stay
1 child had meteorism (group allocation unclear). No adverse events attributed to probiotic
Notes Study location: Turkey (low child and adult mortality)
Cause of diarrhoea: 39 (39.0%) children in probiotic group and 44 (44.0%) in control group had ro-
tavirus diarrhoea. Overall, bacterial pathogens were isolated in 9 and parasites in 11 children
Nutritional status: malnutrition excluded; no other data presented
Hydration status: severe or moderate dehydration in 3 (3.0%) probiotic and 5 (5.0%) control; mild/
moderate dehydration in 17 (17.0%) probiotic and 24 (24.0%) control
Source of funding: not stated
Secondary outcome reporting: length of hospital stay not pre-specified in the methods but reported in
the results
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Not described
Incomplete outcome data
(attrition bias)
High risk Follow-up < 90% in both groups
Kurugol 2005  (Continued)
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Methods Randomized controlled trial, non-blinded; 1 centre
Duration: 6 months (October 1999 to March 2000)
Participants Inclusion criteria: inpatients; consecutive admissions; aged 6 to 60 months; diarrhoea < 5 days and > 3
watery stools in last 24 hours (average dehydration about 5% in both groups)
Exclusion criteria: bloody stools; anti-diarrhoeal or anti-peristaltic drugs; children receiving lac-
tose-free protein hydrolysated formula for malabsorptive disorder; compromised immune system
Numbers completing study: 50/50 (100%) probiotic and 50/50 (100%) control
Interventions • Lyophilized L acidophilus and Bifidobacterium infantis (Infloran Berna; 3 × 109 of each organism/d for
4 days)
• No additional treatment
All children had IV fluids because of vomiting. Interventions were administered after initial fluid thera-
py
Outcomes • Stool frequency by day of intervention
• Duration of diarrhoea (time until last watery stool)
• Recovery rate on day 2
No comment regarding adverse effects
Notes Study location: Taiwan (low child and adult mortality)
Cause of diarrhoea: bloody diarrhoea excluded
Nutritional status: no data presented
Hydration status: % average dehydration 4.3 (SD 1.5) probiotic and 4.0 (1.4) control
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





High risk No placebo
Lee 2001 
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Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized, double-blind, placebo-controlled clinical trial; 1 centre
Duration: 3 months (January to March 2018)
Participants Inclusion criteria: male and female; 18 to 65 years of age; symptoms of acute diarrhoea manifesting
within 48 hours before entering the trial; ≥ 3 incidences of unformed stool and last stool passed of un-
formed consistency (type 7 Bristol stool form scale) within 24 hours before entering the trial; com-
plaints of abdominal discomfort within the last hour; written informed consent by study participants
Exclusion criteria: severe form of diarrhoea or symptoms of more severe disease complexity; purulent
or bloody stools; presence of erythrocytes or leukocytes in stools; required antibiotic treatment; pres-
ence of ulcers
Numbers completing study: 30/30 (100%) in both probiotic and control groups
Interventions • Bacillus coagulans strain LBSC (DSM17654) (Advanced Enzyme Technologies Ltd., Thane, India) 3
times per day for 7 days
• Placebo (maltodextrin 1 g) 3 times per day for 7 days
Participants given supportive treatment as needed
Outcomes • Time to last unformed stool
• Number of unformed stools produced
• Change in severity of abdominal pain
• Time to complete resolution of abdominal discomfort
• Complete remission of diarrhoea
• Rate of reoccurrence
• Quality of life (QoL) assessment
• Adverse events or serious adverse events
No adverse events attributed to probiotic
Notes Study location: India (high child and adult mortality)
Cause of diarrhoea: not specified
Nutritional status: not stated
Hydration status: not stated
Source of funding: Advanced Enzyme Technologies Ltd provided technical inputs, study drugs, and lab-
oratory facilities to carry out the study
Maity 2019 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random numbers
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: not stated
Participants Inclusion criteria: inpatients; infants and children with severe acute diarrhoea (defined as 1 watery or
mucous stool or 3 or more loose stools daily for > 24 hours)
Exclusion criteria: moderate or severe malnutrition; total or partial breast-feeding; diarrhoea > 48
hours; need for antibiotic treatment; allergy to cow's milk; gastrointestinal or other chronic pathology
12/212 (5.7%; 3 study groups) withdrawn after recruitment as they did not match the age criteria. Num-
bers completing study: 70/70 (100%) probiotic and 71/71 (100%) control
Interventions • Live B lactis Bb12 (109 CFUs/g milk powder) and S thermophilus TH4 (5 × 108 CFUs/g milk powder)
administered until 24 hours after diarrhoea ended
• Same probiotic preparation at a lower dose; not included in this review
• Milk-based, lactose-free formula
Interventions administered after oral or parenteral rehydration
Outcomes • Stool frequency and consistency daily until day 7
• Diarrhoea duration (end of episodes defined as first formed stool if followed by 2 consecutive non-
watery stools or 12 hours without evacuation)
• Failure of treatment
No specific comment regarding adverse effects
Mao 2008 
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Notes Study location: China; low child and adult mortality
Cause of diarrhoea: rotavirus diarrhoea occurred in 87% and bacterial diarrhoea in 13% in both groups
Nutritional status: moderate or severe malnutrition excluded
Hydration status: no data presented
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





Unclear risk Not described
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: not stated
Participants Inclusion criteria: inpatients; infants and children with acute rotavirus diarrhoea (stool frequency and
consistency not stated) of duration ≤ 3 days
Exclusion criteria: infectious diarrhoea other than rotaviral diarrhoea; serum sodium > 155 mmol/L or <
130 mmol/L; history of malabsorption, respiratory or systemic infection
Numbers completing study: 40/40 (100%) probiotic and 40/40 (100%) control
Interventions • Bifilac (species of bacteria not mentioned; information from manufacturers; Streptococcus faecalis
T-110 30 million bacteria, Clostridium butyricum TO-A 2 million bacteria, Bacillus mesentericus TO-A
1 million bacteria, Lactobacillus sporogenes 50 million bacteria. Total of 249 × 106 bacteria/d for < 14
days)
• Placebo (no details given)
Narayanappa 2008 
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When interventions started is not stated
Outcomes • Frequency of diarrhoea
• Duration of diarrhoea
• Amount of IV fluid given
• Amount of ORF given
• Rotavirus shedding
No adverse effects attributed to the probiotic
Notes Study location: India; high child and adult mortality
Cause of diarrhoea: all rotavirus diarrhoea
Nutritional status: no data presented
Hydration status: no data presented
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





Unclear risk Not described
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Double-blind randomized placebo-controlled trial; 1 centre
Duration: 9 months (November 2008 to July 2009)
Participants Inclusion criteria: aged 6 months to 6 years; presenting with a complaint of acute diarrhoea; English or
Spanish speaking; had access to a telephone and was available to receive calls daily for 5 days
Nixon 2012 
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Exclusion criteria: admitted to inpatient service; had risk factors for non-viral diarrhoea (prolonged di-
arrhoea longer than 7 days, gross blood, antibiotic exposure, or inflammatory bowel disease); immune
compromised; risk factors for probiotic-associated systemic illness (indwelling central line, short gut
syndrome); allergy to milk products
Numbers completing study: 67/77 (87%) probiotics (10 lost to follow-up); 71/78 (91%) control (7 lost to
follow-up)
Interventions • Lactobacillus caseistrain GG (Amerifit Brands, Cromwell, CT, USA), 1 capsule 2 times per day for 5 days
(not stated whether probiotic alive or killed)
• Placebo capsule containing inulin (Amerifit Brands), 2 times per day for 5 days
Intervention started in paediatric emergency department. Participants advised to avoid yogurt
Outcomes • Time to return of normal stool
• Proportion returning to normal stool
• Number of diarrhoeal stools
• Overall ability of patients or parents to return to their normal activities
• Return to medical care
• Need for hospitalization
No adverse events attributed to probiotic
Notes Study location: USA (very low child and adult mortality)
Cause of diarrhoea: bloody diarrhoea excluded
Nutritional status: not stated
Hydration status: not stated
Source of funding: this study was sponsored by Amerifit Brands (Cromwell, CT, USA), which provided
LGG and placebo powder, as well as a small monetary compensation for participants’ telephone air-
time; supported in part by CTSA Grants UL1 RR025750, KL2 RR025749, and TL1 RR025748 from the Na-
tional Center for Research Resources (NCRR), a component of the NIH, and an NIH roadmap for Medical
Research
Median (IQR) duration of diarrhoea (hours) 60 (37, 111) probiotic and 74 (43, 120) control (P = 0.37). We
did not convert these data to mean (SD) because of non-normal distribution. However, study authors
provided the following further information regarding the duration of diarrhoea, which we have includ-
ed in this review
• Probiotic arm: N = 63; mean (SD) 2.8193 (1.49981) days
• Placebo arm: N = 66; mean (SD) 3.0846 (1.64460) days
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random numbers table
Allocation concealment
(selection bias)





Low risk Identical placebo
Nixon 2012  (Continued)
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Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Overall follow-up <90%
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: 6 months (October 2004 to March 2005)
Participants Inclusion criteria: inpatients and outpatients; previously healthy children; aged 6 months to 10 years;
acute diarrhoea (not defined)
Exclusion criteria: severe systemic infection or sepsis; chronic disease; previous antibiotics; anti-diar-
rhoeal drugs; primary/secondary immune deficiency
Numbers completing study: 16/16 (100%) probiotic and 11/11 (100%) control
Interventions • S boulardii (500 mg/d in 5 mL of water for 7 days)
• Placebo
Start of intervention unclear
Outcomes • Number, characteristics, and frequency of stools
• Blood tests (blood count and lymphocyte subsets, C-reactive protein, blood smear, complement, im-
munoglobulins, and cytokines)
Mean (SD) number of stools on day 3: 1.68 (0.23) probiotic, 3.36 (0.38) placebo (P < 0.05); day 4: 0.43
(0.22) probiotic, 1.81 (0.42) placebo (P < 0.05); no significant differences between groups for stool fre-
quency on days 1 and 2
No adverse events attributed to probiotic
Notes Study location: Turkey (low child, low adult mortality)
Cause of diarrhoea: 1 (6.3%) child in probiotic group and 0 in control group had bacterial diarrhoea
Nutritional status: mild/moderate malnutrition in 2 (12.5%) probiotic and in 1 (9.1%) control
Hydration status: severe dehydration in 1 (6.3%) in probiotic group and in 0 in control group; mild/
moderate dehydration in 3 (18.8%) probiotic and 2 (18.2%) control
Source of funding: Sanofi-Aventis (Paris, France) provided laboratory reagents and a commercial prepa-
ration of S boulardii
Risk of bias
Bias Authors' judgement Support for judgement
Ozkan 2007 
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Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: 6 weeks (July to mid-August 1993)
Participants Inclusion criteria: inpatients; infants and children with > 3 watery stools in last 24 hours and diarrhoea
for < 14 days
Mean (SD) weight-for-age z score -1.15 (0.95) probiotic and -1.8 (1.4) placebo
Exclusion criteria: exclusive breast-feeding; septicaemia
Numbers completing study: 20/20 (100%) probiotic and 19/19 (100%) placebo. However, data ex-
tractable for subset with watery diarrhoea only: 14/20 (70%) probiotic and 12/19 (63.2%) placebo. No
data for children with bloody stools presented
Interventions • Live Lactobacillus GG (109 to 101º CFUs bd for 2 days)
• Placebo
Interventions started after 6 hours ORF
Outcomes • Mean duration of diarrhoea (time to last watery stool)
• Mean stool frequency on days 1 and 2
Vomiting occurred in 1 child in the placebo group. No adverse events were attributed to probiotic
Notes Study location: Thailand (low child and adult mortality)
Cause of diarrhoea: bloody stools in 6 children in probiotic group and in 7 in placebo group. All negative
for parasites and cryptosporidium; 2 rotavirus and 1 astrovirus patients in the probiotic group and 5 ro-
tavirus patients in the control group
Nutritional status: no data presented
Pant 1996 
Probiotics for treating acute infectious diarrhoea (Review)










Cochrane Database of Systematic Reviews
Hydration status: severe dehydration in 2 (10%) probiotic and 4 (21%) control; mild/moderate dehydra-
tion in all remaining children
Source of funding: Scientific Hospital Supplies, UK, provided the probiotic
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes





High risk Follow-up < 90%
Selective reporting (re-
porting bias)





Methods Double-blind randomized placebo-controlled trial; 1 centre
Duration: not stated
Participants Inclusion criteria: aged 9 to 16 months; diagnosed as infected with rotavirus via a latex agglutination
test
Exclusion criteria: not stated
Numbers completing study: 28/28 (100%) probiotics; 29/29 (100%) control
Interventions • Lyophilized Bifidobacterium longum BORI and Lactobacillus acidophilus AD031 (BIFIDO Co., Ltd.,
Hongchun, Korea) packet (containing 20 billion CFUs/g of B longum BORI and 2 billion CFUs/g of L
acidophilus AD031), twice a day within 10 minutes of each meal for 3 days
• Placebo: visually identical packet containing probiotic-free skim milk powder (BIFIDO Co., Ltd.,
Hongchun, Korea), twice a day within 10 minutes of each meal for 3 days
Timing of start of administration not stated
Outcomes • Duration of fever
• Frequency of diarrhoea
• Frequency of vomiting
Park 2017 
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• Duration of diarrhoea before and after the study period in both groups
No adverse events attributed to probiotic
Notes Study location: South Korea (low child and adult mortality)
Cause of diarrhoea: all rotavirus diarrhoea
Nutritional status: not stated
Hydration status: not stated
Source of funding: support of the “Cooperative Research Program for Agriculture Science & Technolo-
gy Development (Project No. PJ01123001)”, the Rural Development Administration, and “the Promot-
ing Regional specialized Industry (Project No. R0004140)”; the Ministry of Trade, Industry and Energy
(MOTIE); and the Korea Institute for Advancement of Technology (KIAT), Republic of Korea
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Unclear risk Not adequately described
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized double-blind placebo-controlled trial; 1 centre
Duration: 18 months (April 2010 to September 2011)
Participants Inclusion criteria: children aged 3 to 72 months; hospitalized due to acute diarrhoea; parents consent-
ed to participate
Exclusion criteria: previously treated during this diarrhoeal episode with probiotics or another anti-di-
arrhoeal drug (i.e. kaolin, pectin, smectite, activated charcoal, racecadotril, or cholestyramine); had
other gastrointestinal disease, chronic disease, or severe dehydration
Phavichitr 2013 
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Numbers completing study: 53/53 (100%) probiotics; 53/53 (100%) control
Interventions • Lyophilized combination of Lactobacillus acidophilus and Bifidobacterium bifidum (Infloran®) (Labo-
ratorio Farmaceutico SIT); aged < 1 year: 1 capsule (containing a minimum of 1 billion organisms of
L acidophilus and B bifidum, with lactose and magnesium stearate as excipients) twice daily; aged ≥ 1
year: 1 capsule 3 times daily for 7 days maximum or until cessation of diarrhoea
• Placebo containing lactose and magnesium stearate excipients (Laboratorio Farmaceutico SIT); aged
< 1 year: 1 capsule twice daily; aged ≥ 1 year: 1 capsule 3 times daily for 7 days maximum or until
cessation of diarrhoea
Intervention started after randomization. All participants given rehydration therapy (orally and intra-
venously)
Outcomes • Direct medical costs (hospital and service expenses, drug cost in Thai Baht (THB))
• Total cost (direct medical cost and indirect cost, i.e. estimated parental income loss)
• Length of stay (days), median (IQR): 2 (2 to 3) in probiotic group and 3 (2 to 4) in placebo group (P =
0.049)
• Duration of illness (days), median (IQR): 4 (3 to 6) in probiotic group and 5 (4 to 6) in placebo group
(P = 0.068)
• Drug acceptability
First day of hospitalization was counted as 1 day only if the patient was admitted before 4:00 PM; dis-
charge day was counted as 1 day only if the patient leT after 12:00 PM. Patients were discharged after
recovery
No serious adverse events attributed to probiotic; no comment regarding non-serious events
Notes Study location: Thailand (low child and adult mortality)
Cause of diarrhoea: rotavirus detected in 39.6% in the probiotic group and in 29.4 in the control group;
bacteria detected in 8.2% probiotic and in 22.4% control. Bloody diarrhoea or mucus in 9.4% probiotic
and in 13.2% control
Nutritional status: not stated
Hydration status: severe dehydration excluded
Source of funding: probiotics and placebo and partial financial support for this study were provided by
Laboratorio Farmaceutico SIT
Median (IQR) duration of diarrhoea (days): 4 (3 to 6) probiotic and 5 (4 to 6) control (P = 0.068). We did
not convert these data to mean (SD) because of non-normal distribution
Median (IQR) duration of hospitalization (days): 2 (2 to 3) probiotic and 3 (2 to 4) control (P = 0.049); no
decimal place reported; therefore calculation of standard deviation unreliable
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomization
Allocation concealment
(selection bias)






Low risk Identical placebo
Phavichitr 2013  (Continued)
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Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: 12 months (May 2005 to May 2006)
Participants Inclusion criteria: inpatients; infants and children with 3 or more watery stools/d for less than 48 hours
and clinical dehydration
Exclusion criteria: bloody stools; hypovolaemic shock; acute systemic illness; antibiotic or anti-diar-
rhoeal medication
18/178 children were withdrawn mainly because of parent non-compliance; likely to have been with-
drawn before recruitment. Numbers completing study: 40/40 (100%) probiotic and 40/40 (100%) place-
bo
Interventions Children randomized to 1 of 4 groups: A, yogurt fermented with L acidophilus; B, L acidophilus supple-
ment; C, conventional yogurt; D, placebo. Groups B and D selected for review
• L acidophilus (10 × 109 CFUs/; duration of treatment not stated; unclear if live or killed)
• Placebo (no details given)
Start of administration not stated
Outcomes • Weight change
• Duration of hospital stay
• Stool frequency on days 1, 2, and 3
• Signs and symptoms on day 3
Mean (SD) stool frequency on day 2: 4.0 (3.2) probiotic, 4.0 (3.6) placebo; on day 3: 1.4 (2.6) probiotic,
2.3 (2.6) placebo
No adverse effects attributed to probiotic
Notes Study location: Iran; low child and adult mortality
Cause of diarrhoea: bloody diarrhoea excluded; no bacteria or parasites identified in stool samples
Nutritional status: severe malnutrition excluded
Hydration status: severe dehydration in 1/40 (2.5%) probiotic and 2/40 (5%) control; all the rest had
mild/moderate dehydration
Source of funding: supported by a grant from Tabriz Medical University
Rafeey 2008a 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Restricted randomization using random permuted blocks
Allocation concealment
(selection bias)





High risk Different forms of treatment given
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: 2 months (July and August 1993)
Participants Inclusion criteria: inpatients; undernourished infants and children with > 3 watery stools in last 24
hours for < 14 days' duration and at least moderate dehydration
Exclusion criteria: severe malnutrition; septicaemia
Numbers completing study: 36/40 participants; 4 withdrawals (2 diagnosed with cholera, 1 developed
pneumonia, 1 refused anything by mouth). Results presented for 19/21 (90.5%) in the probiotic group
and for 17/19 (89.5%) in the placebo group
Interventions • Live Lactobacillus GG (2 × 1011ˉ12 CFUs/d for 2 days)
• Placebo
Interventions started after 4 to 6 hours ORF
Outcomes • Stool frequency on days 1 and 2
• Frequency of vomiting on days 1 and 2
• Weight gain
Outcomes for watery (non-bloody) diarrhoea also presented: mean (SD) stool frequency day 2 for pro-
biotic (n = 16) vs placebo (n = 16) was 4.4 (2.0) vs 6.6 (4.2) (P ≤ 0.05), and persistent diarrhoea at 48
hours was seen in 5 (31%) vs 12 (75%) participants (P ≤ 0.01). Definition of persistent diarrhoea not stat-
ed
Raza 1995 
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Less vomiting in the probiotic group; myoclonic jerks occurred in 1 child in each group. No adverse
events were attributed to probiotic
Notes Study location: Pakistan (high child and adult mortality)
Cause of diarrhoea: bloody diarrhoea included
Nutritional status: all had mild/moderate malnutrition; severe malnutrition excluded
Hydration status: severe dehydration in 14 (66.7) probiotic and 7 (37) control; all the rest had moderate
dehydration
Duration of diarrhoea not measured (many children discharged before stool character had changed)
Source of funding: Scientific Hospital Supplies, UK, provided the probiotic
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Overall follow-up ≥ 90%; no marked differences between arms
Selective reporting (re-
porting bias)





Methods Double-blind randomized controlled trial; 1 centre
Duration: 10 months (January to October 2008)
Participants Inclusion criteria: children aged 2 months to 7 years; admitted to paediatric unit of Srinakharinwirot
University Hospital with a diagnosis of diarrhoea (watery/mucous stool ≥ 3 times in 24 hours) of > 72
hours' duration
Exclusion criteria: evidence of systemic infection; neurological disturbance; history of convulsions; con-
ditions such as chronic immunodeficient gastrointestinal condition; severe dehydration; children who
had received treatment with probiotics and medications that interfere with intestinal motility during
the present illness
Rerksuppaphol 2010 
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Numbers completing study: 20/22 (91%) in the room temperature probiotic group (2 for parental
concern), 23/23 (100%) in the refrigerated probiotic group; 21/22 (95.5%) in the control group (1 for
parental concern). All randomized participants were analysed
Interventions • Live refrigerated Lactobacillus acidophilus (minimum 109/capsule) and Bifidobacterium bifidum (min-
imum 109/capsule) (Infloran, Berna, Switzerland) (data extracted for analysis)
• Lactobacillus acidophilus (minimum 109/capsule) and Bifidobacterium bifidum (minimum 109/cap-
sule) (Infloran, Berna, Switzerland) stored at room temperature (probiotic viability not assessed) (da-
ta not extracted for analysis)
• Refrigerated placebo (capsule of powdered ORS identical in colour and size)
Timing of onset of administration not stated. All capsules opened and powder dissolved in milk or
some other fluid and given as 1 capsule 3 times daily until the end of diarrhoea and up to maximum of
5 days
Outcomes • Duration of diarrhoea
• Number of abnormal watery or mucous stools passed
• Duration of hospital stay
• Requirement for rehydration fluid
No adverse events attributed to probiotic
Notes Study location: Thailand (low child and adult mortality)
Cause of diarrhoea: rotavirus detected in 7 (30.4%) in the refrigerated probiotic group and 9 (40.9%) in
the room temperature probiotic group and in 5 (22.7%) in the control group
Nutritional status: not stated
Hydration status: mild/no dehydration 15 (68.2%) in the room temperature probiotic group, 18 (78.3%)
in the refrigerated probiotic group, and 17 (72.3%) in the control group; moderate dehydration 7
(31.8%) in the room temperature probiotic group, 5 (21.3%) in the refrigerated probiotic group, and 5
(22.7%) in the control group; severe dehydration excluded
Source of funding: this study was supported by grants from the Faculty of Medicine, Srinakharinwirot
University, Thailand
Median (IQR) duration of diarrhoea (hours) 28 (32) in the probiotic arm and 51.5 (44) in the control arm.
Median (IQR) duration of hospitalization (hours) 46 (42) in the probiotic arm and 64 (48) in the control
arm (P > 0.05). We did not convert these data to mean (SD) because of non-normal distribution
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomization
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Outcome assessor blinded to intervention
Rerksuppaphol 2010  (Continued)
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Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized double-blind placebo-controlled trial; 1 centre
Duration: 17 months (May 2008 to September 2009)
Participants Inclusion criteria: children aged 3 to 59 months; acute onset of diarrhoea (of < 48 hours); admitted to
DTTU (diarrhoea treatment and training unit)
Exclusion criteria: clinical evidence of severe malnutrition; systemic infection; encephalopathy and/or
convulsion; electrolyte imbalance; invasive diarrhoea; previous use of any probiotics
Numbers completing study: 43/54 (79.6%) in the probiotics group (6 leT the study; 5 treatment failure);
47/54 (87%) in the control group (3 leT study; 4 treatment failure). All 108 patients included in analysis
Interventions • Saccharomyces boulardii (Econorm, Dr Reddy’s Laboratories) 250 mg, mixed with puJed rice powder,
twice daily for 5 days or to end of illness (whichever was sooner) (not stated whether probiotic alive
or killed)
• Placebo, in an identical packet, mixed with puJed rice powder, twice daily for 5 days or to end of illness
Intervention was started following receipt of informed consent. All participants were managed with
ORS, zinc, and feeding as per guidelines of the IAP task force on diarrhoea
Outcomes • Duration of post-intervention diarrhoea (time from enrolment to recovery)
• Total ORS consumed
• Number of stools passed
• Weight gain
• Total IVF needed
No adverse events attributed to probiotic
Notes Study location: India (high child and adult mortality)
Cause of diarrhoea: rotavirus detected in 14/93 (15.1%) samples tested; V cholerae detected in 4 (7.4%)
in both probiotic and control groups. Invasive diarrhoea excluded
Nutritional status: moderate malnutrition 19 in the probiotic group and 23 in the control group. Mean
weight for age 75.84% (± 13.13) in the probiotic group and 72.87% (± 11.22) in the control group; mean
weight for height 83.39% (± 10.72) in the probiotic group and 82.31% (± 10.82) in the control group. Se-
vere malnutrition excluded (weight for age below 60% or weight for length/height below 70%)
Hydration status: no dehydration 22 in the probiotic group and 23 in the control group; some dehydra-
tion 26 in the probiotic group and 24 in the control group; severe dehydration 6 in the probiotic group
and 7 in the control group
Source of funding: no role for funding source in this trial
Risk of bias
Riaz 2012 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk External block randomization
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Outcomes reported for > 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: 21 months (June 2002 to March 2004)
Participants Inclusion criteria: inpatients; Aboriginal children aged 4 months to 2 years with acute diarrhoea defined
as ≥ 3 loose stools during 24 hours before presentation and duration < 7 days; able to tolerate ORF
Exclusion criteria: oxygen required during the study period; chronic cardiac, renal, or respiratory dis-
ease; previous gastrointestinal surgery; proven sucrose intolerance; suspected or known immunodefi-
ciency; received probiotic before enrolment; younger than 4 months
Numbers completing study: 201 assessed for eligibility; 103 refused participation and 28 failed to con-
sent. Probiotic arm: 4 discharged before intervention, 1 parental withdrawal, 33/38 (86.8%) completed
study. Control arm: 1 parental withdrawal, 31/32 (96.9%) completed study
Interventions • Live L casei strain GG (> 15 × 109 CFUs/d for 3 days)
• Identical placebo (no details given)
Interventions administered within 24 hours of admission
Outcomes • Small intestinal absorption capacity
• Diarrhoea duration (defined as time to last loose stool in which fewer than 3 loose stools occurred
within a 24-hour period)
• Diarrhoeal frequency
• Total stool output
• Proportion of participants with diarrhoea on days 3 and 4
• Change in body weight on days 1 and 4
• Total ORF and IV fluid required
Ritchie 2010 
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• Safety and tolerability
No adverse events attributed to probiotic
Notes Study location: Australia (very low child and low adult mortality). However, this study recruited Aborigi-
nal children who commonly had comorbidities such as pneumonia and malnutrition related to poverty
and social disadvantage in the top end of the Northern Territory. Therefore, data not included in analy-
sis according to country mortality strata
Cause of diarrhoea: bacterial pathogens identified in 4 (12%) probiotic and 4 (13%) control; rotavirus
identified in 11 (33%) probiotic and 6 (19%) control; parasites identified in 2 (6%) probiotic and 2 (6%)
control
Nutritional status: mild/moderate malnutrition common amongst participants; no other data present-
ed
Hydration status: severe dehydration in 0 probiotic and in 1 (3.2%) control; all the rest had mild/moder-
ate dehydration
Source of funding: project supported by Australian National Health and Medical Research Council
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated block randomization
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Overall follow-up ≥ 90%, but marked differences (> 10%) between study arms
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 2 centres
Duration: 6 months (December 1998 to May 1999)
Participants Inclusion: inpatients; children aged 6 to 36 months with 2 or more consecutive loose stools in 24 hours
and duration no longer than 7 days
Rosenfeldt 2002a 
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Exclusion criteria: underlying chronic disease; antibiotics prescribed during the study period
Numbers completing study: 86 children enrolled, of whom 69 (80.2%) completed the study; exclusions
were made after randomization because antibiotics were prescribed (3 in the control group and 2 in the
probiotic group); rapid recovery before intervention started (3 in the control group and one in the pro-
biotic group); non-compliance with the protocol (4 in the control group and 4 in the probiotic group)
Interventions • Live L rhamnosus 19070-2 and L reuteri DSM 12246 (2 × 109 CFUs of each organism/d for 5 days)
• Identical placebo (skimmed milk powder and dextrose anhydrate)
Interventions started as soon as possible after randomization and no wait for rehydration
Outcomes • Duration of diarrhoea (time from treatment start to appearance of first normal stool as recorded by
parents)
• Persistence of diarrhoea at end of intervention (day 5)
No adverse events attributed to probiotic
Notes Study location: Denmark (very low child and adult mortality)
Cause of diarrhoea: overall, rotavirus was the only pathogen in 40 (58%) children; 6 children had ro-
tavirus and a bacterial pathogen was identified; in addition, Campylobacter jejuni was isolated in 3 chil-
dren, and Salmonella typhimurium in 1 child
Nutritional status: no data presented
Hydration status: no severe dehydration; mild/moderate dehydration in 5 (16.7%) probiotic and in 17
(43.6%) control
Probiotics appeared to reduce significantly the duration of diarrhoea in children treated within 60
hours of the onset of diarrhoea
Hospital stay was shorter in the probiotic group than in the control group (mean 1.6 (SD 1.0) vs 2.7 (SD
2.0), respectively; P = 0.02)
Probiotics also appeared to reduce significantly the number of children excreting rotavirus in stools on
day 5
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





Unclear risk Not described
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Not described
Incomplete outcome data
(attrition bias)
High risk Follow-up < 90% in both groups
Rosenfeldt 2002a  (Continued)
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Methods Randomized controlled trial; 19 day care centres
Duration: 6 months (December 1998 to May 1999)
Participants Inclusion criteria: outpatients; children aged 6 to 36 months with 2 or more consecutive loose stools in
24 hours as assessed by parents and with duration no longer than 7 days
Exclusion criteria: underlying chronic disease; antibiotics prescribed during study period
Numbers completing study: 50 children enrolled, of whom 43 (86%) participants completed the study.
Exclusions were made because of hospitalization with excessive vomiting and moderate dehydration
(2 in the placebo group and 3 in the probiotic group), prescribed antibiotics (1 in placebo group), and
non-compliance with protocol (1 in placebo group)
Interventions • Live L rhamnosus 19070-2 and L reuteri DSM 12246 (2 × 109 CFUs of each organism/d for 5 days)
• Identical placebo
Interventions started as soon as possible after randomization
Outcomes • Duration of diarrhoea (time from treatment start to appearance of first normal stool as recorded by
parents)
• Persistence of diarrhoea at end of intervention (day 5)
One participant in the probiotic group complained of constipation (no stools passed from day 3 for 10
days). No adverse events attributed to probiotic
Notes Study location: Denmark (very low child and adult mortality)
Cause of diarrhoea: overall, rotavirus was the only pathogen in 25 children, 2 had rotavirus and a bacte-
rial pathogen identified, 2 had infection with C jejuni and Salmonella typhimurium
Nutritional status: no data presented
Hydration status: mild/moderate dehydration in 3 patients (12.5%) in the probiotic group and in 4
(13.8%) in the control group; no severe dehydration
Probiotics appeared to reduce significantly the duration of diarrhoea in children treated within 60
hours of the onset of diarrhoea
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
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Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Follow-up < 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: 23 months (February 2001 to December 2002)
Participants Inclusion criteria: inpatients; boys aged 4 to 24 months; acute watery diarrhoea (> 4 liquid stools during
24 hours) of < 48 hours' duration
Exclusion criteria: severe malnutrition (< 65% weight for age by the standard of the National Centre for
Health Statistics (NCHS)); systemic infection requiring antimicrobial therapy; bloody diarrhoea; spot
sample of stool revealed V cholerae by dark-field microscopy; antibiotic treatment in the preceding 2
weeks
Numbers completing study: 112/115 (97.4%) probiotic (3 withdrawn by parents) and 115/115 (100.0%)
control
Interventions • Live Lactobacillus paracasei strain ST11 (101º CFUs/d for 5 days)
• Placebo (whey-protein and skimmed milk powder blend)
Interventions started after enrolment. All children received ORF and continued feeding, including
breast milk if breast-fed
Outcomes • Stool output and frequency
• Oral rehydration solution intake
• Daily excretion of rotavirus
No comment regarding adverse outcomes
Notes Study location: Bangladesh (high child and adult mortality)
Cause of diarrhoea: bloody diarrhoea excluded. Rotavirus detected in 78 (69.6%) in the probiotic group
and in 73 (63.5%) in the placebo group; V cholera detected in 14 (12.2%) probiotic and in 16 (13.9%)
placebo
Sarkar 2005 
Probiotics for treating acute infectious diarrhoea (Review)










Cochrane Database of Systematic Reviews
Nutritional status: severe malnutrition (weight < 65% weight for age of NCHS standard) excluded; no
further data presented
Hydration status: mild/moderate dehydration in 54 (47.0%) probiotic and in 65 (56.5%) control
Source of funding: Nestlé Research provided L paracasei. Research supported by the Swedish Agency
for Research in Developing Countries, the Karolinska Institute (Stockholm, Sweden), and Nestlé Re-
search Centre (Lausanne, Switzerland)
Rotavirus outcomes: results presented for < 90% of patients
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomly permutated blocks
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Overall follow-up ≥ 90% for primary outcome
Selective reporting (re-
porting bias)





Methods Prospective double-blind randomized placebo-controlled trial; 10 centres
Duration: 3 years (July 2014 to June 2017)
Participants Inclusion criteria: age 3 months to 4 years; diagnosed with acute gastroenteritis by an ED provider
Exclusion criteria: risk factors for bacteraemia; chronic gastrointestinal disorder; pancreatitis; bilious
emesis; hematochaezia; allergy to L rhamnosus GG, microcrystalline cellulose, erythromycin, clin-
damycin, and beta-lactam antibiotic agents; caregiver did not speak English or Spanish
Numbers completing study: 468/483 (96.9%) probiotic (15 lost to follow-up) and 475/488 (97.3%) con-
trol (13 lost to follow-up)
Interventions • Live Lactobacillus rhamnosus GG (Chr Hansen), 1 × 101º CFUs twice daily for 5 days
• Placebo, twice daily for 5 days
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Interventions started after randomization in the ED
Outcomes • Modified Vesikari scale
• Frequency and duration of diarrhoea
• Frequency and duration of vomiting
• Incidence of unscheduled healthcare visits for symptoms of gastroenteritis within 2 weeks after index
visit
• Number of days of day care missed by participants
• Number of hours of work missed by caregivers
• Rate of household transmission
• Safety
Adverse events reported in 63 (13.3%) and 62 (12.9%) in the probiotic and placebo groups, respectively;
serious adverse events reported in 8 (1.7%) in the probiotic group and in 13 (2.7%) in the placebo group
Study authors were contacted and provided data for the outcomes in this review, including for children
with rotavirus diarrhoea
Notes Study location: USA (very low child and adult mortality)
Cause of diarrhoea: of those who had a stool sample tested (379 in the probiotic group and 382 in the
placebo group), 75 (19.8%) and 60 (15.7%) had rotavirus A, 79 (20.8%) and 70 (18.3%) had norovirus GI/
GII, 28 (7.4%) and 41 (10.7%) had adenovirus 40/41, 25 (6.6%) and 31 (8.1%) had Clostridium difficile tox-
in A/B, 23 (6.1%) and 15 (3.9%) had Shigella, and 153 (40.4%) and 173 (45.3%) had no pathogen detect-
ed in the probiotic and placebo groups, respectively
Nutritional status: not stated
Hydration status: 133/483 (27.5%) in the probiotic group and 133/488 (27.3%) in the placebo group had
dehydration
Source of funding: Eunice Kennedy Shriver National Institute of Child Health and Human Development
and others. Product and placebo were provided in kind by iHealth, the distributors of Culturelle in the
United States
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Web-based randomization (www.randomize.net)
Allocation concealment
(selection bias)





Low risk Identical placebo; participants and personnel who assessed trial outcomes
were unaware of trial group assignments
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk Follow-up ≥ 90% in both groups
Schnadower 2018  (Continued)
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Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: 1 year (1 April 1994 to 31 May 1995)
Participants Inclusion criteria: inpatients; infants and children with ≥ 1 watery stool in the last 24 hours and diar-
rhoea for < 5 days
Exclusion criteria: not stated
Numbers completing study: 123/214 (57%) eligible children admitted during the study period enrolled;
no reasons given for those not recruited. A total of 59/59 (100%) children allocated to the probiotic
group and 64/64 (100%) in the placebo group completed the trial
Interventions • Live L strain GG (American-type culture collection 53 103; 101º CFUs/d as a dried powder for 5 days)
• Placebo
Interventions started with oral rehydration solution. All participants with positive stool cultures re-
ceived antibiotics
Effect of isotonic vs hypotonic oral rehydration solution also assessed
Outcomes • Duration of diarrhoea (defined as last appearance of watery stools)
• Weight gain
• Duration of hospital stay
No comment regarding adverse events
Notes Study location: Russia (low child and high adult mortality)
Cause of diarrhoea: rotavirus identified in 13 (22.0%) probiotic and in 21 (32.8%) control. Bacterial diar-
rhoea identified in 11 (18.7%) probiotic and in 15 (23.4%) control
Nutritional status: no data presented
Hydration status: mean dehydration ~ 4% in both groups
Among children with rotavirus diarrhoea, the probiotic (n = 13) reduced the number of watery stools
compared with placebo (n = 21; P = 0.02, but no data given). No beneficial effect of the probiotic was
seen in those with bacterial diarrhoea (probiotic (n = 11) and placebo (n = 115); P = 0.42)
Stool samples tested for rotavirus (Rotazyme, Dakopotts AS, Denmark) and cultured for Salmonella and
Shigella
Source of funding: Leiras, Turku, Finland, and Valio, Helsinki, Finland
Secondary outcome reporting: duration of hospital stay not pre-specified in the methods but reported
in the results
Risk of bias
Bias Authors' judgement Support for judgement
Shornikova 1997a 
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Random sequence genera-
tion (selection bias)
Unclear risk Not adequately described
Allocation concealment
(selection bias)





Unclear risk Not adequately described
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 2 centres
Duration: 6 months (22 January to 15 July 1996)
Participants Inclusion criteria: inpatients; infants and children with ≥ 3 watery stools in last 24 hours; diarrhoea for
< 7 days; stools positive for rotavirus antigen (IDEIA rotavirus, UK). Mean dehydration about 4% in both
groups
Exclusion criteria: 20 participants who received exclusively or mainly IV fluids were excluded
86/97 (89%) enrolled participants were positive for rotavirus
Numbers completing study: 97 patients enrolled; 86 were positive for rotavirus; 21 in the probiotics
group and 25 in the placebo group (and 20 allocated to a low-dose probiotic group) did not require IV
rehydration and were analysed
Interventions Participants randomized to 1 of 3 groups: 20 in the probiotic small dose (107 CFUs/d) group, 21 in the
probiotic large dose group, 25 in the placebo group. Data from the large dose group were used in this
review
• Live L reuteri (101º to 1011 CFUs/d for maximum 5 days)
• Live L reuteri (107 CFUs/d for maximum 5 days)
• Placebo
Interventions started with ORF
Outcomes • Duration of diarrhoea (time to last watery stool in a 24-hour period with no watery stools)
• Stool frequency on day 2 of treatment
• Weight gain
No comment regarding adverse events
Shornikova 1997b 
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Notes Study location: Finland (very low child and adult mortality)
Cause of diarrhoea: all rotavirus
Nutritional status: no data presented
Hydration status: mean dehydration about 4% in both groups
Data from high-dose probiotic group used for continuous outcomes
Duration of diarrhoea before admission greater in probiotic group (4.2 (SD 1.4) days) than in placebo
group (2.9 (SD 1.2) days). Number with persistent diarrhoea on day 3 derived from graph
Source of funding: BioGaia Biologicals AB
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





High risk Different dosing schedules
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Follow-up < 90%
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: 5 months (29 January to 3 July 1995)
Participants Inclusion criteria: inpatients; infants and children with ≥ 3 watery stools in last 24 hours; diarrhoea for <
7 days; ingested bovine dairy products
Exclusion criteria: immunosuppressive therapy or immune deficiency; allergy to bovine milk; serious
underlying disorder; receiving an investigational product during the preceding month
Numbers completing study: 41 participants initially enrolled: 19/19 (100%) probiotic and 21/22 (95.5%)
placebo (1 participant in the placebo group was removed because the probiotic agent (L reuteri) was
detected in stool; the probiotic was administered to his sibling)
Shornikova 1997c 
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Interventions • Live L reuteri SD 2112 (101º to 1011 CFUs/d for maximum of 5 days)
• Placebo
Interventions started at recruitment
Outcomes • Weight gain
• Duration of diarrhoea (last appearance of watery stools)
• Number of participants with watery diarrhoea according to day of treatment
• Stool frequency on days 2 and 3
• Number of participants with vomiting according to day of treatment
Less vomiting in the probiotic group. No adverse events attributed to probiotic
Notes Study location: Finland (very low child and adult mortality)
Cause of diarrhoea: rotavirus identified in 18 (86%) probiotic and in 12 (63%) control
Nutritional status: no data presented
Hydration status: mean dehydration at baseline greater in the probiotic group (3.9% (SD 1.3)) than in
the control group (3.0 (SD 1.2))
Source of funding: BioGaia Biologicals, Inc., Raleigh, NC, USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not adequately described
Allocation concealment
(selection bias)





Low risk Matching placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Prospective double-blind randomized controlled trial; 3 centres
Simadibrata 2013 
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Duration: 2007 to 2010
Participants Inclusion criteria: acute diarrhea; aged 13 to 60 years; no severe complications
Exclusion criteria: serious complication (renal failure, metabolic acidosis, severe dehydration, hypo-
volaemic shock, heart failure, vomiting, anorexia); history of allergy to Lactobacillus spp; diarrhoea
caused by amoeba, colorectal cancer, or tumour; exclusion criteria with proven cause of diarrhoea,
amoeba, colorectal cancer, or tumour; taking antibiotic therapy
Numbers completing study: 38/45 (84.4%) probiotics (reason for withdrawals not stated); 38/45 (84.4%)
control (reason for withdrawals not stated). All randomized patients analysed
Interventions • Lactobacillus rhamnosus R0011 and Lactobacillus acidophilus R0052 (Lacidofil) (not stated whether
probiotic alive or killed), 2 capsules (containing L rhamnosus (1.9 × 109 CFUs) and L acidophilus (0.1 ×
109 CFUs)) 3 times daily for 7 days
• Placebo: 2 capsules 3 times daily for 7 days
Intervention started as soon after informed consent received as possible. All participants received ORS
(Oralit®)
Outcomes • Stool frequency
• Stool consistency
• Abdominal pain, nausea, vomiting, bloating, tenesmus, headache, fever, thirst
No serious adverse events attributed to probiotic; no comment regarding non-serious events
Notes Study location: Indonesia (low child and adult mortality)
Cause of diarrhoea: pathogen (not defined) detected in 8/38 (21.1%) probiotic and in 7/38 (18.4%) con-
trol. Amoebic diarrhoea excluded
Nutritional status: not stated
Hydration status: severe dehydration excluded
Source of funding: financially supported by Dexa Medica Ltd and Rossel Institute
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not adequately described
Allocation concealment
(selection bias)





Unclear risk Not described
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Follow-up < 90% in both groups
Simadibrata 2013  (Continued)
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Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: not stated
Participants Inclusion criteria: children aged 2 months to 5 years; presenting with acute watery diarrhoea
Exclusion criteria: not stated
Numbers completing study: 145/145 (100%) probiotic; 145/145 (100%) control
Interventions • Saccharomyces boulardii, 50 mg/kg/d, diluted in water or mixed with semi-solid food; duration not
stated
Timing of onset of intervention not stated
All participants received oral rehydration solution
Outcomes • Stool consistency
• Stool frequency
• Duration of diarrhoea
• Appearance of first semi-formed stool
• Rotavirus antigen positive
• Frequency of diarrhoea after 5 days in those with lactose intolerance
• Percentage hospitalized for less than 3 days
No comment regarding adverse events
Notes Study location: India (high child and adult mortality)
Cause of diarrhoea: rotavirus detected in 88/145 (60.7%) probiotic and in 77/145 (53.1%) control
Nutritional status: not stated
Hydration status: not stated
Source of funding: none declared
The frequency of diarrhoea after the third day of intervention was reduced in 60 (64%) probiotic vs 30
(39%) control (P < 0.001)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomization using random numbers table
Allocation concealment
(selection bias)
Unclear risk Not stated
Sirsat 2017 
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High risk No placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Double-blind randomized placebo-controlled parallel-group study; 2 centres
Duration: September to November 2017
Participants Inclusion criteria: patients of either sex; aged 6 months to 5 years; clinical diagnosis of acute diarrhoea;
not had any major illnesses; parents willing to give written informed consent and to follow study proce-
dures
Exclusion criteria: severe malnutrition; requiring antibiotics during study period; severe diarrhoea (re-
quiring treatment other than investigational product and ORS); visible blood in stool; use of probiotics,
antibiotics, or any anti-diarrhoeal medication in the last 3 weeks; participation in any clinical trial or us-
age of any investigational product in the past 90 days; hypersensitivity to any of the active substances
or excipients; previous use (within 48 hours) of kaolin, pectin, bismuth subsalicylate, racecadotril, lop-
eramide, atropine, and other anticholinergic agents
Numbers completing study: 59/60 (98.3%) probiotic (withdrawal due to protocol violation); 60/60
(100%) control
Interventions • Bacillus clausii UBBC-07 (not stated whether probiotic alive or killed) 2 × 109 spores/5 mL 2 times daily
for 5 days
• Placebo suspension (purified water) 2 times daily for 5 days
Timing of start of administration not stated. All participants received ORS
Outcomes • Decrease in frequency of diarrhoea
• Decrease in duration of diarrhoea
• Improvement in consistency of stool
• Decrease in frequency and duration of vomiting episodes
• Decrease in duration of fever
Notes Study location: India (high child and adult mortality)
Cause of diarrhoea: bloody diarrhoea excluded
Nutritional status: severe malnutrition excluded
Sudha 2019 
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Hydration status: not stated
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated block randomization
Allocation concealment
(selection bias)





Unclear risk Unclear whether placebo identical
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: 10 months (September 2003 to June 2004)
Participants Inclusion criteria: inpatients and outpatients; aged 2 months to 6 years with acute diarrhoea (3 or more
stools/d looser than normal that may contain blood or mucus for > 1 and < 5 days)
Exclusion criteria: organic gut disease; underlying chronic illness; immunosuppression; exclusive
breast-feeding
Numbers completing study: 46/49 (93.9%) probiotic; 41/44 (93.2) control. Withdrawals stated to be due
to non-compliance or incomplete data
Interventions • 3 live strains of L rhamnosus 573L/1, 573L/2, 573L/3 (2.4 × 101º CFUs/d; Lakcid L, Biomed, Lublin,
Poland) given orally in glucose
• Identical placebo
Start of intervention delayed > 72 hours for many participants
Outcomes • Duration of diarrhoea (either no abnormal movement for the last 12 hours or time to second normal
stool)
• Weight gain after rehydration
• Number of stools/d
Szymanski 2006 
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• Duration of IV fluids
• Diarrhoea > 7 days
• Gut colonization with probiotics
No adverse events attributed to probiotic
Notes Study location: Poland (low child and adult mortality)
Cause of diarrhoea: bloody diarrhoea included. Overall, 39/87 (45%) had rotavirus (22 probiotic and
17 control), 5/87 (6%) had adenovirus, 9/87 (10%) had a bacterial pathogen, and many children had
norovirus infection
Nutritional status: no data presented
Hydration status: no severe dehydration. Mild/moderate dehydration in 34 (73.9%) probiotic and in 31
(75.6%) control
Source of funding: Wellcome Travel Award
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated block randomization
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized double-blind placebo-controlled trial; 1 centre
Duration: January 2017 to November 2018
Participants Inclusion criteria: younger than 5 years of age; acute gastroenteritis (defined as a change in stool con-
sistency to loose or liquid form and/or an increase in frequency of evacuations (typically ≥ 3 in 24
hours) lasting no longer than 5 days
Szymanski 2019 
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Exclusion criteria: use of antibiotics, gelatin tannate, diosmectite, probiotics, racecadotril, or zinc with-
in a week before enrolment; exclusive breast-feeding; chronic diarrhoeal gastrointestinal disease; im-
munodeficiency disease; malnutrition
Numbers completing study: 44/50 (88%) probiotic (5 LTFU; 1 excluded as mistaken randomization) and
47/50 (94%) control (3 LTFU)
Interventions • L reuteri DSM 17938 2 × 108 colony-forming units (CFUs) daily for 5 days
• Placebo once daily for 5 days
Intervention started immediately after recruitment. All participants given standard rehydration thera-
py
Outcomes • Duration of diarrhoea (time until normalization of stool consistency or normalization of number of
stools and presence of normal stools for 48 hours)
• Need for and duration of intravenous rehydration
• Duration of hospitalization
• Need for hospitalization of outpatients
• Numbers of watery stools
• Vomiting
• Recurrence of diarrhoea (48 hours after intervention)
• Severity of diarrhoea according to modified Vesikari Scale
• Use of concomitant medications
• Adverse events (whether or not they were considered to be related to study products)
Notes Study location: Poland (low child and adult mortality)
Cause of diarrhoea: rotavirus detected in 35/91 (38.5%) (18 (40.9%) probiotic and 17 (36.2%) placebo).
Adenovirus detected in 2/91 (2.2%); Salmonella enteritidis in 2/91 (2.2%); unknown aetiology in 52/91
(57.1%)
Nutritional status: severe malnutrition excluded
Hydration status: 44 children (100%) in the probiotic arm and 44 (93.6%) in the control arm required in-
travenous fluids
Source of funding: no external funding
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomization scheme
Allocation concealment
(selection bias)
Unclear risk No specific details of allocation concealment (and seemed to use fixed block





Low risk Researchers, caregivers, outcome assessors, and a person responsible for sta-
tistical analysis were blinded
Szymanski 2019  (Continued)
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Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Follow-up < 90% in intervention group
Selective reporting (re-
porting bias)





Methods Randomized single-blind controlled trial; 1 centre
Duration: 7 months (August 2007 to February 2008)
Participants Inclusion criteria: inpatients; infants and children with history of acute watery diarrhoea (defined as ≥ 3
stools of liquid consistency/d < 72 hours' duration); positive for rotavirus and with moderate to severe
dehydration
Exclusion criteria: severe malnutrition; systemic infection requiring antibiotic therapy; severe chronic
disease; identification of a second pathogen in the stool; ingestion of antibiotics, probiotics, or nitazox-
anide 3 weeks before admission; recurrence of diarrhoea after discharge
Numbers completing study: 25/30 (83.3%) probiotic; 25/31 (80.6%) control; 25/29 (86.2%) nitazoxanide.
Patients with cause of diarrhoea other than rotavirus were withdrawn (probiotic group: 3 adenovirus, 2
E histolytica; control group: 3 E histolytica, 2 Giardia, 1 S flexneri; nitazoxanide group: 2 adenovirus, 1 E
histolytica, 1 Giardia)
Interventions Participants were allocated to 1 of 3 groups: a nitazoxanide group, a probiotic group, and a control
group that received rehydration solutions only. Data from the probiotic group and from the control
were used for this review
• L acidophilus, L rhamnosus, B longum, S boulardii (total of 2.5 × 109 organisms/d administered for an
average of 4.2 days). Unclear if organisms were live or killed
• Control (ORF only)
Time when interventions started not described
Outcomes • Duration of diarrhoea (time from admission until presence of first soT stool for at least 24 hours)
• Stool number and consistency
• Duration of fever
• Vomiting
• Duration of hospitalization
No adverse events attributed to probiotic
Notes Study location: Bolivia (high child and high adult mortality)
Cause of diarrhoea: all rotavirus diarrhoea
Nutritional status: severe malnutrition excluded; mild/moderate malnutrition in 5 (20%) probiotic and
in 15 (60%) control
Hydration status: all had moderate to severe dehydration; no further data presented
Teran 2009 
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Source of funding: research was not sponsored by any pharmaceutical company
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computerized admissions list
Allocation concealment
(selection bias)





High risk Different dosing schedules
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Follow-up < 90%
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: 1 year (June 200 to May 2001)
Participants Inclusion criteria: consecutive inpatients aged 2 to 29 months with acute, non-bacterial diarrhoea (defi-
nition not stated) lasting > 48 hours able to receive oral medication
Exclusion criteria: concomitant illness; antimicrobial, anti-diarrhoeal, or other drug affecting gut motil-
ity; severe electrolyte disturbance or dehydration
Numbers completing study: 50 cases reported in both arms; numbers withdrawn because of deteriora-
tion in diarrhoea and concomitant disease requiring other drugs unclear
Interventions • Lyophilized Saccharomyces cerevisiae Hansen CBS 5926 (250 mg daily in 5 mL cold liquid)
• 250 mg glucose daily in 5 mL cold liquid
Time of starting interventions and duration of administration not stated
Outcomes Number of children cured at 48 hours
Number of children cured at 96 hours: 42 (84%) probiotic vs 32 (64%) control; P < 0.05
Mean (SD) stool frequency on day 2 after treatment: 3.78 days (0.71) probiotic and 4.24 days (0.99)
placebo (P < 0.01)
Urganci 2001 
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Mean (SD) stool frequency on day 4 after treatment: 2.70 days (0.67) probiotic and 3.12 days (0.93)
placebo (P < 0.05)
No adverse events attributed to probiotic
Notes Study location: Turkey (low child and adult mortality)
Cause of diarrhoea: non-bacterial diarrhoea
Nutritional status: no data presented
Hydration status: none dehydrated
Lactose intolerance identified in 8% in the probiotic group and in 26% in the placebo group
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)





Unclear risk Not described
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Number of children withdrawn not stated
Selective reporting (re-
porting bias)





Methods Single-blind randomized controlled trial; 1 centre
Duration: 8 months (February to September 2017)
Participants Inclusion criteria: children aged 6 months to 36 months; admitted to paediatric department with acute
diarrhoea
Exclusion criteria: blood in stools; clinical signs of a coexisting acute systemic illness like meningitis,
sepsis, pneumonia; severely malnourished and immunocompromised children; prior probiotic or an-
tibiotic drug administration; known hypersensitivity to probiotics
Vidjeadevan 2018 
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Numbers completing study: 34/35 (97.1%) in S boulardii group (1 used antibiotics); 33/35 (94.3%) in B
clausii group (1 used antibiotics, 1 LTFU); 32/35 (91.4%) in control group (2 used antibiotics, 1 LTFU)
Interventions • Saccharomyces boulardii, dose and duration not stated (data extracted for probiotic group)
• Bacillus clausii, dose and duration not stated
Timing of start of intervention not stated
All participants received oral rehydration solution and zinc
Outcomes • Diarrhoea after 72 hours
• Duration of diarrhoea
• Duration of hosptial stay
No comment regarding adverse events
Notes Study location: India (high child and adult mortality)
Cause of diarrhoea: bloody diarrhoea excluded
Nutritional status: not stated
Hydration status: not stated
Source of funding: no funding sources
Median duration of diarrhoea, hours (IQR): 72 (72 to 96) in S boulardii group, 96 (72 to 96) in B clausii
group, and 108 (96-120) in control group. Not appropriate to convert median/IQR to mean/SD for dura-
tion of diarrhoea: small sample size and IQR for Group B either not correct or indicate skewed data
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomization using permuted blocks
Allocation concealment
(selection bias)





Low risk Study participants blinded
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)
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Study characteristics
Methods Randomized controlled trial; 1 centre
Duration: 1 year
Participants Inclusion criteria: outpatients; infants and children aged 3 months to 2 years (urban population, middle
social class); acute, mild to moderate diarrhoea
Exclusion criteria: use of probiotic in the preceding 7 days; chronic intestinal disease; short bowel syn-
drome; malabsorption; ≥ grade 2 malnutrition; severe disease (including dehydration requiring hospi-
talization at the time of consultation); known immunodeficiency; immunosuppressant treatment (oral
or IV corticoids in the preceding 7 days); oral nystatin; oral or parenteral imidazoles; other systemic an-
tifungal agents; macrolides; drugs that alter intestinal motility (antispasmodics, cisapride, antiemetics,
and anti-diarrhoeal drugs) in the preceding 7 days
Numbers completing study: 6/50 (12.0%) excluded from probiotic group and 6/50 (12.0%) from control
group for lack of compliance with protocol medication
Interventions • S boulardii (250 to 500 mg twice daily, according to age, for 6 days)
• Placebo
ORF and antibiotics given when indicated
Outcomes • Number of stools on days 4 and 7
• Number of participants with diarrhoea > 7 days
• Number of participants with liquid stools on days 4 and 7
• Duration of diarrhoea (time to stool frequency < 3/d or stool consistency improved for at least 24
hours)
• Effect when treatment was started within 48 hours after onset of diarrhoea
No comment regarding adverse events
Notes Study location: Argentina (low child and adult mortality)
Cause of diarrhoea: none had bloody diarrhoea; no other data presented
Nutritional status: ≥ grade 2 malnutrition excluded
Hydration status: dehydration requiring hospitalization excluded; all had dehydration < 7%
Stool frequency significantly lower in probiotic than placebo group on days 4 and 7
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random computer-generated into blocks of 20
Allocation concealment
(selection bias)





Low risk Identical placebo
Villarruel 2007 
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Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Follow-up < 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized open study; 1 centre
Duration: 11 months (March 2003 to January 2004)
Participants Inclusion criteria: inpatients and outpatients; infants and children with watery diarrhoea (not defined)
for < 5 days
Exclusion criteria: immunocompromised; suspected dysentery; diagnosed with persistent or chronic
diarrhoea; chronic cardiac, pulmonary, or haematological illness; undergoing antibiotic treatment in
the last 2 weeks; severe dehydration or shock
4/75 withdrawn (1 febrile seizure, 1 urinary tract infection, 2 with pneumonia); 2 participants were with-
drawn from each group
Numbers completing study: 36/38 (94.7%) probiotic; 35/37 (94.6%) control
Interventions • Live L acidophilus, Bifidobacterium infantis (Infloran; 6 × 109 CFUs/d for 2 days)
• Control group did not receive probiotic
Timing of administration not stated
Outcomes • Duration of diarrhoea
• Weight change/d
• Number of bowel motions on day 2
• Vomiting
• Duration of hospitalization
Duration of diarrhoea reported for rotavirus diarrhoea
No adverse events attributed to probiotic
Notes Location: Thailand; low child and adult mortality
Cause of diarrhoea: suspected dysentery excluded; overall, 34% had rotavirus and 12.1% Salmonella in
stools
Nutritional status: no data presented
Hydration status: severe dehydration excluded; mild/moderate dehydration in 25 (69.4%) probiotic
and 23 (65.7%) control
Source of funding: AIS donation fund, Thai Red Cross Society
Vivatvakin 2006 
Probiotics for treating acute infectious diarrhoea (Review)










Cochrane Database of Systematic Reviews
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not adequately described
Allocation concealment
(selection bias)





High risk No placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 10 centres
Duration: not stated
Participants Inclusion criteria: patients with acute diarrhoea (characteristics and duration not stated)
Exclusion criteria: not stated
3 participants from each group were withdrawn on day 4 or later (causes for dropouts stated to be un-
related to medication); 4 participants assigned to the probiotic group and 5 assigned to the placebo
group did not complete the study (reasons not stated). Numbers completing the study (for persisting
diarrhoea outcomes): 40/47 (85.1%) probiotic and 38/46 (82.6%) placebo
Interventions • Live Enterococcus SF 68 (Bioflorin; 225 × 106 bacteria/d for 7 days)
• Placebo
Not stated when interventions started
Outcomes • Number of cases cured by day of treatment (definition of cure not stated)
No adverse events attributed to probiotic
Notes Study location: Switzerland and Lichtenstein (very low child and adult mortality)
Cause of diarrhoea: no data presented
Nutritional status: no data presented
Wunderlich 1989 
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Hydration status: no data presented
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not adequately described
Allocation concealment
(selection bias)





Low risk Identical placebo
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Follow-up < 90% in both groups
Selective reporting (re-
porting bias)





Methods Randomized controlled trial; 1 centre
Duration: 11 days
Participants Inclusion criteria: infants with diarrhoea during autumn and winter; artificial feeding; first day of diar-
rhoea onset; loose stools; no mucus, pus, or blood in stools; rapid stool test of ELISA (Shenzhen Purcell
Biotechnology Co., Ltd.) to detect rotavirus antigen positive; without any micro-agents and antibiotics
before clinic
Exclusion criteria: severe complications, such as severe dehydration, shock, pneumonia, etc.; patients’
stool within pyocyte and erythrocyte, but to include patients with intestinal bacterial infection; treated
with micro-ecological agents and antibiotics; breast-feeding during diarrhoea; change to lactose-free
feeding during diarrhoea
Numbers completing study: 50/50 (100%) probiotics; 50/50 (100%) control
Interventions • Long-type Bifidobacterium and Bulgarian Lactobacillus 0.5 g, 3 times daily, duration unclear (not stat-
ed whether probiotic alive or killed) (data extracted for analysis)
• Anti-rotavirus egg yolk immunoglobulin (IgY), 1 g 3 times daily (data not extracted for analysis)
• Placebo (unclear contents), 3 times daily
Intervention started on recruitment. Participants given basic treatment including oral montmorillonite
powder and fluid replacement therapy and fed with customary milk powder
Xie 2013 
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Outcomes • Clinical symptoms such as stool frequency and stool properties
• Intestinal flora imbalance (detected and divided into 3 degrees by microscopic examination of stool)
• Faecal SIgA level and faecal rotavirus shedding (measured by radioimmunoassay and double-anti-
body sandwich ELISA, respectively)
No specific comment regarding adverse events
Notes Study location: China (low child and adult mortality)
Cause of diarrhoea: all rotavirus diarrhoea; bloody diarrhoea excluded
Nutritional status: not stated
Hydration status: not stated
Source of funding: Youth Science Fund of Sichuan University (No. 2008053)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not adequately described
Allocation concealment
(selection bias)





Unclear risk Not described
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Follow-up ≥ 90% in both groups
Selective reporting (re-
porting bias)




ELISA: enzyme-linked immunosorbent assay.
IQR: interquartile ratio.
IV: intravenous.
NCHS: National Centre for Health Statistics.
ORF: oral rehydration fluid.
RCT: randomized controlled trial.
SD: standard deviation.
WHO: World Health Organization.
 
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Agarwal 2001 No non-probiotic group. Participants included in Agarwal 2002 study
Agarwal 2002 No non-probiotic group
Ahmadipour 2018 Control group received zinc
Alexander 1971 Not a randomized controlled trial; no non-probiotic group
Alvisi 1982 Intervention groups not treated equally; antibiotics given to the non-probiotic group
Asmat 2018 No non-probiotic group
Barone 2000 No non-probiotic group
Beck 1961 Not a randomized controlled trial
Bellomo 1979 Cause of diarrhoea unclear. Additional treatment given to children with persisting diarrhoea
Bellomo 1980 No non-probiotic group. Study included children with diarrhoea secondary to antibiotic treatment
or associated with respiratory infection
Bellomo 1982 Cause of diarrhoea unclear
Bin Li Xie 1995 Intervention groups not treated equally; antibacterials given to the non-probiotic group
Boulloche 1994 Killed probiotic
Brewster 2004 Secondary publication to Ritchie 2010
Camarri 1981 Intervention groups not treated equally; antibiotics given to the non-probiotic group
Cetina Sauri 1990 Secondary publication to Cetina-Sauri 1994
Chandra 2002 Prevention of rotavirus diarrhoea study
Chapoy 1985 Quasi-randomized: alternate allocation to study arms
Chicoine 1973 Unclear if acute diarrhoea
Costa-Ribeiro 2000a Unclear whether a randomized controlled trial
Costa-Ribeiro 2000b Prevention of diarrhoea study
Cui 2004 No non-probiotic group
Czerwionka 2009 No outcomes reported that can be included in this review
Dash 2016 Quasi-randomized
de dios Pozo-O 1978 Assessment of probiotic in prevention of traveller's diarrhoea
Eren 2010 No non-probiotic group
Escribano 2018 Prevention study
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Study Reason for exclusion
Fang 2009 Study of effect of probiotic on rotavirus shedding in stools; no diarrhoea outcomes reported
Fourrier 1968 No non-probiotic group
Freedman 2018b Abstract preceding definitive trial report
Frigerio 1986 No efficacy data
Girola 1995 Children with gastroenteritis and antibiotic-associated diarrhoea studied together
Gracheva 1996 No non-probiotic group
Grandi 2009 No usable efficacy data
Grandy 2010 No outcomes reported that could be included in this review
Hafeez 2002 Quasi-randomized: allocation according to odd and even participant numbers
Henker 2007b Secondary reference to Henker 2007a
Heydarian 2010 No non-probiotic group
Htwe 2008 Quasi-randomized: participants alternately assigned to intervention and control groups
Isolauri 1991 No non-probiotic group
Jimenez-Rodriguez 2018 No usable data to extract
Kaila 1992 No non-probiotic group
Kaila 1995 No non-probiotic group
Khan 2012 No outcomes reported that could be included in this review
Khanna 2005 Killed probiotic
Khoshdel 2018 Synbiotic evaluated
Korviakova 2000 Not a randomized controlled trial; probiotic vs antibiotic
Lahiri 2015a No extractable data
Lahiri 2015b No extractable data
Lei 2006 Probiotic used was not specified
Le Leyur 2010 Intervention group received an adapted lactose-free formula fortified with S boulardii, and control
group received a standard formula; difference in diarrhoea outcomes between groups cannot be
attributed to the probiotic
Lievin Le-Maol 2007 Killed probiotic
Lin 2009 Prevention study
Magreiter 2006 No non-probiotic control group
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Study Reason for exclusion
Majamaa 1995 No non-probiotic group
Maragkoudaki 2018 Intervention group received zinc in addition to probiotic
Maugo 2012 Unpublished MSc thesis
Mazo 2006 Prevention study
Michielutti 1995 Not a randomized controlled trial
Misra 2009 No outcomes reported that could be included in this review
Mitra 1990 No non-probiotic group
Moraes 2001 No non-probiotic group
Niv 1963 Not a randomized controlled trial; some children with diarrhoea thought to be caused by antibiotic
treatment included
Ortlieb 1974 Participants with acute diarrhoea and antibiotic-associated diarrhoea combined
Pashapour 2006 Pasteurized yoghurt; likely killed probiotic
Pearce 1974 Intervention groups not treated equally; calcium carbonate given as placebo and may have re-
duced diarrhoea in the non-probiotic group
Pedone 1999 Prevention of diarrhoea study
Pedone 2000 Prevention of diarrhoea study
Pene 1966 No non-probiotic group; participants with diarrhoea of various causes (infectious, post-antibiotic)
grouped together
Perez 2019 Included children with acute diarrhoea and children with antibiotic-associated diarrhoea
Pernica 2017 No usable efficacy data
Rafeey 2008b Secondary publication to Rafeey 2008a
Rautanen 1998 No data for placebo group presented
Saint-Marc 1991 Not a randomized controlled trial; no non-probiotic group
Salazar-Lindo 2004 Mean duration of diarrhoea reported from responders only; children with ongoing diarrhoea ex-
cluded from analysis
Salazar-Lindo 2007 Active placebo
Satoh 1984 Not a randomized controlled trial; no non-probiotic group
Savas-Erdeve 2009 Study of amoebiasis-associated diarrhoea, not acute infectious diarrhoea
Schrezenmeir 2004 Antibiotic-associated diarrhoea included in the study
Sepp 1995 No usable efficacy data
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Study Reason for exclusion
Sharif 2017 Synbiotic evaluated and controls did not receive prebiotic
Simakachorn 2000 Killed probiotic
Sindhu 2014 Included children with chronic diarrhoea and with a recent history of yoghurt consumption
Singh 1987 No probiotic specified
Singh 2018 No control group
Sudarmo 2003 Other than the probiotic, unclear whether 2 intervention groups were treated the same. Probiotic
group received high-lactose formula containing B bifidum. Unclear whether control group received
high-lactose or normal formula
Sugita 1994 Quasi-ramdomized study
Szymanski 2005 Preliminary publication of Szymanski 2006
Táborská 1997 No efficacy data
Tojo 1987 Unclear whether diarrhoea acute and whether a randomized controlled trial
Urtula 2009 Unclear inclusion criteria
Zareen 2018 Intervention group received zinc in addition to probiotic
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name Effect of probiotic Bacillus clausii UBBC07 in children with acute diarrhoea
Methods RCT
Participants Inclusion criteria
• Children ≥ 6 months and ≤ 5 years of age
• Clinical diagnosis of acute diarrhoea
• More than 3 loose stools in the last 24 hours
• No major illness
Exclusion criteria
• Children with severe malnutrition (weight for height < 3 SD of WHO charts)
• Requiring antibiotics during the study period
• Presence of severe diarrhoea that, in the opinion of the investigator, requires treatment other
than investigational product and ORS
• Presence of visible blood in the stool
• Use of probiotics in the previous 3 weeks; use of antibiotics or any anti-diarrhoeal medication in
the previous 3 weeks
• Participated in any clinical trial or used any investigational product in the past 90 days
• Known or expected hypersensitivity to any of the active substances or excipients
CTRI/2017/08/009543 
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• Previous use (within 48 hours) of kaolin, pectin, bismuth subsalicylate, racecadotril, loperamide,
atropine, and other anticholinergic agents
Interventions • Bacillus clausii (BACIPRO) oral suspension containing Bacillus clausii UBBC07 - 2 billion CFUs/5 mL
suspension. Dosage: 5 mL twice daily for 5 days
• Placebo
Outcomes Primary outcomes
• Number and frequency of diarrhoea episodes post therapy
• Duration of diarrhoea episodes post therapy
• Consistency of stool
Secondary outcomes
• Clinical Global Impression - Improvement (CGI-I) by Investigator
• Number, frequency, and duration of vomiting episodes
• Number of fever episodes
• Assessment of gut microbiota before and after treatment with probiotic
• Number and frequency of required hospital admissions
Starting date Registered 29 August 2017 (completed, not yet published)









• Patients older than 14 years who have acute diarrhoea
Exclusion criteria
• Serious complication (renal failure, metabolic acidosis, severe dehydration, hypovolaemic shock,
heart failure)
• History of allergy to Lactobacillus spp
• History of diarrhoea caused by amoeba (as evidenced by demonstration of motile trophozoites
with blood in stool)
• Colorectal cancer (as diagnosed by a per rectal examination and/or endoscopic procedures where
necessary)
• Known allergy to study drugs
• Patients who are already on probiotics
Interventions • Lactobacillus sporogenes 120 million spores, 1 tablet containing 120 million spores of Lactobacil-
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• Duration of diarrhoea
Secondary outcome
• Frequency of loose stools, abdominal pain, and hospital stay
Starting date Registered 19 April 2018 (open to recruitment in July 2019)





Study name A multicentric, randomized, placebo controlled double blind study to compare safety and tolerabil-
ity of Saccharomyces boulardii in acute diarrhoea
Methods RCT
Participants Inclusion criteria
• Aged 6 months to 5 years; of either gender; presenting with acute diarrhoea of ≤ 72 hours' duration
without history of intake of any antibiotic and without dehydration or with features of mild or
moderate dehydration
Exclusion criteria
• Clinical signs of dysentery, severe dehydration requiring hospitalization, or parenteral fluid ther-
apy
• Intake of any systemic antibiotic or any anti-diarrhoeal medication, in the 3 weeks before screen-
ing
• Debilitated or seriously ill or immunocompromised
• Symptoms or suspicion of an organic lesion of the digestive tract, or undiagnosed abdominal pain
or rectal bleeding or other GI disorder, especially ulcerative colitis, Crohn’s disease, history of car-
cinoma of the bowel, malabsorption syndrome, intolerance to certain food types (lactose), func-
tional diarrhoea, and functional constipation
• Use of probiotics in the 3 weeks before baseline visit
• Current use of any drugs or treatments that are supposed to decrease gastrointestinal motility or
any other concomitant anti-diarrhoeal medication
• Have undergone ileostomy, jejunostomy, or colostomy
• Hypersensitivity to any ingredient in the formulation
• Coexisting features of acute systemic disease like septicaemia, meningitis, pneumonia, etc.




• Duration of diarrhoea (time in hours after study product administration to last abnormal (loose
or liquid) stool preceding normal stool output)
• Stool frequency (number of times the participant passes stool every day)
• Stool consistency (evaluated on a 4-point Likert scale)
Secondary outcomes
• Safety and tolerability of study medications
CTRI/2018/06/014480 
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• Follow-up of participants in both groups up to 3 months post intervention to compare the inci-
dence of acute diarrhoeal episodes between test and placebo groups
Starting date Registered 8 June 2018 (not yet recruiting in July 2019)









• Age 1 to 5 years
• Acute watery diarrhoea
Exclusion criteria




• Use of antibiotics or anti-diarrhoeal drugs
• Having more than 1 complaint
• Immune deficiency
Interventions • 20 mg of zinc gluconate plus ORS in 4 sachets soluble in 250 mL of water daily
• 20,000 IU vitamin A plus ORS in 4 sachets soluble in 250 mL of water daily
• 109 CFU probiotics plus ORS in 4 sachets soluble in 250 mL of water daily
• 20 mg of zinc gluconate, 20,000 IU vitamin A, 109 CFU probiotics plus ORS in 4 sachets soluble in
250 mL of water daily
• ORS in 4 sachets soluble in 250 mL of water daily
Outcomes • Duration of diarrhoea
• Frequency of diarrhoea
Starting date Registered 17 August 2017 (recruitment complete in July 2019)
Contact information Mohsen Taghizadeh; taghizadeh-m@kaums.ac.ir




Study name The effect of yeast probiotic (Saccharomyces boulardii) on acute diarrhoea in children
Methods RCT
IRCT2017090812897N3 
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Participants Inclusion criteria
• Existence of acute diarrhoea
• Mild and moderate dehydration
• Age between 2 and 5 years





• Accompanying disease such as diabetes
• Severe dehydration
• Abdominal distension, suspected to intestinal obstruction
• Vomiting
Interventions • Cap Yomogi (contains 250 mg dried yeast Saccharomyces boulardii) as a single dose per day
• Chickpea flour powder
Outcomes Primary outcome
• Frequency of diarrhoea
Secondary outcome
• Duration of diarrhoea
Starting date Registered 7 October 2017 (recruitment complete in July 2019)
Contact information Abolfazl Mahyar amahyar@qums.ac.ir




Study name Probiotics for treatment of acute childhood diarrhoea
Methods RCT
Participants Inclusion criteria
• Infants and children with an episode of mild to moderate acute diarrhoea (> 4 (semi)-watery
stools/d according to Bristol criteria (Bristol criteria ≥ 6)) lasting longer than 12 hours and less
than 72 hours requiring hospitalization
Exclusion criteria
• Clinical features of hypovolaemic shock and/or necessitating admission to the intensive care unit
• Taking immunosuppressive therapy
• Known immunodeficiency disorder
• Pancreatic dysfunction
• Bloody diarrhoea
• Chronic gastrointestinal disease
• Short bowel syndrome
• Bilious or bloody vomitus
ISRCTN18444252 
Probiotics for treating acute infectious diarrhoea (Review)










Cochrane Database of Systematic Reviews
• Probiotics 1 month before admission
• Severe malnutrition
Interventions • Three combination probiotics containing 3 unique strains of bacteria: Bifidobacterium lactis Bi-07,
Lactobacillus rhamnosus HN001, and Lactobacillus acidophilus NCFM. Given as a single sachet con-
taining more than 10 billion colony-forming units (CFUs) once a day from the beginning of treat-
ment for diarrhoea, for 7 days
• No probiotic medication
Outcomes Primary outcome
• Duration of diarrhoea (time in hours from enrolment to last abnormal (loose or liquid) stool), mea-
sured using an appropriate CRF every day during the intervention
Secondary outcome
• Number of loose stools per day during the entire episode, measured using an appropriate CRF
every day during the intervention
Starting date 1 November 2016 (completed, not yet published in July 2019)
Contact information Dr Ke Chen, No. 1617 Riyue Avenue, Qingyang District, Chengdu, 610031, China




Study name Efficacy and safety of probiotics in the treatment of acute gastroenteritis in children (SABINA)
Methods Randomized parallel assignment trial
Participants Inclusion criteria
• Children of both genders aged between 6 months and 5 years
• Presenting with acute diarrhoea (3 or more loose or liquid stools in a 24-hour period) since at least
the last 24 hours but less than 5 days
• Signed informed consent of legal representatives obtained before any study procedure
• Parents who, according to the physician's opinion, are able to fill in the stool diary
Interventions • Saccharomyces boulardii (Floratil), 250 mg sachets, twice daily (1 in the morning and 1 in the
evening) during 5 consecutive days
• Bacillus clausii (Enterogermina), 5 mL vials, twice daily (1 in the morning and 1 in the evening)
during 5 consecutive days
Outcomes Primary outcome
• Efficacy of probiotics in reducing the duration of diarrhoea in children suffering from acute gas-
troenteritis
Secondary outcomes
• Efficacy of probiotics in improving the frequency and consistency of stools
• Efficacy of probiotics in avoiding recurrence of diarrhoea
• Effects of probiotics on disease severity
• Safety and tolerability of studied probiotics
NCT03539913 
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Starting date June 2017; completed June 2018









• Parents signed informed consent
• Have dehydration according to World Health Organization (WHO) clinical scale
Exclusion criteria
• Severe dehydration
• Coexisting severe infection (e.g. sepsis, pneumonia, meningitis)
• Immune deficiency
• Parents refuse to provide written informed consent
• Do not comply with treatment
Interventions • Probiotics (Saccharomyces boulardii) 1 dose per day (250 mg)
• Zinc (10 mg for participants younger than 6 months and 20 mg for older participants) 1 dose per
day
• Combination of probiotics (Saccharomyces boulardii 250 mg) with zinc (10 mg for participants
younger than 6 months; 20 mg for older participants) 1 dose per day
Outcomes Primary outcome
• Diarrhea consistency (consistency of diarrhoea scored according to the "Bristol Stool Chart")
Secondary outcomes
• Diarrhoea duration (duration of diarrhoea in days)
• Hospital stay (length of hospital stay in days)
Starting date 1 October 2018 (recruiting in July 2019)
Contact information Mariam AlAbdullah A Rajab; drmariam1@hotmail.com (principal investigator)
Notes Location: Makassed General Hospital, Beirut, Lebanon
NCT03684538 
CFU: colony-forming unit.
ORS: oral rehydration solution.
RCT: randomized controlled trial.
WHO: World Health Organization.
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Comparison 1.   Primary diarrhoea outcomes





Statistical method Effect size
1.1 Diarrhoea lasting ≥ 48 hours 36 6053 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.52, 0.79]
1.2 Mean duration of diarrhoea 56 9138 Mean Difference (IV, Random, 95% CI) -21.29 [-26.88, -15.71]
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Heterogeneity: Tau² = 0.33; Chi² = 1531.30, df = 35 (P < 0.00001); I² = 98%
Test for overall effect: Z = 4.12 (P < 0.0001)


































































































































































































M-H, Random, 95% CI
1.08 [0.76 , 1.55]
0.39 [0.20 , 0.77]
0.34 [0.16 , 0.71]
0.47 [0.17 , 1.34]
0.75 [0.62 , 0.90]
0.64 [0.54 , 0.76]
0.71 [0.58 , 0.87]
0.63 [0.51 , 0.78]
0.54 [0.42 , 0.70]
0.71 [0.53 , 0.95]
0.34 [0.13 , 0.91]
0.53 [0.41 , 0.67]
0.51 [0.34 , 0.79]
0.76 [0.68 , 0.86]
1.01 [0.89 , 1.14]
0.83 [0.68 , 1.00]
0.69 [0.46 , 1.04]
0.70 [0.52 , 0.95]
0.45 [0.18 , 1.12]
0.22 [0.05 , 0.91]
0.63 [0.48 , 0.83]
1.00 [0.99 , 1.01]
0.36 [0.24 , 0.56]
0.61 [0.45 , 0.81]
0.35 [0.13 , 0.93]
1.02 [0.55 , 1.88]
0.98 [0.87 , 1.11]
0.65 [0.29 , 1.46]
0.30 [0.10 , 0.92]
1.52 [1.18 , 1.96]
0.95 [0.86 , 1.04]
2.14 [0.41 , 11.09]
0.44 [0.22 , 0.88]
0.67 [0.51 , 0.88]
0.18 [0.04 , 0.74]
0.67 [0.46 , 0.98]
0.64 [0.52 , 0.79]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours probiotic Favours control
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Heterogeneity: Tau² = 390.92; Chi² = 1283.22, df = 55 (P < 0.00001); I² = 96%
Test for overall effect: Z = 7.48 (P < 0.00001)






















































































































































































































































































































































































































IV, Random, 95% CI
-18.00 [-21.69 , -14.31]
4.80 [-3.35 , 12.95]
-50.60 [-56.54 , -44.66]
-15.97 [-24.79 , -7.15]
-17.60 [-30.44 , -4.76]
-50.40 [-70.47 , -30.33]
-62.64 [-73.16 , -52.12]
-37.00 [-45.46 , -28.54]
-26.20 [-34.18 , -18.22]
-0.80 [-2.28 , 0.68]
-7.20 [-21.02 , 6.62]
-29.00 [-37.54 , -20.46]
-33.10 [-42.59 , -23.61]
-13.90 [-24.32 , -3.48]
-24.40 [-31.29 , -17.51]
-2.50 [-9.25 , 4.25]
-23.52 [-35.89 , -11.15]
-9.60 [-31.56 , 12.36]
-28.80 [-50.47 , -7.13]
7.60 [-17.74 , 32.94]
-4.85 [-14.12 , 4.42]
-13.60 [-21.02 , -6.18]
-64.80 [-78.10 , -51.50]
-2.40 [-8.82 , 4.02]
-34.60 [-41.24 , -27.96]
-79.20 [-85.31 , -73.09]
-26.40 [-37.60 , -15.20]
-19.20 [-30.11 , -8.29]
-58.80 [-79.00 , -38.60]
-5.30 [-12.96 , 2.36]
-26.40 [-79.63 , 26.83]
-7.00 [-16.55 , 2.55]
-19.20 [-38.30 , -0.10]
-12.00 [-19.07 , -4.93]
0.00 [-13.32 , 13.32]
-26.40 [-42.07 , -10.73]
-6.30 [-19.33 , 6.73]
-33.60 [-65.73 , -1.47]
-29.52 [-45.23 , -13.81]
-16.79 [-27.76 , -5.82]
1.20 [-21.42 , 23.82]
-19.60 [-39.63 , 0.43]
-39.80 [-81.19 , 1.59]
-3.80 [-15.21 , 7.61]
-2.79 [-10.11 , 4.53]
-26.40 [-47.67 , -5.13]
-24.00 [-42.07 , -5.93]
-28.80 [-58.05 , 0.45]
-24.63 [-44.66 , -4.60]
-6.35 [-11.47 , -1.23]
-12.40 [-39.55 , 14.75]
-8.20 [-29.10 , 12.70]
-17.50 [-31.92 , -3.08]
-35.00 [-64.16 , -5.84]
-31.20 [-45.79 , -16.61]
-7.20 [-22.73 , 8.33]
-21.29 [-26.88 , -15.71]
Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours probiotic Favours control
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Comparison 2.   Secondary diarrhoea outcomes





Statistical method Effect size
2.1 Number of people hospitalized in com-
munity studies
7 2333 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.86, 1.69]
2.2 Duration of hospitalization in inpatient
studies




2.3 Diarrhoea lasting ≥ 14 days 9 2928 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.16, 1.53]
 
 
Analysis 2.1.   Comparison 2: Secondary diarrhoea outcomes,











Heterogeneity: Tau² = 0.00; Chi² = 3.77, df = 5 (P = 0.58); I² = 0%
Test for overall effect: Z = 1.10 (P = 0.27)
















































M-H, Random, 95% CI
0.23 [0.03 , 2.02]
1.09 [0.60 , 1.99]
3.05 [0.13 , 73.40]
1.50 [0.89 , 2.52]
Not estimable
2.12 [0.20 , 22.83]
1.01 [0.50 , 2.05]
1.21 [0.86 , 1.69]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours probiotic Favours control
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Analysis 2.2.   Comparison 2: Secondary diarrhoea outcomes,



























Heterogeneity: Tau² = 478.55; Chi² = 493.36, df = 23 (P < 0.00001); I² = 95%
Test for overall effect: Z = 3.82 (P = 0.0001)






















































































































































































IV, Random, 95% CI
-12.14 [-24.10 , -0.18]
-47.52 [-54.80 , -40.24]
2.40 [-2.23 , 7.03]
-84.96 [-93.27 , -76.65]
-15.62 [-24.39 , -6.85]
-31.20 [-40.01 , -22.39]
-5.28 [-18.30 , 7.74]
-17.00 [-27.53 , -6.47]
-27.60 [-40.58 , -14.62]
-36.48 [-48.06 , -24.90]
-17.50 [-22.54 , -12.46]
0.00 [-6.47 , 6.47]
1.00 [-7.61 , 9.61]
12.00 [-5.53 , 29.53]
-14.40 [-57.77 , 28.97]
-7.00 [-20.86 , 6.86]
-24.00 [-33.04 , -14.96]
-14.40 [-24.97 , -3.83]
-26.40 [-43.74 , -9.06]
-38.40 [-88.88 , 12.08]
-6.10 [-16.51 , 4.31]
-17.90 [-34.90 , -0.90]
1.68 [-10.49 , 13.85]
-12.00 [-24.32 , 0.32]
-18.03 [-27.28 , -8.78]
Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours probiotic Favours control
 
 













Heterogeneity: Tau² = 0.73; Chi² = 7.43, df = 3 (P = 0.06); I² = 60%
Test for overall effect: Z = 1.22 (P = 0.22)






















































M-H, Random, 95% CI
Not estimable
Not estimable
2.00 [0.18 , 21.92]
0.19 [0.08 , 0.48]
Not estimable
Not estimable
0.25 [0.03 , 2.20]
1.01 [0.36 , 2.87]
Not estimable
0.49 [0.16 , 1.53]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours probiotic Favours control
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Comparison 3.   Strain of probiotic organisms





Statistical method Effect size
3.1 Diarrhoea lasting ≥ 48 hours 15   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1.1 Lactobacillus rhamnosus GG 6 1557 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.65, 0.97]
3.1.2 Saccharomyces boulardii 9 1823 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.37, 1.33]
3.2 Mean duration of diarrhoea 31   Mean Difference (IV, Random, 95%
CI)
Subtotals only
3.2.1 Lactobacillus rhamnosus GG 14 3344 Mean Difference (IV, Random, 95%
CI)
-22.50 [-32.73, -12.26]
3.2.2 Saccharomyces boulardii 11 1617 Mean Difference (IV, Random, 95%
CI)
-24.64 [-35.30, -13.98]
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Analysis 3.1.   Comparison 3: Strain of probiotic organisms, Outcome 1: Diarrhoea lasting ≥ 48 hours
Study or Subgroup









Heterogeneity: Tau² = 0.03; Chi² = 15.06, df = 5 (P = 0.01); I² = 67%













Heterogeneity: Tau² = 0.94; Chi² = 1212.91, df = 8 (P < 0.00001); I² = 99%






























































































M-H, Random, 95% CI
0.22 [0.05 , 0.91]
0.83 [0.68 , 1.00]
0.63 [0.48 , 0.83]
0.71 [0.53 , 0.95]
1.02 [0.55 , 1.88]
0.98 [0.87 , 1.11]
0.79 [0.65 , 0.97]
0.71 [0.58 , 0.87]
0.45 [0.18 , 1.12]
0.67 [0.51 , 0.88]
0.36 [0.24 , 0.56]
0.54 [0.42 , 0.70]
0.76 [0.68 , 0.86]
0.75 [0.62 , 0.90]
1.52 [1.18 , 1.96]
1.00 [0.99 , 1.01]
0.70 [0.37 , 1.33]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours probiotic Favours control
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Analysis 3.2.   Comparison 3: Strain of probiotic organisms, Outcome 2: Mean duration of diarrhoea
Study or Subgroup
















Heterogeneity: Tau² = 334.36; Chi² = 500.30, df = 13 (P < 0.00001); I² = 97%














Heterogeneity: Tau² = 269.31; Chi² = 95.15, df = 10 (P < 0.00001); I² = 89%









Heterogeneity: Tau² = 56.95; Chi² = 9.61, df = 5 (P = 0.09); I² = 48%













































































































































































































































IV, Random, 95% CI
-18.00 [-21.69 , -14.31]
4.90 [0.74 , 9.06]
-50.60 [-56.54 , -44.66]
-37.00 [-45.46 , -28.54]
-0.82 [-2.30 , 0.66]
-13.60 [-21.02 , -6.18]
-64.80 [-78.10 , -51.50]
-19.20 [-30.11 , -8.29]
-58.80 [-79.00 , -38.60]
-6.30 [-19.33 , 6.73]
-33.60 [-65.73 , -1.47]
1.20 [-21.42 , 23.82]
-2.79 [-10.11 , 4.53]
-26.40 [-47.67 , -5.13]
-22.50 [-32.73 , -12.26]
-15.97 [-24.79 , -7.15]
-50.40 [-70.47 , -30.33]
-62.64 [-73.16 , -52.12]
-7.20 [-21.02 , 6.62]
-29.00 [-37.54 , -20.46]
-24.40 [-31.29 , -17.51]
-9.60 [-31.56 , 12.36]
-5.30 [-12.96 , 2.36]
-19.20 [-38.30 , -0.10]
-16.79 [-27.76 , -5.82]
-35.00 [-64.16 , -5.84]
-24.64 [-35.30 , -13.98]
-33.10 [-42.59 , -23.61]
-13.90 [-24.32 , -3.48]
-28.80 [-50.47 , -7.13]
-24.00 [-42.07 , -5.93]
-28.80 [-58.05 , 0.45]
-8.20 [-29.10 , 12.70]
-22.83 [-31.95 , -13.72]
Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours probiotic Favours control
 
 
Comparison 4.   Diarrhoea pathogen: rotavirus




Statistical method Effect size
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Heterogeneity: Tau² = 254.32; Chi² = 122.18, df = 19 (P < 0.00001); I² = 84%
Test for overall effect: Z = 5.49 (P < 0.00001)


























































































































































IV, Random, 95% CI
-24.00 [-30.97 , -17.03]
-7.20 [-21.02 , 6.62]
-29.00 [-37.54 , -20.46]
-3.80 [-13.86 , 6.26]
-9.60 [-31.56 , 12.36]
-8.72 [-25.13 , 7.69]
-20.40 [-33.34 , -7.46]
-76.80 [-90.10 , -63.50]
-19.20 [-30.11 , -8.29]
-58.56 [-80.90 , -36.22]
-11.50 [-28.40 , 5.40]
-26.40 [-42.07 , -10.73]
-29.52 [-45.23 , -13.81]
-1.00 [-14.40 , 12.40]
-3.31 [-15.89 , 9.27]
-24.00 [-42.07 , -5.93]
-37.50 [-72.57 , -2.43]
-13.50 [-43.58 , 16.58]
-17.50 [-31.92 , -3.08]
-28.80 [-43.97 , -13.63]
-22.06 [-29.93 , -14.18]
Mean Difference
IV, Random, 95% CI
-50 -25 0 25 50
Favours probiotic Favours control
 
 
Comparison 5.   Age of participants





Statistical method Effect size
5.1 Diarrhoea lasting ≥ 48 hours 31   Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1.1 Participants aged < 5 years 26 5033 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.59, 0.88]
5.1.2 Participants aged ≥ 18 years 5 393 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.54, 0.71]
5.2 Mean duration of diarrhoea 45   Mean Difference (IV, Random, 95% CI) Subtotals only
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Analysis 5.1.   Comparison 5: Age of participants, Outcome 1: Diarrhoea lasting ≥ 48 hours
Study or Subgroup





























Heterogeneity: Tau² = 0.21; Chi² = 829.10, df = 25 (P < 0.00001); I² = 97%
Test for overall effect: Z = 3.22 (P = 0.001)








Heterogeneity: Tau² = 0.00; Chi² = 3.33, df = 4 (P = 0.50); I² = 0%














































































































































































M-H, Random, 95% CI
1.08 [0.76 , 1.55]
0.39 [0.20 , 0.77]
0.75 [0.62 , 0.90]
0.71 [0.58 , 0.87]
0.54 [0.42 , 0.70]
0.71 [0.53 , 0.95]
0.53 [0.41 , 0.67]
0.51 [0.34 , 0.79]
0.76 [0.68 , 0.86]
1.01 [0.89 , 1.14]
0.83 [0.68 , 1.00]
0.69 [0.46 , 1.04]
0.70 [0.52 , 0.95]
0.22 [0.05 , 0.91]
0.63 [0.48 , 0.83]
1.00 [0.99 , 1.01]
1.02 [0.55 , 1.88]
0.98 [0.87 , 1.11]
0.65 [0.29 , 1.46]
0.30 [0.10 , 0.92]
1.52 [1.18 , 1.96]
0.95 [0.86 , 1.04]
2.14 [0.41 , 11.09]
0.44 [0.22 , 0.88]
0.67 [0.51 , 0.88]
0.18 [0.04 , 0.74]
0.72 [0.59 , 0.88]
0.34 [0.16 , 0.71]
0.47 [0.17 , 1.34]
0.64 [0.54 , 0.76]
0.61 [0.45 , 0.81]
0.67 [0.46 , 0.98]
0.62 [0.54 , 0.71]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours probiotic Favours control
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Analysis 5.2.   Comparison 5: Age of participants, Outcome 2: Mean duration of diarrhoea
Study or Subgroup















































Heterogeneity: Tau² = 386.20; Chi² = 1058.56, df = 44 (P < 0.00001); I² = 96%









































































































































































































































































































































IV, Random, 95% CI
-18.00 [-21.69 , -14.31]
-15.97 [-24.79 , -7.15]
-17.60 [-30.44 , -4.76]
-62.64 [-73.16 , -52.12]
-37.00 [-45.46 , -28.54]
-0.80 [-2.28 , 0.68]
-7.20 [-21.02 , 6.62]
-29.00 [-37.54 , -20.46]
-33.10 [-42.59 , -23.61]
-13.90 [-24.32 , -3.48]
-24.40 [-31.29 , -17.51]
-2.50 [-9.25 , 4.25]
-23.52 [-35.89 , -11.15]
-9.60 [-31.56 , 12.36]
-28.80 [-50.47 , -7.13]
7.60 [-17.74 , 32.94]
-4.85 [-14.12 , 4.42]
-13.60 [-21.02 , -6.18]
-64.80 [-78.10 , -51.50]
-34.60 [-41.24 , -27.96]
-79.20 [-85.31 , -73.09]
-19.20 [-30.11 , -8.29]
-58.80 [-79.00 , -38.60]
-5.30 [-12.96 , 2.36]
-26.40 [-79.63 , 26.83]
-7.00 [-16.55 , 2.55]
-12.00 [-19.07 , -4.93]
0.00 [-13.32 , 13.32]
-26.40 [-42.07 , -10.73]
-33.60 [-65.73 , -1.47]
-29.52 [-45.23 , -13.81]
-16.79 [-27.76 , -5.82]
1.20 [-21.42 , 23.82]
-19.60 [-39.63 , 0.43]
-39.80 [-81.19 , 1.59]
-3.80 [-15.21 , 7.61]
-2.79 [-10.11 , 4.53]
-26.40 [-47.67 , -5.13]
-24.00 [-42.07 , -5.93]
-28.80 [-58.05 , 0.45]
-6.35 [-11.47 , -1.23]
-8.20 [-29.10 , 12.70]
-17.50 [-31.92 , -3.08]
-35.00 [-64.16 , -5.84]
-31.20 [-45.79 , -16.61]
-21.63 [-27.83 , -15.42]
Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours probiotic Favours control
 
 
Comparison 6.   Severity of diarrhoea (inpatient vs outpatient)





Statistical method Effect size
6.1 Diarrhoea lasting ≥ 48 hours 21   Risk Ratio (M-H, Random, 95% CI) Subtotals only
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Statistical method Effect size
6.1.1 Inpatient 21 2354 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.52, 0.74]
6.2 Mean duration of diarrhoea 44   Mean Difference (IV, Random, 95% CI) Subtotals only
6.2.1 Inpatient 36 5071 Mean Difference (IV, Random, 95% CI) -21.71 [-29.72, -13.70]
6.2.2 Outpatient 8 828 Mean Difference (IV, Random, 95% CI) -28.55 [-43.09, -14.01]
 
 
Analysis 6.1.   Comparison 6: Severity of diarrhoea (inpatient


























Heterogeneity: Tau² = 0.10; Chi² = 78.48, df = 20 (P < 0.00001); I² = 75%























































































































M-H, Random, 95% CI
1.08 [0.76 , 1.55]
0.39 [0.20 , 0.77]
0.34 [0.16 , 0.71]
0.47 [0.17 , 1.34]
0.75 [0.62 , 0.90]
0.63 [0.51 , 0.78]
0.54 [0.42 , 0.70]
0.71 [0.53 , 0.95]
0.53 [0.41 , 0.67]
0.70 [0.52 , 0.95]
0.45 [0.18 , 1.12]
0.22 [0.05 , 0.91]
0.36 [0.24 , 0.56]
0.35 [0.13 , 0.93]
1.02 [0.55 , 1.88]
0.65 [0.29 , 1.46]
0.30 [0.10 , 0.92]
1.52 [1.18 , 1.96]
0.44 [0.22 , 0.88]
0.67 [0.51 , 0.88]
0.67 [0.46 , 0.98]
0.62 [0.52 , 0.74]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours probiotic Favours control
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Heterogeneity: Tau² = 538.45; Chi² = 1066.23, df = 35 (P < 0.00001); I² = 97%











Heterogeneity: Tau² = 368.22; Chi² = 110.95, df = 7 (P < 0.00001); I² = 94%





































































































































































































































































































































IV, Random, 95% CI
4.80 [-3.35 , 12.95]
-50.60 [-56.54 , -44.66]
-15.97 [-24.79 , -7.15]
-17.60 [-30.44 , -4.76]
-50.40 [-70.47 , -30.33]
-62.64 [-73.16 , -52.12]
-26.20 [-34.18 , -18.22]
-0.80 [-2.28 , 0.68]
-7.20 [-21.02 , 6.62]
-29.00 [-37.54 , -20.46]
-33.10 [-42.59 , -23.61]
-2.50 [-9.25 , 4.25]
-23.52 [-35.89 , -11.15]
-28.80 [-50.47 , -7.13]
-2.40 [-8.82 , 4.02]
-79.20 [-85.31 , -73.09]
-26.40 [-37.60 , -15.20]
-19.20 [-30.11 , -8.29]
-5.30 [-12.96 , 2.36]
-26.40 [-79.63 , 26.83]
-7.00 [-16.55 , 2.55]
-19.20 [-38.30 , -0.10]
-12.00 [-19.07 , -4.93]
0.00 [-13.32 , 13.32]
-26.40 [-42.07 , -10.73]
-33.60 [-65.73 , -1.47]
-29.52 [-45.23 , -13.81]
-16.79 [-27.76 , -5.82]
1.20 [-21.42 , 23.82]
-19.60 [-39.63 , 0.43]
-3.80 [-15.21 , 7.61]
-26.40 [-47.67 , -5.13]
-24.00 [-42.07 , -5.93]
-28.80 [-58.05 , 0.45]
-24.63 [-44.66 , -4.60]
-17.50 [-31.92 , -3.08]
-21.71 [-29.72 , -13.70]
-37.00 [-45.46 , -28.54]
-13.90 [-24.32 , -3.48]
-64.80 [-78.10 , -51.50]
-34.60 [-41.24 , -27.96]
-6.30 [-19.33 , 6.73]
-39.80 [-81.19 , 1.59]
-6.35 [-11.47 , -1.23]
-35.00 [-64.16 , -5.84]
-28.55 [-43.09 , -14.01]
Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours probiotic Favours control
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Comparison 7.   Country mortality stratum





Statistical method Effect size
7.1 Diarrhoea lasting ≥ 48 hours 33   Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1.1 Child and adult mortality low or
very low
23 4100 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.54, 0.71]
7.1.2 Child or adult mortality high 10 1505 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.59, 1.06]
7.2 Mean duration of diarrhoea 53   Mean Difference (IV, Random, 95% CI) Subtotals only
7.2.1 Child and adult mortality low or
very low
34 5225 Mean Difference (IV, Random, 95% CI) -19.18 [-24.98,
-13.39]
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Analysis 7.1.   Comparison 7: Country mortality stratum, Outcome 1: Diarrhoea lasting ≥ 48 hours
Study or Subgroup


























Heterogeneity: Tau² = 0.06; Chi² = 98.85, df = 22 (P < 0.00001); I² = 78%
Test for overall effect: Z = 6.62 (P < 0.00001)













Heterogeneity: Tau² = 0.20; Chi² = 315.20, df = 9 (P < 0.00001); I² = 97%
























































































































































































M-H, Random, 95% CI
0.34 [0.16 , 0.71]
0.47 [0.17 , 1.34]
0.64 [0.54 , 0.76]
0.71 [0.58 , 0.87]
0.63 [0.51 , 0.78]
0.54 [0.42 , 0.70]
0.71 [0.53 , 0.95]
0.34 [0.13 , 0.91]
0.53 [0.41 , 0.67]
0.51 [0.34 , 0.79]
0.76 [0.68 , 0.86]
1.01 [0.89 , 1.14]
0.45 [0.18 , 1.12]
0.22 [0.05 , 0.91]
0.36 [0.24 , 0.56]
0.35 [0.13 , 0.93]
0.98 [0.87 , 1.11]
0.65 [0.29 , 1.46]
0.30 [0.10 , 0.92]
2.14 [0.41 , 11.09]
0.67 [0.51 , 0.88]
0.18 [0.04 , 0.74]
0.67 [0.46 , 0.98]
0.62 [0.54 , 0.71]
1.08 [0.76 , 1.55]
0.39 [0.20 , 0.77]
0.75 [0.62 , 0.90]
0.69 [0.46 , 1.04]
0.70 [0.52 , 0.95]
1.00 [0.99 , 1.01]
0.61 [0.45 , 0.81]
1.52 [1.18 , 1.96]
0.95 [0.86 , 1.04]
0.44 [0.22 , 0.88]
0.79 [0.59 , 1.06]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours probiotic Favours control
 
 
Probiotics for treating acute infectious diarrhoea (Review)










Cochrane Database of Systematic Reviews
Analysis 7.2.   Comparison 7: Country mortality stratum, Outcome 2: Mean duration of diarrhoea
Study or Subgroup




































Heterogeneity: Tau² = 221.86; Chi² = 337.56, df = 33 (P < 0.00001); I² = 90%
Test for overall effect: Z = 6.49 (P < 0.00001)





















Heterogeneity: Tau² = 593.05; Chi² = 803.03, df = 18 (P < 0.00001); I² = 98%




































































































































































































































































































































































































IV, Random, 95% CI
-37.00 [-45.46 , -28.54]
-26.20 [-34.18 , -18.22]
-0.80 [-2.28 , 0.68]
-7.20 [-21.02 , 6.62]
-33.10 [-42.59 , -23.61]
-13.90 [-24.32 , -3.48]
-24.40 [-31.29 , -17.51]
-23.52 [-35.89 , -11.15]
-9.60 [-31.56 , 12.36]
-28.80 [-50.47 , -7.13]
7.60 [-17.74 , 32.94]
-2.79 [-10.11 , 4.53]
-64.80 [-78.10 , -51.50]
-26.40 [-37.60 , -15.20]
-19.20 [-30.11 , -8.29]
-26.40 [-79.63 , 26.83]
-7.00 [-16.55 , 2.55]
-19.20 [-38.30 , -0.10]
-12.00 [-19.07 , -4.93]
0.00 [-13.32 , 13.32]
-6.30 [-19.33 , 6.73]
-33.60 [-65.73 , -1.47]
-29.52 [-45.23 , -13.81]
-19.60 [-39.63 , 0.43]
-39.80 [-81.19 , 1.59]
-4.85 [-14.12 , 4.42]
-24.00 [-42.07 , -5.93]
-28.80 [-58.05 , 0.45]
-24.63 [-44.66 , -4.60]
-12.40 [-39.55 , 14.75]
-8.20 [-29.10 , 12.70]
-35.04 [-64.20 , -5.88]
-31.20 [-45.79 , -16.61]
-7.20 [-22.73 , 8.33]
-19.18 [-24.98 , -13.39]
-18.00 [-21.69 , -14.31]
4.90 [0.74 , 9.06]
-50.60 [-56.54 , -44.66]
-15.97 [-24.79 , -7.15]
-17.60 [-30.44 , -4.76]
-50.40 [-70.47 , -30.33]
-62.64 [-73.16 , -52.12]
-29.00 [-37.54 , -20.46]
-2.50 [-9.25 , 4.25]
-2.40 [-8.82 , 4.02]
-34.60 [-41.24 , -27.96]
-79.20 [-85.31 , -73.09]
-5.30 [-12.96 , 2.36]
-26.40 [-42.07 , -10.73]
-16.79 [-27.76 , -5.82]
-3.80 [-15.21 , 7.61]
-26.40 [-47.67 , -5.13]
-6.35 [-11.47 , -1.23]
-17.50 [-31.92 , -3.08]
-24.05 [-35.28 , -12.83]
Mean Difference
IV, Random, 95% CI
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Analysis 7.2.   (Continued)
Heterogeneity: Tau² = 593.05; Chi² = 803.03, df = 18 (P < 0.00001); I² = 98%
Test for overall effect: Z = 4.20 (P < 0.0001)
-100 -50 0 50 100
Favours probiotic Favours control
 
 
Comparison 8.   Geographical region





Statistical method Effect size
8.1 Diarrhoea lasting ≥ 48
hours
8   Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1.1 Eur-A 8 500 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.43, 0.70]
8.2 Mean duration of diar-
rhoea
35   Mean Difference (IV, Random, 95% CI) Subtotals only
8.2.1 Eur-A 8 601 Mean Difference (IV, Random, 95% CI) -32.95 [-45.40, -20.50]
8.2.2 Eur-B 9 1271 Mean Difference (IV, Random, 95% CI) -16.33 [-23.63, -9.03]
8.2.3 Sear-D 12 2402 Mean Difference (IV, Random, 95% CI) -17.42 [-27.09, -7.75]
8.2.4 Wpr-B 6 850 Mean Difference (IV, Random, 95% CI) -17.14 [-26.05, -8.23]
 
 













Heterogeneity: Tau² = 0.03; Chi² = 9.57, df = 7 (P = 0.21); I² = 27%






















































M-H, Random, 95% CI
0.34 [0.16 , 0.71]
0.34 [0.13 , 0.91]
0.47 [0.17 , 1.34]
0.67 [0.46 , 0.98]
0.22 [0.05 , 0.91]
0.64 [0.54 , 0.76]
0.65 [0.29 , 1.46]
0.30 [0.10 , 0.92]
0.54 [0.43 , 0.70]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours probiotic Favours control
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Heterogeneity: Tau² = 222.32; Chi² = 31.70, df = 7 (P < 0.0001); I² = 78%












Heterogeneity: Tau² = 70.60; Chi² = 22.55, df = 8 (P = 0.004); I² = 65%















Heterogeneity: Tau² = 266.90; Chi² = 229.02, df = 11 (P < 0.00001); I² = 95%









Heterogeneity: Tau² = 88.00; Chi² = 19.88, df = 5 (P = 0.001); I² = 75%












































































































































































































































































IV, Random, 95% CI
-37.00 [-45.46 , -28.54]
-28.80 [-50.47 , -7.13]
-64.80 [-78.10 , -51.50]
-19.20 [-30.11 , -8.29]
-19.60 [-39.63 , 0.43]
-39.80 [-81.19 , 1.59]
-24.00 [-42.07 , -5.93]
-28.80 [-58.05 , 0.45]
-32.95 [-45.40 , -20.50]
-7.20 [-21.02 , 6.62]
-33.10 [-42.59 , -23.61]
-13.90 [-24.32 , -3.48]
-24.40 [-31.29 , -17.51]
-9.60 [-31.56 , 12.36]
-7.00 [-16.55 , 2.55]
-19.20 [-38.30 , -0.10]
-12.40 [-39.55 , 14.75]
-8.20 [-29.10 , 12.70]
-16.33 [-23.63 , -9.03]
-18.00 [-21.69 , -14.31]
4.80 [-3.35 , 12.95]
-50.60 [-56.54 , -44.66]
-15.97 [-24.79 , -7.15]
-50.40 [-70.47 , -30.33]
-29.00 [-37.54 , -20.46]
-2.50 [-9.25 , 4.25]
-2.40 [-8.82 , 4.02]
-26.40 [-42.07 , -10.73]
-16.79 [-27.76 , -5.82]
-3.80 [-15.21 , 7.61]
-6.35 [-11.47 , -1.23]
-17.42 [-27.09 , -7.75]
-26.20 [-34.18 , -18.22]
-26.40 [-37.60 , -15.20]
-12.00 [-19.07 , -4.93]
0.00 [-13.32 , 13.32]
-29.52 [-45.23 , -13.81]
-7.20 [-22.73 , 8.33]
-17.14 [-26.05 , -8.23]
Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours probiotic Favours control
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Comparison 9.   Exposure to antibiotics





Statistical method Effect size
9.1 Diarrhoea lasting ≥ 48 hours 8 1717 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.67, 0.95]
9.2 Duration of diarrhoea 6 1674 Mean Difference (IV, Random, 95% CI) -18.94 [-37.35, -0.52]
 
 












Heterogeneity: Tau² = 0.03; Chi² = 20.26, df = 7 (P = 0.005); I² = 65%
Test for overall effect: Z = 2.59 (P = 0.010)






















































M-H, Random, 95% CI
0.34 [0.16 , 0.71]
0.47 [0.17 , 1.34]
1.08 [0.76 , 1.55]
0.83 [0.68 , 1.00]
0.71 [0.53 , 0.95]
0.69 [0.46 , 1.04]
0.75 [0.62 , 0.90]
1.01 [0.89 , 1.14]
0.80 [0.67 , 0.95]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours probiotic Favours control
 
 









Heterogeneity: Tau² = 494.26; Chi² = 225.94, df = 5 (P < 0.00001); I² = 98%
Test for overall effect: Z = 2.01 (P = 0.04)
























































IV, Random, 95% CI
-13.60 [-21.02 , -6.18]
-0.80 [-2.28 , 0.68]
-34.60 [-41.24 , -27.96]
7.60 [-17.74 , 32.94]
-62.64 [-73.16 , -52.12]
-4.85 [-14.12 , 4.42]
-18.94 [-37.35 , -0.52]
Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours probiotic Favours control
 
 
Comparison 10.   Use of zinc




Statistical method Effect size
10.1 Duration of diarrhoea 7 934 Mean Difference (IV, Random, 95%
CI)
-14.68 [-22.94, -6.42]
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Heterogeneity: Tau² = 86.58; Chi² = 32.58, df = 6 (P < 0.0001); I² = 82%
Test for overall effect: Z = 3.48 (P = 0.0005)































































IV, Random, 95% CI
-18.00 [-21.69 , -14.31]
-15.97 [-24.79 , -7.15]
-50.40 [-70.47 , -30.33]
-7.20 [-21.02 , 6.62]
-2.40 [-8.82 , 4.02]
-16.79 [-27.76 , -5.82]
1.20 [-21.42 , 23.82]
-14.68 [-22.94 , -6.42]
Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours probiotic Favours control
 
 
Comparison 11.   Risk of bias





Statistical method Effect size
11.1 Diarrhoea lasting ≥ 48 hours 36   Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1.1 Adequate random sequence
generation
19 4183 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.66, 0.86]
11.1.2 Adequate allocation conceal-
ment
4 2203 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.99, 1.01]
11.1.3 Adequate blinding of partici-
pants and personnel
16 3677 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.60, 0.81]
11.1.4 Adequate blinding of outcome
assessment
16 3941 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.65, 0.83]
11.1.5 Adequate participant fol-
low-up
25 4622 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.50, 0.80]
11.1.6 Adequate outcome reporting 33 5803 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.53, 0.81]
11.1.7 Low risk of bias for all parame-
ters
2 1770 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.91, 1.09]
11.2 Mean duration of diarrhoea 56   Mean Difference (IV, Random, 95% CI) Subtotals only
11.2.1 Adequate random sequence
generation
28 5949 Mean Difference (IV, Random, 95% CI) -22.20 [-30.88, -13.51]
11.2.2 Adequate allocation conceal-
ment
10 3599 Mean Difference (IV, Random, 95% CI) -11.77 [-24.11, 0.57]
11.2.3 Adequate blinding of partici-
pants and personnel
22 4956 Mean Difference (IV, Random, 95% CI) -18.78 [-30.37, -7.18]
Probiotics for treating acute infectious diarrhoea (Review)










Cochrane Database of Systematic Reviews





Statistical method Effect size
11.2.4 Adequate blinding of outcome
assessment
24 5630 Mean Difference (IV, Random, 95% CI) -21.43 [-31.85, -11.02]
11.2.5 Adequate participant fol-
low-up
43 7785 Mean Difference (IV, Random, 95% CI) -20.93 [-27.24, -14.62]
11.2.6 Adequate outcome reporting 53 8861 Mean Difference (IV, Random, 95% CI) -21.60 [-27.39, -15.81]
11.2.7 Low risk of bias for all parame-
ters
6 3058 Mean Difference (IV, Random, 95% CI) -8.64 [-29.38, 12.10]
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Analysis 11.1.   Comparison 11: Risk of bias, Outcome 1: Diarrhoea lasting ≥ 48 hours
Study or Subgroup






















Heterogeneity: Tau² = 0.06; Chi² = 110.95, df = 18 (P < 0.00001); I² = 84%
Test for overall effect: Z = 4.19 (P < 0.0001)







Heterogeneity: Tau² = 0.00; Chi² = 2.45, df = 3 (P = 0.49); I² = 0%
Test for overall effect: Z = 0.17 (P = 0.87)










































































































































































































































M-H, Random, 95% CI
1.08 [0.76 , 1.55]
0.64 [0.54 , 0.76]
0.71 [0.58 , 0.87]
0.63 [0.51 , 0.78]
0.54 [0.42 , 0.70]
0.53 [0.41 , 0.67]
0.51 [0.34 , 0.79]
0.76 [0.68 , 0.86]
1.01 [0.89 , 1.14]
0.69 [0.46 , 1.04]
0.70 [0.52 , 0.95]
0.61 [0.45 , 0.81]
0.35 [0.13 , 0.93]
1.02 [0.55 , 1.88]
0.98 [0.87 , 1.11]
1.52 [1.18 , 1.96]
0.95 [0.86 , 1.04]
2.14 [0.41 , 11.09]
0.44 [0.22 , 0.88]
0.76 [0.66 , 0.86]
1.01 [0.89 , 1.14]
1.00 [0.99 , 1.01]
0.98 [0.87 , 1.11]
0.95 [0.86 , 1.04]
1.00 [0.99 , 1.01]
0.64 [0.54 , 0.76]
0.63 [0.51 , 0.78]
0.54 [0.42 , 0.70]
0.71 [0.53 , 0.95]
1.01 [0.89 , 1.14]
0.83 [0.68 , 1.00]
0.69 [0.46 , 1.04]
0.70 [0.52 , 0.95]
0.36 [0.24 , 0.56]
0.61 [0.45 , 0.81]
0.35 [0.13 , 0.93]
1.02 [0.55 , 1.88]
0.98 [0.87 , 1.11]
0.30 [0.10 , 0.92]
2.14 [0.41 , 11.09]
0.67 [0.46 , 0.98]
0.69 [0.60 , 0.81]
Risk Ratio
M-H, Random, 95% CI
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Heterogeneity: Tau² = 0.06; Chi² = 71.71, df = 15 (P < 0.00001); I² = 79%
Test for overall effect: Z = 4.71 (P < 0.00001)



















Heterogeneity: Tau² = 0.04; Chi² = 81.04, df = 15 (P < 0.00001); I² = 81%
Test for overall effect: Z = 4.91 (P < 0.00001)






























































































































































































































































0.67 [0.46 , 0.98]
0.69 [0.60 , 0.81]
0.64 [0.54 , 0.76]
0.63 [0.51 , 0.78]
0.54 [0.42 , 0.70]
0.53 [0.41 , 0.67]
0.76 [0.68 , 0.86]
1.01 [0.89 , 1.14]
0.83 [0.68 , 1.00]
0.69 [0.46 , 1.04]
0.70 [0.52 , 0.95]
0.63 [0.48 , 0.83]
0.61 [0.45 , 0.81]
0.35 [0.13 , 0.93]
1.02 [0.55 , 1.88]
0.98 [0.87 , 1.11]
0.95 [0.86 , 1.04]
2.14 [0.41 , 11.09]
0.73 [0.65 , 0.83]
1.08 [0.76 , 1.55]
0.39 [0.20 , 0.77]
0.34 [0.16 , 0.71]
0.47 [0.17 , 1.34]
0.63 [0.51 , 0.78]
0.54 [0.42 , 0.70]
0.71 [0.53 , 0.95]
0.34 [0.13 , 0.91]
0.53 [0.41 , 0.67]
0.51 [0.34 , 0.79]
0.76 [0.68 , 0.86]
1.01 [0.89 , 1.14]
0.69 [0.46 , 1.04]
0.70 [0.52 , 0.95]
0.45 [0.18 , 1.12]
0.22 [0.05 , 0.91]
0.63 [0.48 , 0.83]
1.00 [0.99 , 1.01]
0.61 [0.45 , 0.81]
0.35 [0.13 , 0.93]
0.98 [0.87 , 1.11]
0.30 [0.10 , 0.92]
1.52 [1.18 , 1.96]
0.95 [0.86 , 1.04]
0.18 [0.04 , 0.74]
0.63 [0.50 , 0.80]
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Analysis 11.1.   (Continued)
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.29; Chi² = 1037.63, df = 24 (P < 0.00001); I² = 98%
Test for overall effect: Z = 3.74 (P = 0.0002)




































Heterogeneity: Tau² = 0.33; Chi² = 1422.42, df = 32 (P < 0.00001); I² = 98%
Test for overall effect: Z = 3.89 (P = 0.0001)





Heterogeneity: Tau² = 0.00; Chi² = 0.10, df = 1 (P = 0.75); I² = 0%































































































































































































0.63 [0.50 , 0.80]
1.08 [0.76 , 1.55]
0.39 [0.20 , 0.77]
0.34 [0.16 , 0.71]
0.47 [0.17 , 1.34]
0.75 [0.62 , 0.90]
0.64 [0.54 , 0.76]
0.63 [0.51 , 0.78]
0.54 [0.42 , 0.70]
0.71 [0.53 , 0.95]
0.34 [0.13 , 0.91]
0.53 [0.41 , 0.67]
0.51 [0.34 , 0.79]
0.76 [0.68 , 0.86]
1.01 [0.89 , 1.14]
0.83 [0.68 , 1.00]
0.69 [0.46 , 1.04]
0.70 [0.52 , 0.95]
0.45 [0.18 , 1.12]
0.63 [0.48 , 0.83]
1.00 [0.99 , 1.01]
0.36 [0.24 , 0.56]
0.61 [0.45 , 0.81]
0.35 [0.13 , 0.93]
1.02 [0.55 , 1.88]
0.98 [0.87 , 1.11]
0.65 [0.29 , 1.46]
0.30 [0.10 , 0.92]
1.52 [1.18 , 1.96]
0.95 [0.86 , 1.04]
2.14 [0.41 , 11.09]
0.44 [0.22 , 0.88]
0.67 [0.51 , 0.88]
0.18 [0.04 , 0.74]
0.65 [0.53 , 0.81]
1.01 [0.89 , 1.14]
0.98 [0.87 , 1.11]
1.00 [0.91 , 1.09]
0.5 0.7 1 1.5 2
Favours probiotic Favours control
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Analysis 11.2.   Comparison 11: Risk of bias, Outcome 2: Mean duration of diarrhoea
Study or Subgroup






























Heterogeneity: Tau² = 489.35; Chi² = 687.51, df = 27 (P < 0.00001); I² = 96%
Test for overall effect: Z = 5.01 (P < 0.00001)












Heterogeneity: Tau² = 368.22; Chi² = 220.65, df = 9 (P < 0.00001); I² = 96%
Test for overall effect: Z = 1.87 (P = 0.06)











































































































































































































































































































































































































IV, Random, 95% CI
-18.00 [-21.69 , -14.31]
4.80 [-3.35 , 12.95]
-50.60 [-56.54 , -44.66]
-50.40 [-70.47 , -30.33]
-37.00 [-45.46 , -28.54]
-26.20 [-34.18 , -18.22]
-33.10 [-42.59 , -23.61]
-13.90 [-24.32 , -3.48]
-24.40 [-31.29 , -17.51]
-2.50 [-9.25 , 4.25]
-28.80 [-50.47 , -7.13]
7.60 [-17.74 , 32.94]
-4.85 [-14.12 , 4.42]
-64.80 [-78.10 , -51.50]
-34.60 [-41.24 , -27.96]
-79.20 [-85.31 , -73.09]
-26.40 [-37.60 , -15.20]
-26.40 [-79.63 , 26.83]
-6.30 [-19.33 , 6.73]
-16.79 [-27.76 , -5.82]
1.20 [-21.42 , 23.82]
-3.80 [-15.21 , 7.61]
-2.79 [-10.11 , 4.53]
-6.35 [-11.47 , -1.23]
-12.40 [-39.55 , 14.75]
-8.20 [-29.10 , 12.70]
-17.50 [-31.92 , -3.08]
-35.00 [-64.16 , -5.84]
-22.20 [-30.88 , -13.51]
4.80 [-3.35 , 12.95]
-50.60 [-56.54 , -44.66]
-29.00 [-37.54 , -20.46]
-2.50 [-9.25 , 4.25]
-23.52 [-35.89 , -11.15]
7.60 [-17.74 , 32.94]
-4.85 [-14.12 , 4.42]
-5.30 [-12.96 , 2.36]
-2.79 [-10.11 , 4.53]
-6.35 [-11.47 , -1.23]
-11.77 [-24.11 , 0.57]
4.80 [-3.35 , 12.95]
-50.60 [-56.54 , -44.66]
-26.20 [-34.18 , -18.22]
-0.80 [-2.28 , 0.68]
-2.50 [-9.25 , 4.25]
-28.80 [-50.47 , -7.13]
7.60 [-17.74 , 32.94]
-4.85 [-14.12 , 4.42]
-13.60 [-21.02 , -6.18]
-34.60 [-41.24 , -27.96]
-79.20 [-85.31 , -73.09]
-26.40 [-79.63 , 26.83]
-19.20 [-38.30 , -0.10]
-6.30 [-19.33 , 6.73]
Mean Difference
IV, Random, 95% CI
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Heterogeneity: Tau² = 679.66; Chi² = 924.93, df = 21 (P < 0.00001); I² = 98%
Test for overall effect: Z = 3.17 (P = 0.002)


























Heterogeneity: Tau² = 602.22; Chi² = 647.51, df = 23 (P < 0.00001); I² = 96%
Test for overall effect: Z = 4.03 (P < 0.0001)




































































































































































































































































































































































































































-26.40 [-79.63 , 26.83]
-19.20 [-38.30 , -0.10]
-6.30 [-19.33 , 6.73]
-33.60 [-65.73 , -1.47]
-16.79 [-27.76 , -5.82]
1.20 [-21.42 , 23.82]
-2.79 [-10.11 , 4.53]
-28.80 [-58.05 , 0.45]
-12.40 [-39.55 , 14.75]
-8.20 [-29.10 , 12.70]
-35.00 [-64.16 , -5.84]
-18.78 [-30.37 , -7.18]
4.80 [-3.35 , 12.95]
-50.60 [-56.54 , -44.66]
-37.00 [-45.46 , -28.54]
-26.20 [-34.18 , -18.22]
-33.10 [-42.59 , -23.61]
-24.40 [-31.29 , -17.51]
-2.50 [-9.25 , 4.25]
-28.80 [-50.47 , -7.13]
7.60 [-17.74 , 32.94]
-4.85 [-14.12 , 4.42]
-13.60 [-21.02 , -6.18]
-34.60 [-41.24 , -27.96]
-79.20 [-85.31 , -73.09]
-58.80 [-79.00 , -38.60]
-26.40 [-79.63 , 26.83]
-6.30 [-19.33 , 6.73]
-33.60 [-65.73 , -1.47]
1.20 [-21.42 , 23.82]
-3.80 [-15.21 , 7.61]
-2.79 [-10.11 , 4.53]
-6.35 [-11.47 , -1.23]
-12.40 [-39.55 , 14.75]
-8.20 [-29.10 , 12.70]
-35.00 [-64.16 , -5.84]
-21.43 [-31.85 , -11.02]
-18.00 [-21.69 , -14.31]
4.80 [-3.35 , 12.95]
-50.60 [-56.54 , -44.66]
-15.97 [-24.79 , -7.15]
-17.60 [-30.44 , -4.76]
-50.40 [-70.47 , -30.33]
-37.00 [-45.46 , -28.54]
-26.20 [-34.18 , -18.22]
-0.80 [-2.28 , 0.68]
-7.20 [-21.02 , 6.62]
-29.00 [-37.54 , -20.46]
-33.10 [-42.59 , -23.61]
-13.90 [-24.32 , -3.48]
-24.40 [-31.29 , -17.51]
-2.50 [-9.25 , 4.25]
-23.52 [-35.89 , -11.15]
-9.60 [-31.56 , 12.36]
-28.80 [-50.47 , -7.13]
7.60 [-17.74 , 32.94]
-4.85 [-14.12 , 4.42]
-64.80 [-78.10 , -51.50]
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Heterogeneity: Tau² = 395.15; Chi² = 1181.23, df = 42 (P < 0.00001); I² = 96%
Test for overall effect: Z = 6.50 (P < 0.00001)




















































































































































































































































































































































































































































































7.60 [-17.74 , 32.94]
-4.85 [-14.12 , 4.42]
-64.80 [-78.10 , -51.50]
-2.40 [-8.82 , 4.02]
-34.60 [-41.24 , -27.96]
-79.20 [-85.31 , -73.09]
-26.40 [-37.60 , -15.20]
-19.20 [-30.11 , -8.29]
-58.80 [-79.00 , -38.60]
-5.30 [-12.96 , 2.36]
-26.40 [-79.63 , 26.83]
-7.00 [-16.55 , 2.55]
-12.00 [-19.07 , -4.93]
0.00 [-13.32 , 13.32]
-26.40 [-42.07 , -10.73]
-29.52 [-45.23 , -13.81]
-16.79 [-27.76 , -5.82]
-3.80 [-15.21 , 7.61]
-2.79 [-10.11 , 4.53]
-26.40 [-47.67 , -5.13]
-28.80 [-58.05 , 0.45]
-6.35 [-11.47 , -1.23]
-12.40 [-39.55 , 14.75]
-31.20 [-45.79 , -16.61]
-7.20 [-22.73 , 8.33]
-20.93 [-27.24 , -14.62]
-18.00 [-21.69 , -14.31]
4.80 [-3.35 , 12.95]
-50.60 [-56.54 , -44.66]
-15.97 [-24.79 , -7.15]
-17.60 [-30.44 , -4.76]
-50.40 [-70.47 , -30.33]
-62.64 [-73.16 , -52.12]
-37.00 [-45.46 , -28.54]
-26.20 [-34.18 , -18.22]
-0.80 [-2.28 , 0.68]
-7.20 [-21.02 , 6.62]
-29.00 [-37.54 , -20.46]
-33.10 [-42.59 , -23.61]
-13.90 [-24.32 , -3.48]
-24.40 [-31.29 , -17.51]
-2.50 [-9.25 , 4.25]
-23.52 [-35.89 , -11.15]
-9.60 [-31.56 , 12.36]
-28.80 [-50.47 , -7.13]
7.60 [-17.74 , 32.94]
-4.85 [-14.12 , 4.42]
-13.60 [-21.02 , -6.18]
-64.80 [-78.10 , -51.50]
-2.40 [-8.82 , 4.02]
-34.60 [-41.24 , -27.96]
-79.20 [-85.31 , -73.09]
-26.40 [-37.60 , -15.20]
-58.80 [-79.00 , -38.60]
-5.30 [-12.96 , 2.36]
-19.20 [-38.30 , -0.10]
-12.00 [-19.07 , -4.93]
0.00 [-13.32 , 13.32]
-26.40 [-42.07 , -10.73]
-6.30 [-19.33 , 6.73]
-33.60 [-65.73 , -1.47]
-29.52 [-45.23 , -13.81]
-16.79 [-27.76 , -5.82]
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Heterogeneity: Tau² = 402.59; Chi² = 1280.24, df = 52 (P < 0.00001); I² = 96%
Test for overall effect: Z = 7.31 (P < 0.00001)








Heterogeneity: Tau² = 635.50; Chi² = 192.05, df = 5 (P < 0.00001); I² = 97%






















































































































































































-33.60 [-65.73 , -1.47]
-29.52 [-45.23 , -13.81]
-16.79 [-27.76 , -5.82]
1.20 [-21.42 , 23.82]
-19.60 [-39.63 , 0.43]
-39.80 [-81.19 , 1.59]
-3.80 [-15.21 , 7.61]
-2.79 [-10.11 , 4.53]
-26.40 [-47.67 , -5.13]
-24.00 [-42.07 , -5.93]
-28.80 [-58.05 , 0.45]
-24.63 [-44.66 , -4.60]
-6.35 [-11.47 , -1.23]
-12.40 [-39.55 , 14.75]
-8.20 [-29.10 , 12.70]
-17.50 [-31.92 , -3.08]
-35.00 [-64.16 , -5.84]
-31.20 [-45.79 , -16.61]
-7.20 [-22.73 , 8.33]
-21.60 [-27.39 , -15.81]
4.80 [-3.35 , 12.95]
-50.60 [-56.54 , -44.66]
-2.50 [-9.25 , 4.25]
7.60 [-17.74 , 32.94]
-4.85 [-14.12 , 4.42]
-2.79 [-10.11 , 4.53]
-8.64 [-29.38 , 12.10]
-100 -50 0 50 100
Favours probiotic Favours control
 
 
Comparison 12.   Publication decade







Statistical method Effect size
12.1 Diarrhoea lasting ≥ 48
hours
36   Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1.1 1980s 4 187 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.34, 0.74]
12.1.2 1990s 7 589 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.54, 0.86]
12.1.3 2000s 10 1305 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.52, 0.74]
12.1.4 2010s 15 3972 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.63, 0.98]
12.2 Mean duration of di-
arrhoea
56   Mean Difference (IV, Random, 95% CI) Subtotals only
12.2.1 1990s 6 377 Mean Difference (IV, Random, 95% CI) -33.18 [-51.33, -15.03]
12.2.2 2000s 22 3471 Mean Difference (IV, Random, 95% CI) -24.08 [-36.09, -12.07]
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Statistical method Effect size
12.2.3 2010s 28 5290 Mean Difference (IV, Random, 95% CI) -17.15 [-22.27, -12.03]
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Heterogeneity: Tau² = 0.04; Chi² = 3.84, df = 3 (P = 0.28); I² = 22%











Heterogeneity: Tau² = 0.04; Chi² = 12.44, df = 6 (P = 0.05); I² = 52%














Heterogeneity: Tau² = 0.04; Chi² = 21.07, df = 9 (P = 0.01); I² = 57%






















































































































































































































M-H, Random, 95% CI
0.34 [0.16 , 0.71]
0.47 [0.17 , 1.34]
0.34 [0.13 , 0.91]
0.67 [0.46 , 0.98]
0.50 [0.34 , 0.74]
1.08 [0.76 , 1.55]
0.64 [0.54 , 0.76]
0.71 [0.58 , 0.87]
0.45 [0.18 , 1.12]
0.22 [0.05 , 0.91]
0.65 [0.29 , 1.46]
0.30 [0.10 , 0.92]
0.68 [0.54 , 0.86]
0.39 [0.20 , 0.77]
0.71 [0.53 , 0.95]
0.83 [0.68 , 1.00]
0.69 [0.46 , 1.04]
0.70 [0.52 , 0.95]
0.63 [0.48 , 0.83]
0.36 [0.24 , 0.56]
0.44 [0.22 , 0.88]
0.67 [0.51 , 0.88]
0.18 [0.04 , 0.74]
0.62 [0.52 , 0.74]
0.75 [0.62 , 0.90]
0.63 [0.51 , 0.78]
0.54 [0.42 , 0.70]
0.53 [0.41 , 0.67]
0.51 [0.34 , 0.79]
0.76 [0.68 , 0.86]
1.01 [0.89 , 1.14]
1.00 [0.99 , 1.01]
0.61 [0.45 , 0.81]
0.35 [0.13 , 0.93]
1.02 [0.55 , 1.88]
0.98 [0.87 , 1.11]
1.52 [1.18 , 1.96]
0.95 [0.86 , 1.04]
Risk Ratio
M-H, Random, 95% CI
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Heterogeneity: Tau² = 0.16; Chi² = 528.13, df = 14 (P < 0.00001); I² = 97%





















1.52 [1.18 , 1.96]
0.95 [0.86 , 1.04]
2.14 [0.41 , 11.09]
0.78 [0.63 , 0.98]
0.01 0.1 1 10 100
Favours probiotic Favours control
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Heterogeneity: Tau² = 399.86; Chi² = 29.44, df = 5 (P < 0.0001); I² = 83%

























Heterogeneity: Tau² = 743.78; Chi² = 974.80, df = 21 (P < 0.00001); I² = 98%






















































































































































































































































































































































































































IV, Random, 95% CI
-64.80 [-78.10 , -51.50]
-19.20 [-30.11 , -8.29]
-33.60 [-65.73 , -1.47]
-26.40 [-47.67 , -5.13]
-24.00 [-42.07 , -5.93]
-28.80 [-58.05 , 0.45]
-33.18 [-51.33 , -15.03]
4.80 [-3.35 , 12.95]
-50.60 [-56.54 , -44.66]
-17.60 [-30.44 , -4.76]
-37.00 [-45.46 , -28.54]
-0.80 [-2.28 , 0.68]
-13.60 [-21.02 , -6.18]
-34.60 [-41.24 , -27.96]
-79.20 [-85.31 , -73.09]
-58.80 [-79.00 , -38.60]
-26.40 [-79.63 , 26.83]
-7.00 [-16.55 , 2.55]
-19.20 [-38.30 , -0.10]
-12.00 [-19.07 , -4.93]
0.00 [-13.32 , 13.32]
-26.40 [-42.07 , -10.73]
-19.60 [-39.63 , 0.43]
-39.80 [-81.19 , 1.59]
-3.80 [-15.21 , 7.61]
-12.40 [-39.55 , 14.75]
-17.50 [-31.92 , -3.08]
-35.00 [-64.16 , -5.84]
-31.20 [-45.79 , -16.61]
-24.08 [-36.09 , -12.07]
-18.00 [-21.69 , -14.31]
-15.97 [-24.79 , -7.15]
-50.40 [-70.47 , -30.33]
-62.64 [-73.16 , -52.12]
-26.20 [-34.18 , -18.22]
-7.20 [-21.02 , 6.62]
-29.00 [-37.54 , -20.46]
-33.10 [-42.59 , -23.61]
-13.90 [-24.32 , -3.48]
-24.40 [-31.29 , -17.51]
-2.50 [-9.25 , 4.25]
-23.52 [-35.89 , -11.15]
-9.60 [-31.56 , 12.36]
-28.80 [-50.47 , -7.13]
7.60 [-17.74 , 32.94]
-4.85 [-14.12 , 4.42]
-2.40 [-8.82 , 4.02]
-26.40 [-37.60 , -15.20]
-5.30 [-12.96 , 2.36]
-6.30 [-19.33 , 6.73]
-29.52 [-45.23 , -13.81]
-16.79 [-27.76 , -5.82]
1.20 [-21.42 , 23.82]
-2.79 [-10.11 , 4.53]
Mean Difference
IV, Random, 95% CI
 
 
Probiotics for treating acute infectious diarrhoea (Review)










Cochrane Database of Systematic Reviews









Heterogeneity: Tau² = 149.11; Chi² = 213.69, df = 27 (P < 0.00001); I² = 87%





















































-16.79 [-27.76 , -5.82]
1.20 [-21.42 , 23.82]
-2.79 [-10.11 , 4.53]
-24.63 [-44.66 , -4.60]
-6.35 [-11.47 , -1.23]
-8.20 [-29.10 , 12.70]
-7.20 [-22.73 , 8.33]
-17.15 [-22.27 , -12.03]
-100 -50 0 50 100
Favours probiotic Favours control
 
 
Comparison 13.   Prospective trial registration





Statistical method Effect size
13.1 Diarrhoea lasting ≥ 48 hours 8 2756 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.70, 0.93]
13.2 Mean duration of diarrhoea 12 3437 Mean Difference (IV, Random, 95% CI) -16.43 [-22.43, -10.43]
 
 












Heterogeneity: Tau² = 0.03; Chi² = 38.20, df = 7 (P < 0.00001); I² = 82%
Test for overall effect: Z = 2.88 (P = 0.004)






















































M-H, Random, 95% CI
0.63 [0.51 , 0.78]
0.51 [0.34 , 0.79]
0.76 [0.68 , 0.86]
1.01 [0.89 , 1.14]
0.98 [0.87 , 1.11]
2.14 [0.41 , 11.09]
0.95 [0.86 , 1.04]
0.61 [0.45 , 0.81]
0.81 [0.70 , 0.93]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours probiotic Favours control
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Heterogeneity: Tau² = 87.32; Chi² = 73.72, df = 11 (P < 0.00001); I² = 85%
Test for overall effect: Z = 5.37 (P < 0.00001)


































































































IV, Random, 95% CI
-18.00 [-21.69 , -14.31]
-37.00 [-45.46 , -28.54]
-26.20 [-34.18 , -18.22]
-13.90 [-24.32 , -3.48]
-24.40 [-31.29 , -17.51]
-4.85 [-14.12 , 4.42]
-26.40 [-37.60 , -15.20]
-16.79 [-27.76 , -5.82]
-2.79 [-10.11 , 4.53]
-6.35 [-11.47 , -1.23]
-8.20 [-29.10 , 12.70]
-7.20 [-22.73 , 8.33]
-16.43 [-22.43 , -10.43]
Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours probiotic Favours control
 
 
A P P E N D I C E S




CIDG SRa CENTRAL MEDLINEb Embaseb LILACSb
1 Diarrhea* DIARRHEA DIARRHEA INFECTIOUS DIARRHEA Diarrhea$
2 Diarrhoea* Diarrhoea* Diarrhoea* Diarrhoea* Diarrhoea$
3 1 or 2 1 or 2 1 or 2 1 or 2 1 or 2
4 Probiotic* Probiotic* PROBIOTICS PROBIOTIC AGENT Probiotic$
5 Lactobacill* Lactobacill* Lactobacill* Lactobacill$ Lactobacill$
6 Lactococc* Lactococc* Lactococc* Lactococc$ Lactococc$
7 Bifidobacter* Bifidobacter* Bifidobacter* Bifidobacter$ Bifidobacter$
8 Enterococc* Enterococc* Enterococc* Enterococc$ Enterococc$
9 Streptococc* Streptococc* Streptococc* Streptococc$ Streptococc$
10 saccharomyces saccharomyces saccharomyces saccharomyces saccharomyces
11 4 or 5 or 6 or 7 or 8
or 9 or 10
4 or 5 or 6 or 7 or 8
or 9 or 10
4 or 5 or 6 or 7 or 8 or 9
or 10
4 or 5 or 6 or 7 or 8 or 9 or
10
4 or 5 or 6 or 7 or 8
or 9 or 10
12 3 and 11 3 and 11 3 and 11 3 and 11 3 and 11
13     Limit 12 to Humans Limit 12 to Human  
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Footnotes
aCochrane Infectious Diseases Group Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by Cochrane (Higgins 2008); upper case: MeSH
or EMTREE heading; lower case: free text term.
W H A T ' S   N E W
 
Date Event Description
1 December 2020 New search has been performed We updated the search to 17 December 2019, and have included
36 new studies in this review update.
In this review, only published, randomized controlled trials of
live probiotics were included. Seventeen trials that were unpub-
lished, were quasi-randomized, assessed killed probiotics, or
had no usable outcome data that were included in Allen 2010
were excluded.
We revised the outcomes according to a consensus statement
regarding a core outcome measurement set for clinical trials in
acute diarrhoea (Karas 2016).
To better assess the quality of research methods and publication
bias, we have included analyses according to the decade of trial
publication and trial registration.
1 December 2020 New citation required and conclusions
have changed
In our conclusions, under Implications for practice, we now con-
sider that our findings do not support the use of probiotics for
treatment of acute diarrhoea. Under Implications for research,
we have highlighted that limiting inclusion of trials to those reg-
istered in a clinical trials database may improve the reliability of
study findings.
 
H I S T O R Y
Protocol first published: Issue 2, 2001
Review first published: Issue 2, 2004
 
Date Event Description
9 November 2010 Amended Detailed search strategy added to appendices
11 August 2010 New citation required but conclusions
have not changed
Title changed ("acute" added) to emphasize that persistent di-
arrhoea is not considered. The authorship of the update has
changed due to the untimely death of Dr Okoko
11 August 2010 New search has been performed The table showing clinical variability among studies has been re-
moved and this information added to the Characteristics of in-
cluded studies table. A table has been added to show the marked
statistical heterogeneity in primary outcomes and subgroup
analyses (Table 1)
The following secondary outcomes have been removed as they
were uncommon or were not reported: need for unscheduled in-
travenous (IV) rehydration after randomization; death; adverse
events, such as vomiting; withdrawal from the study. Details re-
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Date Event Description
garding adverse events and reasons for withdrawal are included
in the "Details of included studies" table
22 July 2008 Amended Converted to new review format
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